Collaborative Testing Services, Inc
FORENSIC TESTING PROGRAM

P.O. Box 650820
Sterling, VA 20165-0820
e-mail: forensics@cts-interlab.com
Telephone: +1-571-434-1925
Web site: www.cts-forensics.com

Blood Drug Analysis
Test No. 25-5661 Summary Report

Each participant received a sample pack containing blood samples from four individual cases with unique scenarios; they were asked to analyze the samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used. Data were returned from 138 participants and are compiled into the following tables:

This report contains the data received from the participants in this test. Since these participants are located in many countries around the world, and it is their option how the samples are to be used (e.g., training exercise, known or blind proficiency testing, research and development of new techniques, etc.), the results compiled in the Summary Report are not intended to be an overview of the quality of work performed in the profession and cannot be interpreted as such. The Summary Comments are included for the benefit of participants to assist with maintaining or enhancing the quality of their results. These comments are not intended to reflect the general state of the art within the profession.

Participant results are reported using a randomly assigned "WebCode". This code maintains participant's anonymity, provides linking of the various report sections, and will change with every report.

Manufacturer's Information

Each sample pack contained blood samples from four cases, each with an individual case scenario. Each item consisted of two grey-top glass vials. Participants were asked to analyze the blood samples and report the presence of any drugs/metabolites and quantitative data obtained, including uncertainty and the methods used.

SAMPLE PREPARATION: A stock solution of each drug was used to spike specific items. These solutions were obtained in sealed ampoules and were not opened until needed for production. Items were prepared at separate times using the following procedure.

ITEM PREPARATION: A predetermined amount of drug stock solution was added to whole blood and mixed thoroughly. Mixing continuously to ensure homogeneity, 10 mL aliquots of the mixture were pipetted into each of the pre-labeled vials which contained potassium oxalate and sodium fluoride. The vials were sealed and inverted multiple times to mix the preservatives in the vials with the blood solution. All vials were placed in a refrigerator immediately after production and stored there until the sample sets were prepared.

VERIFICATION: Predistribution results were consistent with each other and the manufacturer's preparation information.

SAMPLE PACK ASSEMBLY: One of each item was placed into a Department of Transportation regulated shipping container. The sample packs were then returned to the refrigerator until shipment.

Preparation Concentrations

Item 1 Drug(s) [Sheep Blood]	Item 2 Drug(s) [Sheep Blood]	Item 3 Drug(s) [Human Blood]	Item 4 Drug(s) [Human Blood]
Phencyclidine [PCP] (60 ng/mL)	No drugs or metabolites added	Ketamine (1200 ng/mL)	Doxylamine (250 ng/mL)
Tetrahydrocannabinol [THC] (25 ng/mL)		MDA (100 ng/mL)	Fentanyl (40 ng/mL)
Carboxy-THC (100 ng/mL)		MDMA (900 ng/mL)	Gabapentin (800 ng/mL)

This section provides details on test sample preparation and design, including preparation concentrations which may not necessarily represent the results that could or should be obtained. The statistical analysis, including the calculation of the Grand Mean statistics, was performed on participant results and is available in this Summary Report.

Summary Comments

This test was designed to allow participants to assess their proficiency in the examination for the presence and concentration of drugs and/or metabolites in blood. Participants were supplied with four blood samples from individual cases with unique scenarios; each item was composed of two 10 mL vials of blood. Each of the blood specimens was spiked with varying concentrations of specific drugs and/or metabolites in case-like ranges. The sample specifications are as follows: Item 1 contained 60 ng/mL phencyclidine (PCP), 25 ng/mL tetrahydrocannabinol (THC), and 100 ng/mL carboxy-THC. No drugs or metabolites were added by CTS to Item 2. Item 3 contained 1200 ng/mL ketamine, 100 ng/mL methylenedioxyamphetamine (MDA), and 900 ng/mL methylenedioxymethamphetamine (MDMA). Item 4 contained 250 ng/mL doxylamine, 40 ng/mL fentanyl, and 800 ng/mL gabapentin. Refer to the Manufacturer's Information for preparation details.

A total of 138 participants returned data for this test.

Of the 134 participants who reported screening results for Item 1, the most commonly reported drug category was cannabinoids, followed by the miscellaneous category. 105 participants reported the presence of PCP, 56 reported 11-nor-9-carboxy-THC, and 40 reported delta-9-THC. Of the 126 participants who returned confirmatory results, 113 participants detected carboxy-THC, 109 participants detected THC, and 95 detected PCP.

Of the 134 participants who reported screening results for Item 2, the majority of participants, 124, reported that no drugs were detected utilizing screening methods, and 10 reported the presence of one or more drugs in the sample. Of the 56 participants who returned confirmatory results, 54 indicated that no drugs/metabolites were identified, and two detected other drugs/metabolites.

Of the 133 participants who reported screening results for Item 3, the most commonly reported drug categories were CNS stimulants and the miscellaneous category. 79 participants reported the presence of ketamine, 72 reported MDMA, 60 reported MDA, and 45 reported methamphetamine. Of the 125 participants who returned confirmatory results, 123 detected MDMA, 113 detected MDA, and 108 detected ketamine.

Of the 130 participants who reported screening results for Item 4, the most commonly reported drug category was analgesics, followed by antihistamines/cold treatments and anticonvulsants. 95 participants reported the presence of fentanyl, 60 reported doxylamine, and 23 reported gabapentin. Of the 115 participants who returned confirmatory results, 92 detected fentanyl, 84 detected doxylamine, and 27 detected gabapentin.

For all four items, the majority of the population used immunoassay, GC/MS and LC/MS/MS for screening, GC/MS and LC/MS/MS for confirmation testing, and LC/MS/MS for quantitation.

If a participant did not provide raw data, but indicated that their result was a single determination and reported in ng/mL, the conclusive quantitative result was included in the raw data table. The raw data was used to calculate the grand mean and standard deviation for this item, which are supplied to assist the participants and accrediting bodies in determining the acceptability of results. Participants with extreme data have been marked with an "X" and their results were excluded from the calculations of the grand mean and standard deviation. Extreme data has been determined using the Critical Value of h defined within ASTM E691-19, and calculated for each analyte as ± (CrH * STD) from the grand mean.

Nineteen participants' data were marked as extreme for one or more analytes in statistical analysis of the raw data. The breakdown of extreme data is as follows: five reported extreme data for Item 1 (five for THC and one for carboxy-THC), eleven reported extreme data for Item 3 (two for ketamine, five for MDMA, and four for both MDA and MDMA), and five reported extreme data for Item 4 (one for doxylamine, two for fentanyl, one for gabapentin, and one for both doxylamine and fentanyl).

Screening Results - Item 1

TABLE 1A

Item Scenario:

A 29 year old female was pulled over for driving recklessly while taking friends home from a night club. The female, as well as many of the passengers, showed signs of impairment, including a lack of convergence, slurred speech, and nystagmus. A blood specimen was collected from the driver 1.5 hours later.

Item Contents and Preparation Concentration: Phencyclidine [PCP] (60 ng/mL)
Tetrahydrocannabinol [THC] (25 ng/mL)
Carboxy-THC (100 ng/mL)

WebCode	Category	Drug/Metabolite
27ZRVP	No drugs detected utilizing screening methods.	
28CJRC	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
2R2ZW7	No drugs detected utilizing screening methods.	
3KUQ3H	Cannabinoids	
3L7B8L	Cannabinoids	Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
3X2H8C	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
47C7EH	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
4CX2FM	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
4UFZKK	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
4Y8J8Z	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
4Z33A3	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
634A8K	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
66DDZB	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
69ZW6E	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
6CXF6R	Cannabinoids	Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
6RMMYJ	Cannabinoids	Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
6RNHNG	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
6VMUJG	Cannabinoids	
6YM3QD	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
76WJY2	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
7DM2DA	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
7FQWWC	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
7THLUX	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
82MZ8J	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
82RCVE	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
8ALF2W	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
8JNXCZ	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
8N3D4C	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
94RZMA	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
9E9MWB	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
9E9R8D	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
9L6JJD	Cannabinoids	11-nor-9-carboxy-THC
9UNPH6	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
9WQNRD	Cannabinoids	11-nor-9-carboxy-THC
A8462V	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
ARQYNB	Cannabinoids	
BBLR99	Cannabinoids	
	CNS Stimulants	
	Miscellaneous	Phencyclidine (PCP)
BEHBB8	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
BKMCB2	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
BTXFFE	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
BUY9F9	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
CHEJU8	No drugs detected utilizing screening methods.	
CU8ZLU	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
CYLKNA	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
CZG4PB	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
D333M7	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
D3GPYT	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
DAH2VP	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
DQQXEN	Cannabinoids	
DTCHJT	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
EATAEA	Miscellaneous	Phencyclidine (PCP)
EAXM37	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
EC3D8Z	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
EDHCQP	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
EHN6JZ	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
EQHD26	Miscellaneous	Phencyclidine (PCP)
ERDW48	Analgesics	
	Cannabinoids	
EVXLRQ	Analgesics	Tramadol
	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
F7PV7B	Cannabinoids	Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
FDCNHA	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
FJGK7G	Miscellaneous	Phencyclidine (PCP)
FN9UC9	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
FXJWXA	No drugs detected utilizing screening methods.	

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
FYVPUW	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
GKQMUZ	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
GVA796	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
H33YT6	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
H97X9Z	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
HD3K3N	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
HEVFPX	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
HHGZU2	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
HJCHV3	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
J6RHGN	No drugs detected utilizing screening methods.	
JAHYN8	CNS Stimulants	Cocaine
JDG92U	Cannabinoids	
JR4HMZ	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
KHU9V2	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
KKY2RK	Cannabinoids	11-nor-9-carboxy-THC
L2ETM2	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
L44VYG	Cannabinoids	
LFXJL4	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
LJV3N3	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
LT9P6J	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
M43KEX	Cannabinoids	
MDQGHK	No drugs detected utilizing screening methods.	
MEHD6T	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
MT3R8T	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
MVA8GJ	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
MW344T	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
N6T7KU	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
NC8RUX	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
NM9FLV	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
NMQB83	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
NQPM33	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
NUPVAY	Cannabinoids	
	Miscellaneous	
PBUPGX	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
PNKA4G	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
QC2GRC	Cannabinoids	
QQ3VBU	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
R7V8YN	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
RACEFW	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
RYVNWT	Analgesics	Buprenorphine
	Cannabinoids	
T38TAE	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
T6EB7P	Cannabinoids	
	CNS Stimulants	
	Miscellaneous	Phencyclidine (PCP)
TB4N8D	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
UAL4UT	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
UEJHLP	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
UHWFTC	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
UN22YU	Cannabinoids	
UR2DVU	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
UXAUBA	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
UZFC8J	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
V3YTZN	Cannabinoids	
VMLHAG	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
VNF7TC	Miscellaneous	Phencyclidine (PCP)
VWVTKT	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
VX7V8R	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
WGDDXM	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
WQ2AZA	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
X6ZFLR	Miscellaneous	Phencyclidine (PCP)
XE3VDH	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
XMZKW8	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
XT673P	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
Y4NX9E	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
Y8Z7AH	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
YJVEV7	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)
YN6HYM	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)

TABLE 1 A: Screening Results - Item 1

WebCode	Category	Drug/Metabolite
YQCUGN	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
YXCCXL	Cannabinoids	
Z2UNE4	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
ZEF76L	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
ZFBUGP	Cannabinoids	
	Miscellaneous	Phencyclidine (PCP)
ZHZWT6	Cannabinoids	11-nor-9-carboxy-THC
	Miscellaneous	Phencyclidine (PCP)
ZJ89B8	Cannabinoids	11-nor-9-carboxy-THC
		Delta-9-THC
	Miscellaneous	Phencyclidine (PCP)

Screening Response Summary for Item 1 **Participants: 134**

Drug Category Totals		Drug/Metabolite Totals	
Cannabinoids	122	**Phencyclidine (PCP)**	105
Miscellaneous	106	**11-nor-9-carboxy-THC**	56
Analgesics	3	**Delta-9-THC**	40
CNS Stimulants	3		
No drugs detected utilizing screening methods	6		

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 1

TABLE 1B

Item Scenario:

A 29 year old female was pulled over for driving recklessly while taking friends home from a night club. The female, as well as many of the passengers, showed signs of impairment, including a lack of convergence, slurred speech, and nystagmus. A blood specimen was collected from the driver 1.5 hours later.

Item Contents and Preparation Concentration: Phencyclidine [PCP] (60 ng/mL)
Tetrahydrocannabinol [THC] (25 ng/mL)
Carboxy-THC (100 ng/mL)

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
28CJRC	Phencyclidine (PCP)		44.4	+/-5.3	ng/mL
	Delta-9-THC		18.2	+/-4.9	ng/mL
	11-nor-9-carboxy-THC		95.9	+/-20.1	ng/mL
2R2ZW7	Phencyclidine	✓			
3KUQ3H	Tetrahydrocannabinol		27	18.74%	ng/mL
	Carboxy-tetrahydrocannabinol		112	15.90%	ng/mL
3L7B8L	Phencyclidine (PCP)	✓			
	Delta-9-THC	✓			
	11-nor-9-carboxy-THC	✓			
3X2H8C	Tetrahydrocannabinol	✓			
	Carboxy-tetrahydrocannabinol	✓			
47C7EH	Phencyclidine (PCP)	✓			
	Delta-9 THC		18.4	3.4	ng/mL
	Delta-9 Carboxy THC (THC metabolite)	✓			
4UFZKK	Phencycldine (PCP)	✓			
	Delta-9-THC		31	5	ng/mL
	11-nor-9-carboxy-THC		120	22	ng/mL
4Y8J8Z	Phencyclidine	✓			
	Delta-9 THC		9.6 ng/mL	+/- 1.2	ng/mL
	Delta-9 Carboxy THC		37 ng/mL	+/- 4	ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
4Z33A3	PCP	✓			
	Delta-9-THC		>19.8		ng/mL
	Delta-9 Carboxy THC	✓			
66DDZB	phencyclidine (PCP)	✓			
	delta-9-THC		19	3	ng/mL
	11-nor-9-carboxy-THC		92	17	ng/mL
69ZW6E	Phencyclidine (PCP)	✓			
	Delta-9-THC		25	6	ng/mL
	11-nor-9-carboxy-THC		95	24	ng/mL
6CXF6R	Phencyclidine	✓	Detected		
	Tetrahydrocannabinol (THC)		17	15%	ug/L
6RMMYJ	Phencyclidine (PCP)	✓			
	11-Nor-9-carboxy-delta9-tetrahydrocannabinol	✓			
6RNHNG	THC		25	5	ng/ml
	THC-COOH		114	18	ng/ml
6VMUJG	THC		25	18.74%	ng/mL
	THC-COOH		107	15.90%	ng/mL
6YM3QD	Delta-9-Tetrahydrocannabinol		18.0	2.57	ng/ml
	11-nor-9-Carboxy-Delta-9-Tetrahydrocannabinol		76	13.68	ng/ml
76WJY2	Phencyclidine	✓			
	Delta-9-THC		>20		ng/mL
	11-nor-9-carboxy-THC	✓			
7DM2DA	Phencyclidine (PCP)	✓			
	Delta-9-THC		21	4	ng/mL
	11-nor-9-carboxy-THC		98	18	ng/mL
7THLUX	THC		19	4	ng/mL
	Carboxy THC		85	14	ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
82MZ8J	THC		20.80	+/- 13%	ng/mL
	carboxy-THC	✓			
82RCVE	THC		27	5	ng/mL
	THC-COOH		114	18	ng/mL
8ALF2W	Phencyclidine		49.78	5.97	ng/mL
	THC		23.12	3.23	ng/mL
	THC-COOH		92.53	16.65	ng/mL
8JNXCZ	Phencyclidine (PCP)	✓			
	Delta-9-THC-COOH	✓			
8N3D4C	Phencyclidine (PCP)	✓			
	THC		25	6	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA)		99	25	ng/mL
94RZMA	Phencyclidine	✓			
	Delta-9-THC		21		ng/mL
	11-nor-9-carboxy-THC		95		ng/mL
9E9MWB	Phencyclidine	✓			
	Delta-9-THC		19		ng/mL
	11-nor-9-Carboxy-Delta-9-THC		76		ng/mL
9E9R8D	Phencyclidine (PCP)	✓			
	Delta-9-THC		17.7	3.2	ng/mL
	11-nor-9-carboxy-THC	✓			
9L6JJD	THC		21	18.74%	ng/mL
	THCCOOH		89	15.90%	ng/mL
9UNPH6	Tetrahydrocannabinol	✓			
	Carboxy-tetrahydrocannabinol	✓			

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
9WQNRD	THC		24	5	ng/mL
	THC-COOH		103	16	ng/mL
A8462V	PCP	✓			
	THC		17		ng/ml
	THC-COOH		85		ng/ml
ARQYNB	THC		25	18.74%	ng/ml
	carboxy THC		114	15.90%	ng/ml
BBLR99	Phencyclidine	✓			
	Tetrahydrocannabinol		26	6	ng/mL
	Carboxy-THC		99	25	ng/mL
BEHBB8	phencyclidine (PCP)		61		ng/mL
	delta-9-tetrahydrocannabinol		20		ng/mL
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		124		ng/mL
BKMCB2	PCP		29 ng/mL		
	Delta-9-THC		21 ng/mL		
	11-nor-Carboxy-THC		76 ng/mL		
BTXFFE	Phencyclidine (PCP)	✓			
	Delta-9-THC		24		ng/mL
	11-nor-9-carboxy-delta-9-THC		120		ng/mL
BUY9F9	Phencyclidine	✓			
	Delta9-THC		20		ng/mL
	11-nor-9-Carboxy-Delta-9-THC		102		ng/mL
CU8ZLU	Phencyclidine	✓			
	Delta-9-THC		Greater than 20		ng/mL
	11-nor-9-carboxy-THC	✓			
CYLKNA	Phencyclidine	✓			
	THC-COOH	✓			

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
CZG4PB	Phencyclidine (PCP)	✓			
	Delta-9 Tetrahydrocannabinol (THC)		17.0	+/- 3.1	ng/mL
	Delta-9 Carboxy THC (THC metabolite)	✓			
D333M7	Phencyclidine	✓			
	Delta-9-THC		16		ng/mL
	11-nor-9-carboxy-THC		73		ng/mL
D3GPYT	Phencyclidine	✓			
	Delta-9-THC		>20		ng/ml
	11-nor-9-carboxy-THC	✓			
DAH2VP	Phencyclidine		48.43	5.81	ng/ml
	THC		22.17	3.10	ng/ml
	THC-COOH		90.95	16.37	ng/ml
DQQXEN	THC		21	18.74%	ng/mL
	THC-COOH		87	15.90%	ng/mL
DTCHJT	Phencyclidine (PCP)	✓			
	Delta-9-THC		19.5	3.6	ng/mL
	Delta-9 Carboxy THC (THC metabolite)	✓			
EATAEA	Phencyclidine	✓			
EAXM37	Phencyclidine		42	±8	ng/mL
	delta-9-tetrahydrocannabinol		20	±4	ng/mL
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		90	±17	ng/mL
EC3D8Z	phencyclidine	✓			
	Delta-9-THC		18 ng/mL	3	ng/mL
	11-now-9-carboxy-THC		94 ng/mL	17	ng/mL
EDHCQP	THC		20	4	ng/mL
	Carboxy THC		85	14	ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
EHN6JZ	Phencyclidine (PCP)		44	9	ng/mL
	Delta-9-THC		23	6	ng/mL
	11-nor-9-carboxy-THC		109	26	ng/mL
EQHD26	Phencyclidine	✓			
	cannabinoids	✓			
ERDW48	Delta-9-THC		24	18.74%	ng/mL
	THC-COOH		103	15.90%	ng/mL
EVXLRQ	Tetrahydrocannabinol		23	6.0	ng/mL
	11-nor-9-Carboxy-THC		93	19	ng/mL
F7PV7B	Phencyclidine (PCP)	✓			
	Delta-9-THC	✓			
FDCNHA	Phencyclidine	✓			
	THC		20.62	± 2.68	ng/ml
	Carboxy THC	✓			
FJGK7G	(PCP) Phencyclidine	✓			
FN9UC9	PCP	✓			
	Tetrahydrocannabinol-carboxy-thc	✓			
FXJWXA	Delta-9-tetrahydrocannabinol		21		ug/L
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid		98		ug/L
FYVPUW	Phencyclidine (PCP)	✓			
	Delta-9-THC	✓			
	11-nor-9-carboxy-THC	✓			
GKQMUZ	PCP		58		ng/mL
	delta9-THC		20		ng/mL
	11-nor-9-carboxy-d9thc carboxy		115		ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
GVA796	Phencyclidine (PCP)	✓			
	Delta-9-THC		18.4	3.4	ng/mL
	11-nor-9-carboxy-THC	✓			
H33YT6	Phencyclidine	✓			
	Delta-9-THC		19.0	3.5	ng/mL
	11-nor-9-carboxy-THC	✓			
H97X9Z	Phencyclidine (PCP)		0.034	0.009	mg/L
	Delta-9-THC		20.8	6.2	ng/mL
	11-nor-9-carboxy-THC		112	31	ng/mL
HD3K3N	phencylcidine	✓			
	delta-9-THC	✓			
	delta-9-carboxy-THC	✓			
HEVFPX	phencyclidine	✓			
	Delta-9-THC		17	3	ng/mL
	11-nor-9-carboxy-THC		90	16	ng/mL
HHGZU2	Phencyclidine (PCP)		43.65	8.73	ng/mL
	Delta9-THC		23.51	4.71	ng/mL
	COOH-delta9-THC		94.57	18.92	ng/mL
HJCHV3	Phencyclidine		43.6	6.5	ng/mL
	Delta-9-tetrahydrocannabinol		19.8	4.0	ng/mL
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		86	18	ng/mL
J6RHGN	No drugs/metabolites detected utilizing confirmatory methods.				
JAHYN8	Cocaine		16.79	7.41	ng/ml
JDG92U	PCP		33.0	1.6	ng/mL
	Delta-9-THC		16.3	1.7	ng/mL
	Delta-9-Carboxy-THC		75.3	8.6	ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
JR4HMZ	Phencyclidine	✓			
	Delta-9-THC		20		ng/mL
	11-nor-9-Carboxy-delta-9-THC		82		ng/mL
KHU9V2	Phencyclidine (PCP)		39	±8	ng/ml
	Delta-9-THC		20	±4	ng/ml
	11-nor-9-carboxy-THC		89	±17	ng/ml
L2ETM2	Phencyclidine	✓			
	11-nor-9-carboxy-THC	✓			
L44VYG	Tetrahydrocannabinol (THC)		20	18.74%	ng/mL
	Carboxy-tetrahydrocannabinol (THC-COOH)		95	15.90%	ng/mL
LFXJL4	Phencyclidine	✓			
	THC		19.83	+/- 2.57	ng/mL
	Carboxy-THC	✓			
LJV3N3	PCP		39.9	6.8	ng/mL
	Delta-9-THC		17.5	3.6	ng/mL
	11-nor-9-carboxy-THC		75.3	15.9	ng/mL
LT9P6J	Tetrahydrocannabinol		23	6.0	ng/mL
	11-nor-9-Carboxy-THC		80	16	ng/mL
M43KEX	THC		24	18.74%	ng/mL
	THC-COOH		115	15.90%	ng/mL
MDQGHK	No drugs/metabolites detected utilizing confirmatory methods.				
MEHD6T	Phencyclidine	✓			
	Delta-9-THC		20	4	ng/mL
	THC-COOH		98	18	ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
MT3R8T	Phencyclidine (PCP)	✓			
	Delta-9-THC		17	3	ng/mL
	Nor-11-carboxy-9-THC		90	16	ng/mL
MVA8GJ	Phencyclidine	✓			
	Delta-9-THC		20,18		ng/mL
	11-nor-9-carboxy-THC		98,6		ng/mL
MW344T	phencyclidine	✓			
	delta-9-tetrahydrocannabinol		18	3	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid		96	17	ng/mL
N6T7KU	Phencyclidine	✓			
	Tetrahydrocannabinol		25	6	ng/mL
	Carboxy-THC		95	24	ng/mL
NC8RUX	THC		23	4	ng/mL
	THC-COOH		110	18	ng/mL
NM9FLV	PCP	✓			
NMQB83	phencyclidine	✓			
	11-nor-9-carboxy-THC	✓			
NQPM33	Phencyclidine (PCP)		45	7	ng/mL
	Delta-9 THC		20	3	ng/mL
	Delta-9 Carboxy THC		86	13	ng/mL
NUPVAY	Phencyclidine	✓			
	Delta-9 Tetrahydrocannabinol		17.7	3.2	ng/mL
	11 Nor-9 Carboxy Delta 9 THC	✓			
PBUPGX	Phencyclidine (PCP)	✓			
	Delta-9 THC		24	4	ng/mL
	Delta-9 Carboxy THC		123	23	ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
PNKA4G	Phencyclidine	✓			
	Delta-9-THC		above 19.7		
	11-nor-9-Carboxy-THC	✓			
QC2GRC	Tetrahydrocannabinol (THC)		22	18.74%	ng/mL
	Carboxy-Tetrahydrocannabinol (THC-COOH)		92	15.90%	ng/mL
QQ3VBU	PCP		41	±8	ng/mL
	delta-9-tetrahydrocannabinol		23	±4	ng/mL
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		0.10	±0.02	µg/mL
R7V8YN	Phencyclidine	✓			
	Delta-9-THC		19	3	ng/mL
	11-nor-9-carboxy-THC		98	18	ng/mL
RACEFW	Delta-9-THC		24	2	ng/mL
	11-nor-9-carboxy-THC		96	11	ng/mL
RYVNWT	THC		28	18.74%	ng/mL
	Carboxy THC		126	15.90%	ng/mL
T38TAE	PCP	✓			
	delta-9-THC		36	14%	ng/mL
	delta-9-THC-COOH		74	13%	ng/mL
TB4N8D	Phencyclidine (PCP)		37	11	ng/mL
	Delta-9-THC (THC)		18	3	ng/mL
	11-nor-9-carboxy-THC (THCCOOH)		84	16	ng/mL
UAL4UT	PCP	✓			
	Delta-9-THC		18.2	+/- 3.3	ng/mL
	11-nor-9-carboxy-THC	✓			
UEJHLP	Phencyclidine (PCP)	✓			
	Delta-9-THC		19		ng/mL
	11-nor-9-carboxy-THC		79		ng/mL

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
UHWFTC	Phencyclidine	✓			
	Delta-9Tetrahydrocannabinol (THC)		greater than 20		ng/mL
	Delta-9 Carboxy THC (THC metabolite)	✓			
UN22YU	Phencyclidine (PCP)		49	+/-17%	ng/mL
	Delta-9-Tetrahydrocannabinol (Delta-9-THC)		31	+/- 23%	ng/mL
	11-Nor-9-Carboxy-THC (Carboxy-THC), a metabolite of THC		0.11	+/-24%	ug/mL
UR2DVU	Phencyclidine	✓			
	Delta 9-THC		19.7	3.6	ng/mL
	11-nor-9-carboxy-THC	✓			
UXAUBA	Phencyclidine (PCP)	✓			
	Delta 9 THC	✓			
	11-nor-9-carboxy-THC	✓			
UZFC8J	Delta-9-THC	✓			
	11-nor-9-Carboxy-THC	✓			
V3YTZN	Phencyclidine	✓			
VMLHAG	Delta-9-tetrahydrocannabinol		17	4	ng/mL
	Delta-9-THC Acid		84	14	ng/mL
VNF7TC	Phencyclidine (PCP)	✓			
VWVTKT	Phencyclidine	✓			
	Delta-9-THC	✓			
	11-nor-9-carboxy-THC	✓			
VX7V8R	Phencyclidine	✓			
	Delta-9-THC	✓			
	11-nor-9-carboxy-THC	✓			

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
WGDDXM	Phencyclidine		42	±9	ng/mL
	delta-9-THC		20	±4	ng/mL
	Carboxy-THC		97	±18	ng/mL
WQ2AZA	Phencyclidine	✓			
	Delta-9-THC		>19.98		ng/mL
	11-nor-9-carboxy-THC	✓			
X6ZFLR	Phencyclidine (PCP)	✓			
XE3VDH	phencyclidine	✓			
	Delta-9-THC		20	4	ng/mL
	11-nor-9-carboxy-THC		0.10	0.02	mg/L
XMZKW8	Phencyclidine (PCP)	✓			
	Tetrahydrocannabinols (THC)	✓			
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCA)	✓			
XT673P	Phencyclidine (PCP)	✓			
	Delta-9-THC		17.9	3.3	ng/mL
	Delta-9-Carboxy-THC	✓			
Y4NX9E	phencyclidine (PCP)		47	3	ng/mL
	THC		26	3	ng/mL
	11-nor-9-carboxy-THC	✓			
Y8Z7AH	Phencyclidine		63		ng/mL
	delta-9-THC		21		ng/mL
	11-nor-9-carboxy-THC		106		ng/mL
YJVEV7	Phencyclidine (PCP)	✓			
	Delta-9-THC		> 20		ng/ml
	11-nor-9-Carboxy-THC	✓			

TABLE 1B: Confirmatory Results - Item 1

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
YN6HYM	Phencyclidine (PCP)	✓			
	Delta-9 Tetrahydrocannabinol (THC)		18.4	3.4	ng/mL
	Delta-9 Carboxy THC	✓			
YXCCXL	THC		30	18.74%	ng/mL
	THC-COOH		115	15.90%	ng/mL
Z2UNE4	Phencyclidine (PCP)	✓			
	Delta-9-THC	✓			
	11-nor-9-carboxy-THC	✓			
ZEF76L	THC		23	4	ng/mL
	THC-COOH		108	17	ng/mL
ZFBUGP	Phencyclidine (PCP)	✓			
	Delta-9-THC		21		ng/mL
	11-nor-9-carboxy-delta-9-THC		110		ng/mL
ZHZWT6	Phencyclidine (PCP)	✓			
	Tetrahydrocannabinols (THC)	✓			
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCA)	✓			
ZJ89B8	Phencyclidine (PCP)		44.07	6.16	ng/mL
	Delta-9-Tetrahydrocannabinol		24.93	4.73	ng/mL
	11-nor-9-Carboxy-Tetrahydrocannabinol		105.03	21.00	ng/mL

Confirmatory Response Summary for Item 1	Participants: 126
Phencyclidine (PCP):	95
Delta-9-THC:	109
11-nor-9-carboxy-THC:	113
Other identified drugs/metabolites:	1
No drugs/metabolites detected utilizing confirmatory methods:	2

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 1

TABLE 1C

Item 1 Raw Data - Phencyclidine (PCP)
Preparation concentration: 60 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean
28CJRC	47.800	44.400	46.100
8ALF2W	49.780		49.780
BEHBB8	61.500		61.500
BKMCB2	29.000		29.000
DAH2VP	48.430	48.690	48.560
EAXM37	42.090		42.090
EHN6JZ	44.000		44.000
GKQMUZ	58.300		58.300
H97X9Z	34.500		34.500
HHGZU2	43.650		43.650
HJCHV3	43.600		43.600
JDG92U	34.060	31.880	32.970
KHU9V2	39.568		39.570
LJV3N3	39.920		39.920
NQPM33	45.000		45.000
QQ3VBU	41.103		41.100
TB4N8D	37.610		37.610
UN22YU	49.079		49.080
WGDDXM	42.478		42.480
Y4NX9E	48.530	44.910	46.720
Y8Z7AH	63.900		63.900
ZJ89B8	44.070		44.070

Statistical Analysis for Item 1 - Phencyclidine (PCP) (ng/mL)

Grand Mean **44.70**

Standard Deviation **8.50**

Number of Participants Included **22**

Number of Participants Excluded **0**

by Critical H value of **2.580**

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - Delta-9-THC
Preparation concentration: 25 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
28CJRC	18.200		18.200	
3KUQ3H	27.090		27.090	
4UFZKK	31.000		31.000	X
4Y8J8Z	9.6000		9.6000	X
4Z33A3	19.860	20.860	20.360	
66DDZB	19.162	19.000	19.080	
69ZW6E	25.490		25.490	
6CXF6R	17.000	17.000	17.000	
6RNHNG	25.700		25.700	
6VMUJG	25.160		25.160	
6YM3QD	18.390		18.390	
76WJY2	20.460	20.950	20.710	
7DM2DA	20.890		20.890	
7THLUX	19.460		19.460	
82MZ8J	20.800		20.800	
82RCVE	27.900		27.900	
8ALF2W	23.120		23.120	
8N3D4C	25.810		25.810	
94RZMA	21.470		21.470	
9E9MWB	19.560		19.560	
9E9R8D	17.590	17.840	17.720	
9L6JJD	21.370		21.370	
9WQNRD	24.220		24.220	
A8462V	17.000		17.000	
ARQYNB	25.200		25.200	
BBLR99	26.980		26.980	
BEHBB8	20.900		20.900	
BKMCB2	21.000		21.000	
BTXFFE	23.860		23.860	
BUY9F9	20.950		20.950	

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - Delta-9-THC
Preparation concentration: 25 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)			Participant Mean
CU8ZLU	20.470	20.670		20.570
CZG4PB	17.090	16.930		17.010
D333M7	16.310			16.310
D3GPYT	20.570	21.650		21.110
DAH2VP	22.250	22.170		22.210
DQQXEN	21.900			21.900
DTCHJT	19.480	19.630		19.560
EAXM37	20.681			20.680
EC3D8Z	18.187			18.190
EDHCQP	20.040			20.040
EHN6JZ	23.000			23.000
ERDW48	24.000			24.000
EVXLRQ	23.240	24.600		23.920
FDCNHA	20.620			20.620
FXJWXA	21.455	21.050		21.250
GKQMUZ	20.900			20.900
GVA796	18.430	18.470		18.450
H33YT6	19.000	19.000		19.000
H97X9Z	20.805			20.800
HEVFPX	17.320			17.320
HHGZU2	23.513			23.510
HJCHV3	19.800			19.800
JDG92U	19.330	13.630	16.040	16.330
JR4HMZ	20.100			20.100
KHU9V2	20.267			20.270
L44VYG	20.920			20.920
LFXJL4	19.830			19.830
LJV3N3	17.510			17.510
LT9P6J	23.350	25.210		24.280
M43KEX	24.850			24.850

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - Delta-9-THC
Preparation concentration: 25 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
MEHD6T	19.860	19.630	19.740	
MT3R8T	17.050		17.050	
MVA8GJ	20.180		20.180	
MW344T	17.800		17.800	
N6T7KU	25.310		25.310	
NC8RUX	23.200		23.200	
NQPM33	20.000		20.000	
NUPVAY	17.720	17.790	17.760	
PBUPGX	24.580		24.580	
PNKA4G	20.210	19.710	19.960	
QC2GRC	22.730		22.730	
QQ3VBU	23.716		23.720	
R7V8YN	19.184		19.180	
RACEFW	24.333		24.330	
RYVNWT	28.590		28.590	
T38TAE	36.000		36.000	X
TB4N8D	18.910		18.910	
UAL4UT	17.710	18.720	18.220	
UEJHLP	19.450		19.450	
UHWFTC	20.920	21.390	21.160	
UN22YU	30.566		30.570	X
UR2DVU	19.820	19.760	19.790	
VMLHAG	16.900	16.200	16.550	
WGDDXM	20.553		20.550	
WQ2AZA	19.980	20.060	20.020	
XE3VDH	20.000		20.000	
XT673P	18.080	17.790	17.940	
Y4NX9E	26.080	25.260	25.670	
Y8Z7AH	21.400		21.400	
YJVEV7	22.450	21.080	21.770	

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - Delta-9-THC
Preparation concentration: 25 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
YN6HYM	18.470	18.450	18.460	
YXCCXL	30.880		30.880	X
ZEF76L	23.600		23.600	
ZFBUGP	21.180		21.180	
ZJ89B8	24.930		24.930	

Statistical Analysis for Item 1 - Delta-9-THC (ng/mL)

Grand Mean	21.15	Number of Participants Included	90
Standard Deviation	2.87	Number of Participants Excluded	5
		by Critical H value of	2.753

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - 11-nor-9-carboxy-THC
Preparation concentration: 100 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
28CJRC	95.900		95.900	
3KUQ3H	112.95		113.00	
4UFZKK	120.00		120.00	
4Y8J8Z	37.380		37.380	X
66DDZB	103.20	92.000	97.600	
69ZW6E	95.890		95.890	
6RNHNG	114.00		114.00	
6VMUJG	107.98		108.00	
6YM3QD	76.200		76.200	
7DM2DA	98.378		98.380	
7THLUX	85.090		85.090	
82MZ8J	91.610		91.610	
82RCVE	114.00		114.00	
8ALF2W	92.530		92.530	
8N3D4C	99.740		99.740	
94RZMA	95.000		95.000	
9E9MWB	76.900		76.900	
9L6JJD	89.630		89.630	
9WQNRD	103.00		103.00	
A8462V	85.000		85.000	
ARQYNB	114.00		114.00	
BBLR99	99.870		99.870	
BEHBB8	124.40		124.40	
BKMCB2	76.000		76.000	
BTXFFE	122.73		122.70	
BUY9F9	102.50		102.50	
D333M7	73.680		73.680	
DAH2VP	91.660	90.950	91.310	
DQQXEN	87.220		87.220	
EAXM37	90.871		90.870	

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - 11-nor-9-carboxy-THC
Preparation concentration: 100 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean
EC3D8Z	93.600		93.600
EDHCQP	85.300		85.300
EHN6JZ	109.00		109.00
ERDW48	103.18		103.20
EVXLRQ	93.760	96.290	95.030
FXJWXA	97.942	98.960	98.450
GKQMUZ	115.80		115.80
H97X9Z	112.52		112.50
HEVFPX	89.671		89.670
HHGZU2	94.573		94.570
HJCHV3	86.000		86.000
JDG92U	81.310	69.340	75.330
JR4HMZ	82.900		82.900
KHU9V2	89.897		89.900
L44VYG	95.160		95.160
LJV3N3	75.350		75.350
LT9P6J	80.470	86.530	83.500
M43KEX	115.27		115.30
MEHD6T	100.52	97.670	99.090
MT3R8T	89.901		89.900
MVA8GJ	98.600		98.600
MW344T	96.204		96.200
N6T7KU	95.060		95.060
NC8RUX	110.60		110.60
NQPM33	86.000		86.000
PBUPGX	123.32		123.30
QC2GRC	92.150		92.150
QQ3VBU	101.33		101.30
R7V8YN	97.691		97.690
RACEFW	96.588		96.590

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - 11-nor-9-carboxy-THC
Preparation concentration: 100 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean
RYVNWT	126.31		126.30
T38TAE	74.000		74.000
TB4N8D	84.270		84.270
UEJHLP	79.380		79.380
UN22YU	108.04		108.00
VMLHAG	85.800	81.900	83.850
WGDDXM	97.929		97.930
XE3VDH	100.00		100.00
Y4NX9E	102.45		102.50
Y8Z7AH	106.30		106.30
YXCCXL	115.35		115.40
ZEF76L	108.00		108.00
ZFBUGP	114.62		114.60
ZJ89B8	105.03		105.00

Statistical Analysis for Item 1 - 11-nor-9-carboxy-THC (ng/mL)

Grand Mean **97.62**

Standard Deviation **13.26**

Number of Participants Included **73**

Number of Participants Excluded **1**

by Critical H value of **2.741**

Reporting Procedures - Item 1

TABLE 1D - Item 1

WebCode	Quantitative Reporting Procedures
28CJRC	The sample is analyzed in duplicate, and the results have to be within +/-20% of their mean. The lowest of the two quantitative results is reported.
3KUQ3H	A single determination.
3X2H8C	A single determination.
47C7EH	The mean of duplicate/several determinations.
4UFZKK	A single determination.
4Y8J8Z	A single determination.
4Z33A3	The mean of duplicate/several determinations.
66DDZB	The mean of duplicate/several determinations.
69ZW6E	A single determination.
6CXF6R	The mean of duplicate/several determinations.
6RNHNG	A single determination.
6VMUJG	A single determination.
6YM3QD	A single determination.
76WJY2	The mean of duplicate/several determinations.
7DM2DA	A single determination.
7THLUX	A single determination.
82MZ8J	A single determination.
82RCVE	A single determination.
8ALF2W	A single determination.
8N3D4C	A single determination.
94RZMA	A single determination.
9E9MWB	A single determination.
9E9R8D	The mean of duplicate/several determinations.
9L6JJD	A single determination.
9WQNRD	A single determination.
A8462V	A single determination.
ARQYNB	A single determination.
BBLR99	A single determination.
BEHBB8	A single determination.

TABLE 1D: Reporting Procedures - Item 1

WebCode	Quantitative Reporting Procedures
BKMCB2	A single determination.
BTXFFE	A single determination.
BUY9F9	A single determination.
CU8ZLU	The mean of duplicate/several determinations.
CZG4PB	The mean of duplicate/several determinations.
D333M7	A single determination.
D3GPYT	The mean of duplicate/several determinations.
DAH2VP	lowest of two quantitative values due to screen and confirmation being performed on the quantitative/confirmatory method
DQQXEN	A single determination.
DTCHJT	The mean of duplicate/several determinations.
EAXM37	A single determination.
EC3D8Z	A single determination.
EDHCQP	A single determination.
EHN6JZ	A single determination.
ERDW48	A single determination.
EVXLRQ	The lowest duplicate concentration
FDCNHA	A single determination.
FXJWXA	The mean of duplicate/several determinations.
GKQMUZ	A single determination.
GVA796	The mean of duplicate/several determinations.
H33YT6	The mean of duplicate/several determinations.
H97X9Z	A single determination.
HEVFPX	A single determination.
HHGZU2	A single determination.
HJCHV3	A single determination.
JAHYN8	A single determination.
JDG92U	The mean of duplicate/several determinations.
JR4HMZ	A single determination.
KHU9V2	A single determination.
L44VYG	A single determination.

TABLE 1D: Reporting Procedures - Item 1

WebCode	Quantitative Reporting Procedures
LFXJL4	A single determination.
LJV3N3	A single determination.
LT9P6J	The lowest of the duplicates
M43KEX	A single determination.
MEHD6T	Delta-9-THC-The mean of Duplicate/several determinations, THC-COOH-single determination
MT3R8T	A single determination.
MVA8GJ	A single determination.
MW344T	A single determination.
N6T7KU	A single determination.
NC8RUX	A single determination.
NQPM33	A single determination.
NUPVAY	The mean of duplicate/several determinations.
PBUPGX	A single determination.
PNKA4G	The mean of duplicate/several determinations.
QC2GRC	A single determination.
QQ3VBU	A single determination.
R7V8YN	The mean of duplicate/several determinations.
RACEFW	A single determination.
RYVNWT	A single determination.
T38TAE	A single determination.
TB4N8D	A single determination.
UAL4UT	The mean of duplicate/several determinations.
UEJHLP	A single determination.
UHWFTC	The mean of duplicate/several determinations.
UN22YU	A single determination.
UR2DVU	The mean of duplicate/several determinations.
VMLHAG	The mean of duplicate/several determinations.
WGDDXM	A single determination.
WQ2AZA	The mean of duplicate/several determinations.

TABLE 1D: Reporting Procedures - Item 1

WebCode	Quantitative Reporting Procedures
XE3VDH	First quantitative Cannabinoid was higher than the highest calibrator for the two quantitated analytes, and the testing was repeated with reduced specimen to get concentration to fall on the calibration curve.
XT673P	The mean of duplicate/several determinations.
Y4NX9E	The mean of duplicate/several determinations.
Y8Z7AH	A single determination.
YN6HYM	The mean of duplicate/several determinations.
YXCCXL	A single determination.
ZEF76L	A single determination.
ZFBUGP	A single determination.
ZJ89B8	A single determination.

Response Summary for Item 1		Participants: 97
A single determination:	66	(68.0%)
The mean of duplicate/several determinations:	25	(25.8%)
Other:	6	(6.2%)

Methods of Analysis - Item 1

TABLE 1E - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
27ZRVP	GC/MS	✓		
28CJRC	LC/MS/MS	✓	✓	✓
	GC/MS/MS		✓	✓
2R2ZW7	GC/MS		✓	
3KUQ3H	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓
3L7B8L	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
	LC-QTOF-MS	✓	✓	
3X2H8C	Immunoassay	✓		
	LC/MS		✓	
47C7EH	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
4CX2FM	Immunoassay	✓		
4UFZKK	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	✓
4Y8J8Z	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	✓
4Z33A3	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
634A8K	Immunoassay	✓		
66DDZB	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
69ZW6E	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
6CXF6R	LC-QTOF-MS	✓	✓	
	LC/MS/MS	✓	✓	
6RMMYJ	Immunoassay	✓		
	LC-QTOF	✓		
	GC/MS		✓	
6RNHNG	Immunoassay	✓		
	LC/MS/MS		✓	✓
6VMUJG	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
6YM3QD	Immunoassay	✓		
	LC/MS/MS	✓	✓	
76WJY2	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
7DM2DA	LC-HRMSMS	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
7FQWWC	Immunoassay	✓		
7THLUX	Immunoassay	✓		
	LC/MS/MS		✓	✓
82MZ8J	LC/MS/MS	✓	✓	✓
82RCVE	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS	✓	✓	
8ALF2W	LC/MS/MS	✓	✓	✓
8JNXCZ	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
8N3D4C	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
	LC/MS		✓	✓
94RZMA	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
9E9MWB	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
9E9R8D	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS			✓
9L6JJD	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS	✓	✓	
	GC/FID		✓	✓
9UNPH6	Immunoassay	✓		
	LC/MS/MS		✓	
9WQNRD	LC/MS/MS		✓	✓
A8462V	LC/MS/MS	✓	✓	✓
	GC/MS	✓	✓	✓
ARQYNB	Immunoassay	✓		
	LC/MS		✓	✓
BBLR99	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
BEHBB8	Immunoassay	✓		
	LC/MS/MS		✓	✓
BKMCB2	Immunoassay	✓		
	GC/MS		✓	✓
BTXFFE	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
BUY9F9	Immunoassay	✓		
	LC/MS/MS		✓	✓
CHEJU8	LC/MS/MS	✓		
CU8ZLU	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
CYLKNA	LC/MS/MS	✓		
	LC-QTOF	✓	✓	
	GC/MS	✓	✓	
CZG4PB	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS		✓	✓
D333M7	Immunoassay	✓		
	LC/MS	✓	✓	✓
D3GPYT	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
DAH2VP	LC/MS/MS	✓	✓	✓
DQQXEN	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS	✓	✓	
	GC-FID		✓	✓
DTCHJT	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
EATAEA	Immunoassay	✓		
	GC/MS		✓	
	UPLC-QTOF		✓	
EAXM37	Immunoassay	✓		
	LC/MS/MS		✓	✓
EC3D8Z	LC/MS/MS		✓	✓
	LC-HRMS/MS	✓		
	GC/MS	✓	✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
EDHCQP	Immunoassay	✓		
	LC/MS/MS		✓	✓
EHN6JZ	LC/HRAM/MS	✓		
	LC/MS/MS		✓	✓
EQHD26	Immunoassay	✓		
	LC-QTOF	✓	✓	
ERDW48	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
EVXLRQ	Immunoassay	✓		
	LC/MS/MS		✓	✓
F7PV7B	LC/MS/MS	✓	✓	
FDCNHA	LC/MS/MS	✓	✓	
FJGK7G	GC/MS	✓		
	LC/MS/MS		✓	
FN9UC9	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	
FXJWXA	High resolution accurate mass LC/MS	✓		
	LC/MS/MS			✓
FYVPUW	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS/MS		✓	
GKQMUZ	Immunoassay	✓		
	LC/MS/MS		✓	
GVA796	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
H33YT6	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
H97X9Z	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓
HD3K3N	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
HEVFPX	LC-HRMS/MS	✓		
	GC/MS		✓	
	LC/MS/MS			✓
HHGZU2	LC/MS/MS	✓	✓	✓
HJCHV3	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓
J6RHGN	LC-QTOF	✓		
	GC/MS	✓	✓	
JAHYN8	LC/MS/MS	✓	✓	✓
JDG92U	LC/MS/MS		✓	✓
	LC-QTOF	✓	✓	
	Immunoassay	✓		
JR4HMZ	Immunoassay	✓		
	LC/MS/MS		✓	✓
KHU9V2	Immunoassay	✓		
	LC/MS/MS		✓	✓
KKY2RK	LC/MS/MS	✓		
L2ETM2	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
L44VYG	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
LFXJL4	LC/MS/MS	✓	✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
LJV3N3	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
LT9P6J	Immunoassay	✓		
	LC/MS/MS		✓	✓
M43KEX	Immunoassay	✓		
	LC/MS		✓	✓
	GC/MS	✓		
MDQGHK	LC/MS/MS	✓	✓	
MEHD6T	LC/HRMS/MS	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
MT3R8T	LC-HRMS/MS	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
MVA8GJ	LC/MS/MS	✓	✓	
	GC/MS		✓	✓
MW344T	LC-HRMS/MS	✓	✓	
	LC/MS/MS		✓	✓
N6T7KU	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
NC8RUX	Immunoassay	✓		
	LC/MS/MS		✓	✓
NM9FLV	Randox Investigator Immunoassay	✓		
	LC/MS		✓	
NMQB83	GC/MS	✓	✓	
NQPM33	LC-TOF	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
NUPVAY	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
PBUPGX	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	✓
PNKA4G	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
QC2GRC	LC/MS/MS		✓	✓
	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
QQ3VBU	Immunoassay	✓		
	LC/MS/MS		✓	✓
R7V8YN	LC-HRMS/MS	✓		
	LC/MS		✓	✓
RACEFW	Immunoassay	✓		
	LC/MS/MS		✓	✓
RYVNWT	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
	GC/FID		✓	✓
T38TAE	LC/MS/MS	✓	✓	✓
	GC/MS		✓	
T6EB7P	Randox Evidence MutiStat DOA Blood Assays	✓		
TB4N8D	Immunoassay	✓		
	LC/MS/MS		✓	✓
UAL4UT	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
UEJHLP	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
UHWFTC	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
UN22YU	Immunoassay	✓		
	LC/MS		✓	✓
	GC/MS		✓	
UR2DVU	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS			✓
UXAUBA	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
UZFC8J	Immunoassay	✓		
	LC/MS/MS		✓	
V3YTZN	Immunoassay	✓		
	LC-QTOF	✓	✓	
VMLHAG	Immunoassay	✓		
	LC/MS/MS		✓	✓
VNF7TC	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
VWVTKT	LC/MS/MS	✓	✓	
VX7V8R	GC/MS	✓		
	LC/MS/MS	✓	✓	
	LC-HRMS	✓		
WGDDXM	Immunoassay	✓		
	LC/MS/MS		✓	✓
WQ2AZA	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
X6ZFLR	Immunoassay	✓		
	GC/MS		✓	
	LC-QTOF-MS		✓	
XE3VDH	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
XMZKW8	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
XT673P	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
Y4NX9E	LC/MS/MS	✓	✓	✓
	LC-QTOF-MS	✓		
Y8Z7AH	Immunoassay	✓		
	LC/MS/MS		✓	✓
YJVEV7	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS		✓	✓
YN6HYM	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
YQCUGN	Immunoassay	✓		
YXCCXL	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓
Z2UNE4	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
ZEF76L	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
ZFBUGP	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
ZHZWT6	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
ZJ89B8	LC/MS/MS	✓	✓	✓
	GC/MS		✓	✓

Response Summary for Item 1 - Methods of Analysis **Participants: 134**

	Screening	Confirmatory	Quantitation
Immunoassay:	92	0	0
GC/MS:	41	69	9
LC/MS:	1	10	8
LC/MS/MS:	31	100	81
LC-QTOF:	6	4	0
LC-QTOF-MS:	9	3	0
Other:	15	9	6

Additional Comments for Item 1

TABLE 1F

WebCode	Item Comments
27ZRVP	Extraction with Acetonitrile and Quechers. Washing of remaining aqueous extract with Hexane. Acidification, and extraction with DCM with and without derivatization . Sample volume : 600 uL. Derivatization : BSTFA (50 uL) + EtOAc (100 uL). Washing of remaining aqueous extract with Hexane. Basification, and extraction with DCM with and without derivatization . Sample volume : 600 uL. Derivatization : BSTFA (50 uL) + EtOAc (100 uL). Washing of remaining aqueous extract with Hexane. Basification, and extraction with EtOAc with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL). Basification, and extraction with Hexane:EtOAc (9:1) with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL).
28CJRC	Phencyclidine lower limit of quantitation (LLOQ) is 2 ng/mL with a working range of 2-100 ng/mL. The internal standard used was Phencyclidine-D5. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. 11-nor-9-carboxy-THC (THCA) was screened using LC/MS/MS method and confirmed using the GC/MS/MS method: Delta-9-THC (THC) was confirmed on the GC/MS/MS with a cut off of 0.5 ng/mL and a working range of 0.5-20 ng/mL. The internal standard used was Delta-9-THC-D3. 11-nor-9-carboxy-THC (THCA) was confirmed on the GC/MS/MS with a cut off of 5 ng/mL and a working range of 5-200 ng/mL. The internal standard used was 11-nor-9-carboxy-THC-D9. The extraction method used was Liquid/Liquid targeting free, nonconjugated/nonprotien bound, compounds. NOTE: Cannabinoids quantitative (GC/MS/MS) analysis results were reported from a single determination.
2R2ZW7	THE PARTICIPANT DID NOT SCREENING ITEM 1, BUT THE OPTION SELECTED IN ITEM 1-1 CANNOT BE ELIMINATED.
3KUQ3H	I also found phencyclidine (PCP) present in my basic drug analysis. This drug however is not confirmed in our laboratory so a comment of "Testing indicates the possibility of drugs outside our scope of analysis" was added to my final report. This case would be sent to an independent lab if requested by the requesting officer for PCP. ELISA was used as the Immunoassay screening method. Mepivacaine was used as the internal standard for the basic drug analysis (GC/MS). Internal standards used for the Cannabinoids method were THC-OH-d3, THC-COOH-d3, and delta9-THC-d3. Expanded Uncertainty 95.45%, k=2
3X2H8C	Immunoassay: Cannabinoids (Carboxy-Tetrahydrocannabinol) cutoff 10ng/mL and Phencyclidine cutoff 5ng/mL. LC/MS: Carboxy-tetrahydrocannabinol LOQ 5ng/mL and Hydroxy-tetrahydrocannabinol and Tetrahydrocannabinol LOQ 1ng/mL. Internal standards Carboxy-tetrahydrocannabinol-D3, Hydroxy-tetrahydrocannabinol-D3 and Tetrahydrocannabinol-D3.
47C7EH	Drug Screen and Phencyclidine Extraction utilized Promazine as the Internal Standard. THC Quantitation utilized D3-Delta-9 THC and Qualitatively used D3-Delta-9 Carboxy THC as the Internal Standard.
4CX2FM	Screening testing only is performed.
66DDZB	Internal Standards: mepivacaine, delta-9-THC-d3, & 11-nor-9-carboxy-THC-d9. 11-nor-9-carboxy-THC: highest calibrator for this analyte in our laboratory is 100 ng/mL so quantitation results were not averaged and results were reported using only the on curve value.
69ZW6E	LC-QTOF-MS IS: Mepivacaine, GC/MS IS: Mepivacaine, LC/MS/MS IS: THC-D3, 11-OH-THC-D3, THCA-D3.
6CXF6R	Internal standards used for LC-QTOF-MS screen/confirmation were D3-Morphine, D3 Hydromorphine, D3 Oxycodone, D5 MA, D3 BZE, D5 Doxylamine, D3 Tramadol, D3 Cocaine, D6 Zolpidem, D5-Fentanyl, D4 Buprenorphine, D3 Nortriptyline, D3 Methadone, D3 Sertraline, D9 25-NB2OMe, D5 desmethyldiazepam. Internal standard used for THC analysis (LC/MS/MS) is D3 Tetrahydrocannabinol and limit of reporting for THC = 1 ug/L.
6VMUJG	Phencyclidine was found in our GCMS method, however it is not included in our calibrators or controls. This drug is outside our scope of analysis so we are unable to quantitate or call it positive.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
7DM2DA	Delta-9-THC Internal standard=Delta-9-THC-d3. Limit of detection=1.0 ng/mL. 11-nor-9-carboxy-THC internal standard=11-nor-9-carboxy-THC. Limit of detection=5.0 ng/mL. Phencyclidine (PCP) internal standard=mepivacaine.
7THLUX	Cannabinoids confirmation panel: Analyte Quantitative Range (ng/mL) THC 0.5 – 50 Hydroxy THC 0.5 – 50 Carboxy THC 5.0 - 500 Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses. Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Meprobamate 100 Barbiturates 50 Methadone 10 Benzodiazepines 10 Opiates 10 Buprenorphine 1 Opioids 10 Cannabinoids 10 Phencyclidine 5 Benzoylecgonine 50 TCA 25 Dextromethorphan 5 Tramadol 5 Fentanyl 1 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive.
82MZ8J	Preliminary testing indicates the possible presence of phencyclidine (PCP); confirmatory was testing not pursued due to the presence of other compounds. PCP is included in an infrequently run method. Due to the cost to perform the analysis, if we have an indication of a drug that is part of that method, we typically put a statement on the report like the one above.
8ALF2W	THC/metabolite isomers are not determined on screen or confirmation methods. THC LOQ 1ng/mL; ISTD Delta-9-THC-d3; Linear range 1-500ng/mL THC-COOH LOQ 5ng/mL; ISTD 11-nor-9-carboxy-THC-d9; Linear range 5-500ng/mL Phencyclidine LOQ 5ng/mL; ISTD Phencyclidine-d5; Linear range 5-500ng/mL
8JNXCZ	Delta-9-THC was screened as positive on GC/MS but was unable to be confirmed by subsequent SPE extractions and confirmatory testing on GC/MS. Therefore Delta-9-THC is found to be unconfirmed. Internal standards used for GC/MS include Phenyltoloxamine, Hexobarbital, and 11-OH-delta 9-THC-d3-diTMS. The low limit of detection on the analytes and/or analyte groups on ELISA immunoassay are as follows: 10 ng/mL THC-COOH, 20 ng/mL d-Methamphetamine, 10ng/mL Oxycodone, 2ng/mL Fentanyl, 20ng/mL d-Amphetamine, 150ng/mL Carisoprodol, 50ng/mL Benzoylecgonine, 25ng/mL Methadone, 10ng/mL Morphine, 50ng/mL Oxazepam, 10 ng/mL Phencyclidine, 50ng/mL Secobarbital, 50ng/mL Tramadol, and 10ng/mL Zolpidem.
8N3D4C	Internal standards used, mepivacaine (LC-QTOF-MS, GC/MS), and for LC/MS: THC-D3, 11-OH-THC-D3, THCA-D3. Limit of Detection for THC and 11-OH-THC: 1 ng/mL, THCA: 5ng/mL
9E9R8D	ELISA cut-off for THC is 5 ug/L. Internal standards for THC Quantitation for blood are Delta-9-THC D3 and Delta-9-Carboxy-THC D3. Reporting Limit for Delta-9-THC is 2 ng/mL. ELISA cut-off for PCP is 20 ug/L. Internal standard for GC/MS drug screening is Promazine.
9L6JJD	Testing indicates the possibility of drugs outside our scope of analysis. The drug PCP was indicated.
9UNPH6	Immunoassay: Cannabinoids cutoff 10ng/mL. THC and OH-THC LOQ 1ng/mL, C-THC LOQ 5ng/mL. Internal standards: THC-D3, OH-THC-D3, C-THC-D3.
ARQYNB	Evidence of a drug that is outside our scope of testing.
BBLR99	[From Table 1A - Screening Results]: CNS Stimulants - Methamphetamine/MDA. Note: Immunoassay kit is specific for these two compounds but does not provide definitive identification of one compound over another. The indication by immunoassay of these CNS stimulants was not confirmed in subsequent analysis of the specimen.
BKMCB2	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP.
CU8ZLU	Both Delta-9-THC aliquots greater than the highest calibrator, 20 ng/mL.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
DAH2VP	THC/metabolite isomers are not determined on screen or confirmation methods. Sample was screened and confirmed using two extractions run on the confirmation/quantitative method with the lower of the two results utilized for reporting. Phencyclidine linear range is 5ng/ml-500ng/ml with Phencyclidine-d5 utilized as the ISTD. THC linear range is 1ng/ml-500ng/ml with Delta-9-THC-d3 utilized as the ISTD. THC-COOH linear range is 5ng/ml-500ng/ml with 11-nor-9-carboxy-THC-d9 utilized as the ISTD.
DQQXEN	Phencyclidine indicated on mass spectrometer, could not confirm because we do not test for it.
EAXM37	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive phencyclidine screen, confirmation/quantitation of phencyclidine (PCP) is performed using PCP-D5 as the internal standard. LOD for PCP is 0.5 ng/mL; LOQ for PCP is 1 ng/mL. Following a positive cannabinoid screen, confirmation/quantitation of delta-9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (carboxy-THC), and 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) is performed using THC-D3, carboxy-THC-D3, and 11-OH-THC-D3 as internal standards, respectively. LOD for THC and 11-OH-THC is 0.5 ng/mL; LOD for carboxy-THC is 2.5 ng/mL. LOQ for THC and 11-OH-THC is 1 ng/mL; LOQ for carboxy-THC is 5 ng/mL.
EDHCQP	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Barbiturates 50 Benzodiazepines 10 Buprenorphine 1 Cannabinoids 10 Benzoylecgonine 50 Dextromethorphan 5 Fentanyl 1 Meprobamate 100 Methadone 10 Opiates 10 Opioids 10 Phencyclidine 5 TCA 25 Tramadol 5 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive. Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Analyte Quantitative Range (ng/mL) THC 0.5 – 50 Hydroxy THC 0.5 – 50 Carboxy THC 5.0 - 500
ERDW48	Screening test with ELISA was positive but at edge of cut-off for buprenorphine. However, no buprenorphine was present on confirmation using LC/MS/MS. In the basic/neutral extraction, 1 drug was present but is outside our scope of testing and therefore, was not confirmed. This drug was PCP. It is only reported as drug outside scope of testing.
EVXLRQ	Item 1 screened presumptive positive for tramadol and phencyclidine (PCP). The [Laboratory] is not currently able to confirm and quantitate these classes of drugs. These results are presumptive only. Item 1 was analyzed using Immunoassay Drug Screen and Cannabinoids Confirmation via LC-MS/MS. The scope of testing for both methods is listed below. Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem Cannabinoids Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: THC, 11-nor-9-Carboxy-THC, 11-Hydroxy-THC Qualitatively: delta-8-THC, 11-nor-9-Carboxy-delta-8-THC
F7PV7B	PCP LOD: 20ng/mL Delta-9-THC LOD: 1 ng/mL
FDCNHA	THC uncertainty K3 13%
FN9UC9	Codeine-D3 was used as the internal standard.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
FXJWXA	The result reported above for delta-9-tetrahydrocannabinol does not include a deduction for analytical variation, in accordance with the [State Guidelines]. Quantitative results were obtained using a dedicated Section 5A method. The blood was examined for the full panel of Section 5A drugs (6-monoacetylmorphine (6-MAM, from heroin use), amphetamine, benzoylecgonine (from cocaine use), clonazepam, cocaine, diazepam, flunitrazepam, ketamine, lorazepam, lysergic acid diethylamide (LSD), methadone, methylamphetamine, methylenedioxymethamphetamine (MDMA, 'ecstasy'), morphine, oxazepam, temazepam and delta-9-tetrahydrocannabinol (THC, from cannabis use)) as well as etizolam, 11-hydroxy-delta-9-tetrahydrocannabinol (from cannabis use), 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (from cannabis use), commonly prescribed antidepressants, other amphetamine related compounds, other benzodiazepines, other opiates, zaleplon, zolpidem and a range of new psychoactive substances including cathinones, phenethylamines, piperazines, aminoindanes, pipradrols, tryptamines and synthetic cannabinoids. The sample was further analysed for alcohol, however the result was not available at time of submission.
GVA796	The internal standard used for the full panel drug screen procedure was promazine. The internal standards used for the THC quantitative method were delta-9-COOH THC d3 and delta-9-THC d3. Additionally, the limit of detection for this method is 2ng/mL for delta-9-THC and delta-9-COOH THC.
H33YT6	Butyl Acetate Internal Standard: Promazine THC Quantitation Deuterated Internal Standards: Delta-9-THC/11-nor-9-Carboxy-Delta 9-THC
H97X9Z	The immunoassay was positive for the cannabinoids and PCP categories. There is a 95.45% level of confidence for the uncertainty calculation.
HD3K3N	d3-delta-9-THC, d3-carboxy-thc used for istd. SKF-525a used for istd
HEVFPX	IS: mepivacaine, mephobarbital, delta-9-thc-d3, 11-OH-THC-d3, 11-nor-9-carboxy-thc-d9. LOR: delta-9-thc 1 ng/mL, 11-nor-9-carboxy-THC 5 ng/mL.
J6RHGN	ESTAZOLAM WAS USED AS INTERNAL ESTANDAR. IN THE METHODOLOGIES USED IN OUR LABORATORY, NO ANALYSES HAVE BEEN PERFORMED ON SHEEP BLOOD SAMPLES.
JAHYN8	Internal standard cocaine D-3 was used
JDG92U	Limit of Detection; Delta-9-THC - 1 ng/mL, Delta-9-Carboxy-THC - 5 ng/mL, PCP - 5 ng/mL. Internal standard for Delta-9-THC - Delta-9-THC-d3; Internal standard for Delta-9-Carboxy-THC - Delta-9-Carboxy-THC-d3; Internal standard for PCP - PCP-d5. Results for Delta-9-Carboxy-THC from analysis performed on 6/19/25 were qualitative only due to unacceptable quality control data and were not included in average result. PCP screened for via LC-QTOF.
KHU9V2	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Cannabinoid confirmation panel includes Delta-9-THC, Carboxy-THC and 11-Hydroxy-THC. LOD for Delta-9-THC and 11-Hydroxy-THC is 0.5 ng/ml and LOQ is 1 ng/ml. LOD for Carboxy-THC is 2.5 ng/ml and LOQ is 5 ng/ml. D-9-THC-D3, COOH-THC-D3 and 11-OH-THC-D3 used as internal standards. Phencyclidine (PCP) confirmation panel includes phencyclidine. LOD for PCP is 0.5 ng/ml and LOQ is 1 ng/ml. Phencyclidine-D5 is used as the internal standard.
L2ETM2	The cut-off value of phencyclidine and 11-nor-9-carboxy-THC is 10 ng/mL for GC/MS.
L44VYG	Internal Standard in GC/MS/FID is Mepivacaine. Internal Standard in LC/MS/MS confirmation is delta-9-THC-d3, THC-OH-d3, and THC-COOH-d3. Testing indicates the possibility of drugs outside our scope of analysis.
LJV3N3	Cannabinoids screened by ELISA and PCP screened by LC-Ion Trap. Internal standards - THC-D3, THC-COOH-D3, and PCP-D5. Cal 1 was dropped for three analytes due to Control 1 being out of range. Reportable ranges: THC - 5-100 ng/mL. THC-COOH - 10-200 ng/mL. PCP - 5-100 ng/mL. LODs: THC - 0.62 ng/mL. THC-COOH - 1.25 ng/mL. PCP - 1 ng/mL.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
LT9P6J	Item 1 screened presumptive positive for PCP, however our laboratory does not currently have the capability to confirm this drug so confirmation was not performed.
M43KEX	Phencyclidine identified via GC/MS. This drug is not part of our scope of testing.
MEHD6T	Internal standards-mephobarbital, mepivacaine, delta-9-tetrahydrocannabinol-d3, 11-hydroxy-delta-9-tetrahydrocannabinol-d3, 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid-d9 Limit of detection for delta-9-tetrahydrocannabinol and 11-hydroxydelta-9-tetrahydrocannabinol 1 ng/mL Limit of detection for 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid 5 ng/mL Calibration range for delta-9-tetrahydrocannabinol and 11-hydroxydelta- 9-tetrahydrocannabinol 1ng/mL-20 ng/mL Calibration range for 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid 5 ng/ mL-100 ng/mL Acetaminophen was also found in screen
MT3R8T	Internal Standard for LC-HRMS/MS: Mepivacaine and Mephobarbital Internal Standard for GC/MS: Mepivacaine Internal Standard for LC/MS/MS: THC-d3, THC-OH-d3, THC-COOH-d9
MW344T	mepivacaine internal standard for phencyclidine screening and confirmation mephobarbital internal standard for cannabinoid screening THC-d3 internal standard for THC quantitation THC-COOH-d9 internal standard for THC-COOH quantitation
NM9FLV	[From Table 1A: Screening Results - Item 1: Cannabinoids - THC.] Internal standard - PCP-D5. LOD 10 ng.
NQPM33	Sheep's blood produces a known fentanyl interferent on our screening method, and did appear presumptive positive in this testing. The opioid confirmation method is currently in development.
NUPVAY	Internal standard used for drug screen was Promazine. Internal standards used for THC quantitation was Delta-9 Tetrahydrocannabinol D3 and 11 Nor-9 Carboxy Delta 9 THC D3.
PBUPGX	5 ng/mL confirmation LOD for PCP. 1 ng/mL confirmation LOQ for Delta-9 THC. 5 ng/mL confirmation LOQ for Delta-9 Carboxy THC.
QC2GRC	GC/MS-FID Internal Standard: Mepivacaine. LC/MS/MS Internal Standards: delta9-THC-d3, THC-OH-d3, THC-COOH-d3. Testing indicates the possibility of drugs outside our scope of analysis via GC/MS.
QQ3VBU	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. LOD and LOQ for PCP are 0.5 ng/ml and 1 ng/ml, respectively. PCP-D5 is used as the internal standard. Cannabinoid confirmation panel includes delta-9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (carboxy-THC), and 11-hydroxy-delta-9-tetrahydrocannabinol (hydroxy-THC). LOD for THC and hydroxy-THC is 0.5 ng/mL; LOQ is 1 ng/mL. LOD for carboxy-THC is 2.5 ng/mL; LOQ is 5 ng/mL. delta-9-THC-D3, carboxy-THC-D3, and 11-OH-THC-D3 are used as internal standards.
R7V8YN	Internal Standards: Mepivacaine/Mephobarbital, delta-9THC, THC-OH, THC-COOH, Mepivacaine, Amphetamine d-11, Methamphetamine d-11, Benzoylecgonine d-8, Cocaine d-3 Amphetamine was present in the LCMSMS screen, but it was negative after further confirmation.
RACEFW	Phencyclidine screening cut off is 5 ng/mL. Phencyclidine (PCP) is not confirmed at our laboratory. It would be sent to a reference laboratory for quantitation. Cannabinoid screening cut off is 10 ng/mL. The cannabinoid quantification can confirm Delta-8 THC, Delta-9 THC, 11-OH THC, Delta-8 COOH, and Delta-9 COOH. The lower reporting limits are as follows; Delta-8 THC is 0.5 ng/mL, Delta-9 THC is 0.5 ng/mL, 11-OH THC is 1.0 ng/mL, Delta-9 COOH is 5.0 ng/mL, and Delta-8 COOH is qualitatively reported as positive only. Dilutions of the sample was prepared for analysis but not included in the raw data.
RYVNWT	PCP was identified via GC-MS. Drugs is outside of our scope and is unconfirmed.
T38TAE	Confirmatory method for PCP is GC/MS and confirmatory method for cannabinoids is LCMSMS.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
T6EB7P	Test result for Cannabinoids - "Positive for THC" (dropdown menu does not have that as an option) Test result for CNS STimulants - "Positive for BZG" (dropdown menu does not have that as an option for Cocaine) The Evidence MultiSTAT DOA Blood Assays competitive enzyme immunoassays run on the automated biochip array analyser, Evidence MultiSTAT. A competitive chemiluminescent immunoassay is employed for analysis. The Evidence MultiSTAT DOA Blood Assays provide only a preliminary analytical test result. The Evidence MultiSTAT DOA Blood Assay is designed for use only with human whole blood samples.
TB4N8D	Screening Performed on 05/28/2025 THC (Confirmation performed on 06/17/2025) Internal Standard: THC-D3 Limit of Detection: 1 ng/mL THCCOOH (Confirmation performed on 06/17/2025) Internal Standard: THCCOOH-D9 Limit of Detection: 4 ng/mL PCP (Confirmation performed on 06/03/2025) Internal Standard: PCP-D5 Limit of Detection: 1 ng/mL
UAL4UT	Promazine used as ISTD for GC/MS screening and PCP confirmation. Delta-9-THC-d3 and 11-nor-9-carboxy-THC-d3 used as ISTD for LC/MS/MS Cannabinoid testing. Limit of detection for both reported cannabinoids is 2 ng/mL.
UN22YU	PCP was confirmed by two confirmation tests as it is not part of our ELISA screening panel. Matched deuterated internal standards were used for quantitative values. LODs for reported compounds are as follows: Delta-9-THC: 1.0 ng/ml Carboxy-THC: 5.0 ng/ml (THC metabolite reporting is not isomer specific) PCP: 5.0 ng/ml
UR2DVU	1. 11-nor-9-carboxy-THC is reported as Delta 9-Carboxy-THC by laboratory. 2. Internal standards used: Promazine, Delta 9-THC-D3, and 11-nor-9-carboxy-THC-D3.
UZFC8J	Immunoassay Screening: Analyte/Cutoff (ng/mL) Amphetamine: 20 ng/mL Phenobarbital: 50 ng/mL Oxazepam: 10 ng/mL Lorazepam: 10 ng/mL Buprenorphine: 5 ng/mL C-THC: 10 ng/mL Benzoylecgonine: 50 ng/mL Dextromethorphan: 5 ng/mL Fentanyl: 2 ng/mL Oxycodone: 10 ng/mL Meprobamate: 100 ng/mL Methadone: 10 ng/mL Methamphetamine: 20 ng/mL Morphine: 10 ng/mL Phencyclidine: 5 ng/mL Tramadol: 5 ng/mL Nortriptyline: 60 ng/mL Zolpidem: 10 ng/mL Cannabinoid Confirmation Reporting Limits OH-THC: 1 ng/mL C-THC: 5 ng/mL THC: 1 ng/mL
V3YTZN	Cannabinoids indicated on report. Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, Triazolam-D4 IS used for LC-QTOF analysis.
VMLHAG	Screening: Immunoassay Quantitation: LC MS/MS (Sciex) IS: D3-delta-9-terahydrocannabinol delta-9-terahydrocannabinol_LOD: 0.2 ng/mL delta-9-tetrahydrocannabinoic acid_LOD: 0.5 ng/mL
VX7V8R	Traces of paracetamol was detected in the sample.
WGDDXM	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Phencyclidine confirmation uses PCP-D5 as internal standard. LOD for PCP is 0.5ng/ml, LOQ is 1ng/ml and ULOQ is 50ng/ml. Cannabinoid confirmation panel includes d-9-THC, carboxy-THC and hydroxy-THC. LOD for d-9-THC and hydroxy-THC is 0.5 ng/ml and LOQ is 1 ng/ml. LOD for carboxy-THC is 2.5 ng/ml and LOQ is 5 ng/ml. D-9-THC-D3, COOH-THC-D3 and 11-OH-THC-D3 used as internal standards.
XE3VDH	GC/MS Confirmatory: Phencyclidine LC-HRMS/MS Screening: Delta-9-THC, 11-nor-9-carboxy-THC, Phencyclidine LC/MS/MS Confirmatory/Quantitation: Delta-9-THC, 11-nor-9-carboxy-THC Internal Standards for Screening: Mepivacaine/Mephobarbital Internal Standards for GC/MS Confirmatory: Mepivacaine Internal Standards for LC/MS/MS Confirmatory/Quantitation: Delta-9-THC-d3, 11-nor-9-carboxy THC-d9, 11-hydroxy-THC-d3
XMZKW8	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS. Deuterated 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCA-D3), deuterated 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH-D3), and deuterated delta-9-tetrahydrocannabinol (THC-D3) are the internal standards used for cannabinoids analysis by LC/MS/MS.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
XT673P	Promazine used for internal standard for Drug Screen by GC/MS and PCP confirmation by GC/MS. Deuterated Delta-9-THC and Delta-9-Carboxy-THC was used for the internal standards for LC/MS/MS Delta-9-THC quantitation and Delta-9-Carboxy-THC confirmation respectively. Limit of quantitation for Delta-9-THC is 2.0 - 20.0 ng/mL.
YN6HYM	ISTD Drug Screen - Promazine THC Quant - Deuterated Delta-9 THC and Delta-9 THC-COOH
YQCUGN	Immunological Screen Cut-off blood: 9-Carboxy-THC 20ng/mL; Benzoylecgonine 25ng/mL; Amphetamines (AMP, MAMP, cross reaction MDMA) 20ng/mL; Opiates 10ng/mL; Generic Opioids & Oxycodone 10ng/mL; Methadone 10ng/mL, Benzodiazepines 10ng/mL; Barbiturates 50ng/mL; PCP 5ng/mL; Meprobamate 100ng/mL; Dextromethorphan 5ng/mL; Zolpidem 10ng/mL; Tricyclic Antidepressants 60ng/mL; Fentanyl 1ng/mL; Norbuprenorphine 1ng/mL, Tramadol 5ng/mL.
YXCCXL	Phencyclidine was seen in the Basic GC/MS testing, however, we do not confirm nor report this drug.
Z2UNE4	Our methods are only validated for human blood, therefore only qualitative results are reported for Item 1.
ZHZWT6	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS. Deuterated 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCA-D3), deuterated 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH-D3), and deuterated delta-9-tetrahydrocannabinol (THC-D3) are the internal standards used for cannabinoids analysis by LC/MS/MS.

Screening Results - Item 2

TABLE 2A

Item Scenario:

A 24 year old female was arrested after swerving across lanes on a busy highway. She claimed to have fallen asleep at the wheel. A blood specimen was collected 1 hour after arrest.

Item Contents and Preparation Concentration: No drugs/metabolites

WebCode	Category	Drug/Metabolite
27ZRVP	No drugs detected utilizing screening methods.	
28CJRC	No drugs detected utilizing screening methods.	
3KUQ3H	No drugs detected utilizing screening methods.	
3L7B8L	No drugs detected utilizing screening methods.	
3X2H8C	No drugs detected utilizing screening methods.	
47C7EH	No drugs detected utilizing screening methods.	
4CX2FM	No drugs detected utilizing screening methods.	
4UFZKK	No drugs detected utilizing screening methods.	
4Y8J8Z	No drugs detected utilizing screening methods.	
4Z33A3	No drugs detected utilizing screening methods.	
634A8K	No drugs detected utilizing screening methods.	
66DDZB	No drugs detected utilizing screening methods.	
69ZW6E	No drugs detected utilizing screening methods.	
6CXF6R	No drugs detected utilizing screening methods.	
6RMMYJ	No drugs detected utilizing screening methods.	
6RNHNG	No drugs detected utilizing screening methods.	
6VMUJG	No drugs detected utilizing screening methods.	
6YM3QD	No drugs detected utilizing screening methods.	
76WJY2	No drugs detected utilizing screening methods.	
7DM2DA	No drugs detected utilizing screening methods.	
7FQWWC	No drugs detected utilizing screening methods.	
7THLUX	No drugs detected utilizing screening methods.	
82MZ8J	No drugs detected utilizing screening methods.	
82RCVE	No drugs detected utilizing screening methods.	
8ALF2W	No drugs detected utilizing screening methods.	
8JNXCZ	No drugs detected utilizing screening methods.	
8N3D4C	No drugs detected utilizing screening methods.	
94RZMA	No drugs detected utilizing screening methods.	
9E9MWB	No drugs detected utilizing screening methods.	

TABLE 2 A: Screening Results - Item 2

WebCode	Category	Drug/Metabolite
9E9R8D	No drugs detected utilizing screening methods.	
9L6JJD	No drugs detected utilizing screening methods.	
9UNPH6	No drugs detected utilizing screening methods.	
9WQNRD	No drugs detected utilizing screening methods.	
A8462V	No drugs detected utilizing screening methods.	
ARQYNB	No drugs detected utilizing screening methods.	
BBLR99	No drugs detected utilizing screening methods.	
BEHBB8	No drugs detected utilizing screening methods.	
BKMCB2	No drugs detected utilizing screening methods.	
BTXFFE	No drugs detected utilizing screening methods.	
BUY9F9	No drugs detected utilizing screening methods.	
CHEJU8	No drugs detected utilizing screening methods.	
CU8ZLU	No drugs detected utilizing screening methods.	
CYLKNA	No drugs detected utilizing screening methods.	
CZG4PB	No drugs detected utilizing screening methods.	
D333M7	No drugs detected utilizing screening methods.	
D3GPYT	No drugs detected utilizing screening methods.	
DAH2VP	No drugs detected utilizing screening methods.	
DQQXEN	No drugs detected utilizing screening methods.	
DTCHJT	No drugs detected utilizing screening methods.	
EATAEA	No drugs detected utilizing screening methods.	
EAXM37	No drugs detected utilizing screening methods.	
EC3D8Z	No drugs detected utilizing screening methods.	
EDHCQP	No drugs detected utilizing screening methods.	
EHN6JZ	No drugs detected utilizing screening methods.	
EQHD26	No drugs detected utilizing screening methods.	
ERDW48	Analgesics	
EVXLRQ	Analgesics	Tramadol
	Cannabinoids	11-nor-9-carboxy-THC
F3UZQW	No drugs detected utilizing screening methods.	
F7PV7B	No drugs detected utilizing screening methods.	
FDCNHA	No drugs detected utilizing screening methods.	
FJGK7G	Miscellaneous	Zolpidem

TABLE 2 A: Screening Results - Item 2

WebCode	Category	Drug/Metabolite
FN9UC9	No drugs detected utilizing screening methods.	
FXJWXA	No drugs detected utilizing screening methods.	
FYVPUW	No drugs detected utilizing screening methods.	
GKQMUZ	No drugs detected utilizing screening methods.	
GVA796	No drugs detected utilizing screening methods.	
H33YT6	No drugs detected utilizing screening methods.	
H97X9Z	No drugs detected utilizing screening methods.	
HD3K3N	No drugs detected utilizing screening methods.	
HEVFPX	No drugs detected utilizing screening methods.	
HHGZU2	No drugs detected utilizing screening methods.	
HJCHV3	No drugs detected utilizing screening methods.	
J6RHGN	No drugs detected utilizing screening methods.	
JAHYN8	CNS Stimulants	Cocaine
JDG92U	No drugs detected utilizing screening methods.	
JR4HMZ	No drugs detected utilizing screening methods.	
KHU9V2	No drugs detected utilizing screening methods.	
KKY2RK	No drugs detected utilizing screening methods.	
L2ETM2	Benzodiazepines	Lorazepam
L44VYG	No drugs detected utilizing screening methods.	
LFXJL4	No drugs detected utilizing screening methods.	
LJV3N3	No drugs detected utilizing screening methods.	
LT9P6J	Cannabinoids	
M43KEX	Analgesics	
MDQGHK	No drugs detected utilizing screening methods.	
MEHD6T	No drugs detected utilizing screening methods.	
MT3R8T	No drugs detected utilizing screening methods.	
MVA8GJ	No drugs detected utilizing screening methods.	
MW344T	No drugs detected utilizing screening methods.	
N6T7KU	No drugs detected utilizing screening methods.	
NC8RUX	No drugs detected utilizing screening methods.	
NM9FLV	No drugs detected utilizing screening methods.	
NMQB83	No drugs detected utilizing screening methods.	
NQPM33	No drugs detected utilizing screening methods.	

TABLE 2 A: Screening Results - Item 2

WebCode	Category	Drug/Metabolite
NUPVAY	No drugs detected utilizing screening methods.	
PBUPGX	No drugs detected utilizing screening methods.	
PNKA4G	No drugs detected utilizing screening methods.	
QC2GRC	No drugs detected utilizing screening methods.	
QQ3VBU	No drugs detected utilizing screening methods.	
R7V8YN	No drugs detected utilizing screening methods.	
RACEFW	No drugs detected utilizing screening methods.	
RYVNWT	Analgesics	Buprenorphine
T38TAE	No drugs detected utilizing screening methods.	
T6EB7P	No drugs detected utilizing screening methods.	
TB4N8D	No drugs detected utilizing screening methods.	
UAL4UT	No drugs detected utilizing screening methods.	
UEJHLP	No drugs detected utilizing screening methods.	
UHWFTC	No drugs detected utilizing screening methods.	
UN22YU	No drugs detected utilizing screening methods.	
UR2DVU	No drugs detected utilizing screening methods.	
UXAUBA	No drugs detected utilizing screening methods.	
UZFC8J	No drugs detected utilizing screening methods.	
V3YTZN	No drugs detected utilizing screening methods.	
VMLHAG	No drugs detected utilizing screening methods.	
VNF7TC	No drugs detected utilizing screening methods.	
VWVTKT	No drugs detected utilizing screening methods.	
VX7V8R	No drugs detected utilizing screening methods.	
WGDDXM	No drugs detected utilizing screening methods.	
WQ2AZA	No drugs detected utilizing screening methods.	
X6ZFLR	No drugs detected utilizing screening methods.	
XE3VDH	No drugs detected utilizing screening methods.	
XMZKW8	No drugs detected utilizing screening methods.	
XT673P	No drugs detected utilizing screening methods.	
Y4NX9E	No drugs detected utilizing screening methods.	
Y8Z7AH	No drugs detected utilizing screening methods.	
YJVEV7	No drugs detected utilizing screening methods.	
YN6HYM	No drugs detected utilizing screening methods.	

TABLE 2 A: Screening Results - Item 2

WebCode	Category	Drug/Metabolite
YQCUGN	No drugs detected utilizing screening methods.	
YXCCXL	No drugs detected utilizing screening methods.	
Z2UNE4	Analgesics	Buprenorphine
ZEF76L	Cannabinoids	
ZFBUGP	No drugs detected utilizing screening methods.	
ZHZWT6	No drugs detected utilizing screening methods.	
ZJ89B8	No drugs detected utilizing screening methods.	

Screening Response Summary for Item 2 **Participants: 134**

Drug Category Totals

Analgesics	5
Cannabinoids	3
No drugs detected utilizing screening methods	124

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 2

TABLE 2B

Item Scenario:

A 24 year old female was arrested after swerving across lanes on a busy highway. She claimed to have fallen asleep at the wheel. A blood specimen was collected 1 hour after arrest.

Item Contents and Preparation Concentration: No drugs/metabolites

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2R2ZW7	No drugs/metabolites detected utilizing confirmatory methods.				
3KUQ3H	No drugs/metabolites detected utilizing confirmatory methods.				
3L7B8L	No drugs/metabolites detected utilizing confirmatory methods.				
4Y8J8Z	No drugs/metabolites detected utilizing confirmatory methods.				
69ZW6E	No drugs/metabolites detected utilizing confirmatory methods.				
6CXF6R	No drugs/metabolites detected utilizing confirmatory methods.				
6RNHNG	No drugs/metabolites detected utilizing confirmatory methods.				
6VMUJG	No drugs/metabolites detected utilizing confirmatory methods.				
7DM2DA	No drugs/metabolites detected utilizing confirmatory methods.				
82RCVE	No drugs/metabolites detected utilizing confirmatory methods.				
8JNXCZ	No drugs/metabolites detected utilizing confirmatory methods.				
8N3D4C	No drugs/metabolites detected utilizing confirmatory methods.				
9L6JJD	No drugs/metabolites detected utilizing confirmatory methods.				
9WQNRD	No drugs/metabolites detected utilizing confirmatory methods.				
BBLR99	No drugs/metabolites detected utilizing confirmatory methods.				
CYLKNA	No drugs/metabolites detected utilizing confirmatory methods.				

TABLE 2B: Confirmatory Results - Item 2

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
DAH2VP	No drugs/metabolites detected utilizing confirmatory methods.				
DQQXEN	No drugs/metabolites detected utilizing confirmatory methods.				
EATAEA	No drugs/metabolites detected utilizing confirmatory methods.				
EQHD26	No drugs/metabolites detected utilizing confirmatory methods.				
ERDW48	No drugs/metabolites detected utilizing confirmatory methods.				
EVXLRQ	No drugs/metabolites detected utilizing confirmatory methods.				
F3UZQW	No drugs/metabolites detected utilizing confirmatory methods.				
FDCNHA	No drugs/metabolites detected utilizing confirmatory methods.				
FJGK7G	Zolpidem	✓			
FN9UC9	No drugs/metabolites detected utilizing confirmatory methods.				
FXJWXA	No drugs/metabolites detected utilizing confirmatory methods.				
H33YT6	No drugs/metabolites detected utilizing confirmatory methods.				
H97X9Z	No drugs/metabolites detected utilizing confirmatory methods.				
HD3K3N	No drugs/metabolites detected utilizing confirmatory methods.				
J6RHGN	No drugs/metabolites detected utilizing confirmatory methods.				
JAHYN8	Cocaine		7.48	7.41	ng/ml
L2ETM2	No drugs/metabolites detected utilizing confirmatory methods.				
L44VYG	No drugs/metabolites detected utilizing confirmatory methods.				

TABLE 2B: Confirmatory Results - Item 2

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
LFXJL4	No drugs/metabolites detected utilizing confirmatory methods.				
LT9P6J	No drugs/metabolites detected utilizing confirmatory methods.				
M43KEX	No drugs/metabolites detected utilizing confirmatory methods.				
MDQGHK	No drugs/metabolites detected utilizing confirmatory methods.				
N6T7KU	No drugs/metabolites detected utilizing confirmatory methods.				
NC8RUX	No drugs/metabolites detected utilizing confirmatory methods.				
NM9FLV	No drugs/metabolites detected utilizing confirmatory methods.				
NMQB83	No drugs/metabolites detected utilizing confirmatory methods.				
QC2GRC	No drugs/metabolites detected utilizing confirmatory methods.				
RYVNWT	No drugs/metabolites detected utilizing confirmatory methods.				
TB4N8D	No drugs/metabolites detected utilizing confirmatory methods.				
UN22YU	No drugs/metabolites detected utilizing confirmatory methods.				
UR2DVU	No drugs/metabolites detected utilizing confirmatory methods.				
V3YTZN	No drugs/metabolites detected utilizing confirmatory methods.				
VNF7TC	No drugs/metabolites detected utilizing confirmatory methods.				
X6ZFLR	No drugs/metabolites detected utilizing confirmatory methods.				
XE3VDH	No drugs/metabolites detected utilizing confirmatory methods.				
XMZKW8	No drugs/metabolites detected utilizing confirmatory methods.				

TABLE 2B: Confirmatory Results - Item 2

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
YXCCXL	No drugs/metabolites detected utilizing confirmatory methods.				
Z2UNE4	No drugs/metabolites detected utilizing confirmatory methods.				
ZEF76L	No drugs/metabolites detected utilizing confirmatory methods.				
ZHZWT6	No drugs/metabolites detected utilizing confirmatory methods.				

Confirmatory Response Summary for Item 2	Participants: 56
Other identified drugs/metabolites: 2	
No drugs/metabolites detected utilizing confirmatory methods: 54	

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 2

TABLE 2C

WebCode	List of Raw Data Determinations (ng/mL)	Participant Mean

No Raw Data results were reported for this Drug/Analyte for Item 2.

Reporting Procedures - Item 2

TABLE 2D - Item 2

WebCode	Quantitative Reporting Procedures
JAHYN8	A single determination.

Response Summary for Item 2	Participants: 1
A single determination:	1 (100.0%)
The mean of duplicate/several determinations:	0 (0.0%)
Other:	0 (0.0%)

Methods of Analysis - Item 2

TABLE 2E - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
28CJRC	LC/MS/MS	✓		
2R2ZW7	GC/MS		✓	
3KUQ3H	Immunoassay	✓		
	GC/MS		✓	✓
3L7B8L	Immunoassay	✓		
	GC/MS	✓		
	LC-QTOF-MS	✓		
3X2H8C	Immunoassay	✓		
47C7EH	Immunoassay	✓		
	GC/MS	✓		
4CX2FM	Immunoassay	✓		
4UFZKK	Immunoassay	✓		
	LC-QTOF-MS	✓		
4Y8J8Z	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
4Z33A3	Immunoassay	✓		
	GC/MS	✓		
634A8K	Immunoassay	✓		
66DDZB	LC-HRMS/MS	✓		
	GC/MS	✓		
69ZW6E	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
6CXF6R	LC-QTOF-MS	✓	✓	
	LC/MS/MS	✓	✓	
6RMMYJ	Immunoassay	✓		
	LC-QTOF	✓		
6RNHNG	Immunoassay	✓		
	GC/MS		✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
6VMUJG	Immunoassay	✓		
	GC/MS		✓	✓
6YM3QD	Immunoassay	✓		
	LC/MS/MS	✓		
76WJY2	Immunoassay	✓		
	GC/MS	✓		
7DM2DA	LC-HRMSMS	✓		
	GC/MS		✓	
7FQWWC	Immunoassay	✓		
7THLUX	Immunoassay	✓		
82MZ8J	LC/MS/MS	✓		
82RCVE	Immunoassay	✓		
	GC/MS	✓	✓	
8ALF2W	LC/MS/MS	✓		
8JNXCZ	Immunoassay	✓		
	GC/MS	✓	✓	
8N3D4C	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
94RZMA	Immunoassay	✓		
	LC/MS/MS	✓		
9E9MWB	Immunoassay	✓		
	LC/MS/MS	✓		
9E9R8D	Immunoassay	✓		
	GC/MS	✓		
9L6JJD	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
9UNPH6	Immunoassay	✓		
9WQNRD	GC/MS	✓	✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
A8462V	LC/MS/MS	✓		
	GC/MS	✓		
ARQYNB	Immunoassay	✓		
	GC/MS	✓		
BBLR99	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
BEHBB8	Immunoassay	✓		
	LC/MS/MS	✓		
BKMCB2	Immunoassay	✓		
BTXFFE	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓		
	LC-QTOF	✓		
BUY9F9	Immunoassay	✓		
	LC/MS/MS	✓		
CHEJU8	LC/MS/MS	✓		
CU8ZLU	Immunoassay	✓		
	GC/MS	✓		
CYLKNA	LC/MS/MS	✓		
	LC-QTOF	✓	✓	
	GC/MS		✓	
CZG4PB	Immunoassay	✓		
	GC/MS	✓	✓	
D333M7	Immunoassay	✓		
	LC/MS	✓		
D3GPYT	Immunoassay	✓		
	GC/MS	✓		
DAH2VP	LC/MS/MS	✓	✓	
DQQXEN	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
DTCHJT	Immunoassay	✓		
	GC/MS	✓		
EATAEA	Immunoassay	✓		
	GC/MS		✓	
	UPLC-QTOF		✓	
EAXM37	Immunoassay	✓		
EC3D8Z	LC-HRMS/MS	✓		
EDHCQP	Immunoassay	✓		
EHN6JZ	LC/HRAM/MS	✓		
EQHD26	Immunoassay	✓		
	LC-QTOF	✓	✓	
ERDW48	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
EVXLRQ	Immunoassay	✓		
	LC/MS/MS		✓	✓
F3UZQW	Immunoassay	✓		
	LC-QTOF	✓		
	GC/MS	✓		
	LC/MS	✓		
F7PV7B	LC/MS/MS	✓	✓	
FDCNHA	LC/MS/MS	✓		
FJGK7G	GC/MS	✓	✓	
FN9UC9	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS	✓	✓	
FXJWXA	High resolution accurate mass LC-MS	✓		
	LC/MS/MS			✓
FYVPUW	Immunoassay	✓		
	LC/MS/MS	✓		
GKQMUZ	Immunoassay	✓		

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
GVA796	Immunoassay	✓		
	GC/MS	✓		
H33YT6	Immunoassay	✓		
	GC/MS	✓	✓	
H97X9Z	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
HD3K3N	Immunoassay	✓		
	GC/MS		✓	
HEVFPX	LC-HRMS/MS	✓		
HHGZU2	LC/MS/MS	✓		
HJCHV3	Immunoassay	✓	✓	
J6RHGN	LC-QTOF	✓		
	GC/MS	✓	✓	
JAHYN8	LC/MS/MS	✓	✓	✓
JDG92U	Immunoassay	✓		
	LC-QTOF	✓		
JR4HMZ	Immunoassay	✓		
	LC/MS/MS	✓		
KHU9V2	Immunoassay	✓		
KKY2RK	LC/MS/MS	✓		
L2ETM2	LC/MS/MS	✓	✓	
L44VYG	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
LFXJL4	LC/MS/MS	✓	✓	
LJV3N3	Immunoassay	✓		
	LC/MS/MS	✓		
LT9P6J	Immunoassay	✓		
	LC/MS/MS		✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
M43KEX	Immunoassay	✓		
	LC/MS/MS		✓	✓
MDQGHK	LC/MS/MS	✓	✓	
MEHD6T	LC/HRMS/MS	✓		
	GC/MS		✓	
MT3R8T	LC-HRMS/MS	✓		
MVA8GJ	LC/MS/MS	✓		
MW344T	LC-HRMS/MS	✓		
N6T7KU	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
NC8RUX	Immunoassay	✓		
	GC/MS		✓	
NM9FLV	Randox Investigator Immunoassay	✓		
	LC/MS		✓	
NMQB83	GC/MS	✓	✓	
NQPM33	LC-TOF	✓		
NUPVAY	Immunoassay	✓		
	GC/MS	✓		
PBUPGX	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS	✓		
PNKA4G	Immunoassay	✓		
	GC/MS	✓		
QC2GRC	GC/MS	✓	✓	
	Immunoassay	✓		
	GC/FID		✓	✓
QQ3VBU	Immunoassay	✓		
R7V8YN	LC-HRMS/MS	✓		
	GC/MS		✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
RACEFW	Immunoassay	✓		
RYVNWT	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
	GC/FID		✓	✓
T38TAE	LC/MS/MS	✓		
T6EB7P	Randox Evidence MutiStat DOA Blood Assays	✓		
TB4N8D	Immunoassay	✓		
	LC/MS/MS		✓	
UAL4UT	Immunoassay	✓		
	GC/MS	✓		
UEJHLP	Immunoassay	✓		
	LC/MS/MS	✓		
UHWFTC	Immunoassay	✓		
	GC/MS	✓		
UN22YU	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
UR2DVU	Immunoassay	✓		
	GC/MS	✓		
UXAUBA	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓		
UZFC8J	Immunoassay	✓		
V3YTZN	Immunoassay	✓		
	LC-QTOF	✓	✓	
	LC/MS/MS		✓	
VNF7TC	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
VWVTKT	LC/MS/MS	✓	✓	
WGDDXM	Immunoassay	✓		

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
WQ2AZA	Immunoassay	✓		
	GC/MS	✓		
X6ZFLR	Immunoassay	✓		
	GC/MS		✓	
	LC-QTOF-MS		✓	
XE3VDH	LC-HRMS/MS	✓		
	GC/MS		✓	
XMZKW8	Immunoassay	✓		
	GC/MS		✓	
XT673P	Immunoassay	✓		
	GC/MS	✓		
Y4NX9E	LC-QTOF-MS	✓		
	GC/MS	✓		
	LC/MS/MS	✓		
Y8Z7AH	Immunoassay	✓		
	LC/MS/MS	✓		
YJVEV7	Immunoassay	✓		
	GC/MS	✓		
YN6HYM	Immunoassay	✓		
	GC/MS	✓		
YQCUGN	Immunoassay	✓		
YXCCXL	GC/MS		✓	✓
	Immunoassay	✓		
Z2UNE4	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓	✓	
ZEF76L	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
ZFBUGP	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓		
	LC-QTOF	✓		
ZHZWT6	Immunoassay	✓		
	GC/MS		✓	
ZJ89B8	LC/MS/MS	✓		

Response Summary for Item 2 - Methods of Analysis **Participants: 132**

	Screening	Confirmatory	Quantitation
Immunoassay:	91	1	0
GC/MS:	43	40	3
LC/MS:	2	1	0
LC/MS/MS:	39	22	5
LC-QTOF:	9	3	0
LC-QTOF-MS:	9	2	0
Other:	14	6	5

Additional Comments for Item 2

TABLE 2F

WebCode	Item Comments
27ZRVP	Extraction with Acetonitrile and Quechers. Washing of remaining aqueous extract with Hexane. Acidification, and extraction with DCM with and without derivatization . Sample volume : 600 uL. Derivatization : BSTFA (50 uL) + EtOAc (100 uL). Washing of remaining aqueous extract with Hexane. Basification, and extraction with DCM with and without derivatization . Sample volume : 600 uL. Derivatization : BSTFA (50 uL) + EtOAc (100 uL). Washing of remaining aqueous extract with Hexane. Basification, and extraction with EtOAc with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL). Basification, and extraction with Hexane:EtOAc (9:1) with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL).
28CJRC	The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration.
3KUQ3H	ELISA was used as the Immunoassay screening method. Mepivacaine was used as the internal standard for the basic drug analysis (GC/MS).
47C7EH	Drug Screen utilized Promazine as the Internal Standard.
4CX2FM	Screening testing only is performed.
66DDZB	Internal Standards: mepivacaine.
69ZW6E	Mepivacaine was used as the internal standard for the LC-QTOF-MS screen and GC/MS confirmatory tests
6CXF6R	Internal standards used for LC-QTOF-MS screen/confirmation were D3-Morphine, D3 Hydromorphine, D3 Oxycodone, D5 MA, D3 BZE, D5 Doxylamine, D3 Tramadol, D3 Cocaine, D6 Zolpidem, D5-Fentanyl, D4 Buprenorphine, D3 Nortriptyline, D3 Methadone, D3 Sertraline, D9 25-NB2OMe, D5 desmethyldiazepam.
7THLUX	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Meprobamate 100 Barbiturates 50 Methadone 10 Benzodiazepines 10 Opiates 10 Buprenorphine 1 Opioids 10 Cannabinoids 10 Phencyclidine 5 Benzoylecgonine 50 TCA 25 Dextromethorphan 5 Tramadol 5 Fentanyl 1 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive.
8JNXCZ	Internal standards used for GC/MS include Phenyltoloxamine, Hexobarbital, and 11-OH-delta 9-THC-d3-diTMS. The low limit of detection on the analytes and/or analyte groups on ELISA immunoassay are as follows: 10 ng/mL THC-COOH, 20 ng/mL d-Methamphetamine, 10ng/mL Oxycodone, 2ng/mL Fentanyl, 20ng/mL d-Amphetamine, 150ng/mL Carisoprodol, 50ng/mL Benzoylecgonine, 25ng/mL Methadone, 10ng/mL Morphine, 50ng/mL Oxazepam, 10 ng/mL Phencyclidine, 50ng/mL Secobarbital, 50ng/mL Tramadol, and 10ng/mL Zolpidem.
8N3D4C	Internal standard used: mepivacaine
9E9R8D	Internal standard for GC/MS drug screening is Promazine.
BKMCB2	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP.
DAH2VP	Sample was screened and confirmed using two extractions run on the confirmation/quantitative method for Panel 2, Negative 2 and THC/metabolite panels; therefore, 3 panels were confirmed negative.
EAXM37	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a negative screen, no confirmation/quantitation is performed.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
EDHCQP	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Barbiturates 50 Benzodiazepines 10 Buprenorphine 1 Cannabinoids 10 Benzoylecgonine 50 Dextromethorphan 5 Fentanyl 1 Meprobamate 100 Methadone 10 Opiates 10 Opioids 10 Phencyclidine 5 TCA 25 Tramadol 5 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive.
ERDW48	Screening test with ELISA was positive but at edge of cut-off for buprenorphine. However, no buprenorphine was present on confirmation using LC/MS/MS. No basic/neutral drugs were detected.
EVXLRQ	Item 2 screened presumptive positive for tramadol. The [Laboratory] is not currently able to confirm and quantitate this class of drugs. These results are presumptive only. Item 2 was analyzed using Immunoassay Drug Screen and Cannabinoids Confirmation. The scope of both methods are listed below. Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem Cannabinoids Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: THC, 11-nor-9-Carboxy-THC, 11-Hydroxy-THC Qualitatively: delta-8-THC, 11-nor-9-Carboxy-delta-8-THC
FDCNHA	A finding of no drugs confirmed does not necessarily indicate that no drug was present; only that it was not confirmed during our analysis. This may be due to several reasons including: the drug was not present in the sample, the drug is not included in our testing panel, or the drug was present at a response level that is below our reporting limit.
FN9UC9	Codeine-D3 was used as the internal standard.
FXJWXA	The blood was examined for the full panel of Section 5A drugs (6-monoacetylmorphine (6-MAM, from heroin use), amphetamine, benzoylecgonine (from cocaine use), clonazepam, cocaine, diazepam, flunitrazepam, ketamine, lorazepam, lysergic acid diethylamide (LSD), methadone, methylamphetamine, methylenedioxymethamphetamine (MDMA, 'ecstasy'), morphine, oxazepam, temazepam and delta-9-tetrahydrocannabinol (THC, from cannabis use)) as well as etizolam, 11-hydroxy-delta-9-tetrahydrocannabinol (from cannabis use), 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (from cannabis use), commonly prescribed antidepressants, other amphetamine related compounds, other benzodiazepines, other opiates, zaleplon, zolpidem and a range of new psychoactive substances including cathinones, phenethylamines, piperazines, aminoindanes, pipradrols, tryptamines and synthetic cannabinoids. The sample was further analysed for alcohol, however the result was not available at time of submission.
GVA796	The internal standard used for the full panel drug screen procedure was promazine.
H33YT6	Butyl Acetate Internal Standard: Promazine
HD3K3N	SKF-525a and barbital used as istds.
HEVFPX	IS: mepivacaine, mephobarbital
J6RHGN	ESTAZOLAM WAS USED AS INTERNAL ESTANDAR. IN THE METHODOLOGIES USED IN OUR LABORATORY, NO ANALYSES HAVE BEEN PERFORMED ON SHEEP BLOOD SAMPLES.
JAHYN8	Cocaine D-3 was used as internal standard
JDG92U	Limit of detection on ELISA Immunoassay: Methamphetamine screen - 20 ng/mL d-methamphetamine, Barbiturate screen - 1000 ng/mL phenobarbital, Cannabinoids screen - 1 ng/mL Delta-9-Carboxy-THC
KHU9V2	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem.
L2ETM2	This item was analyzed for the LC/MS/MS method. Lorazepam was detected, but in the analysis this drug was below the cut-off value (60 ng/mL), so we did not report it.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
L44VYG	Internal Standard in GC/MS/FID is Mepivacaine.
LFXJL4	A finding of no drugs confirmed does not necessarily indicate that no drug was present; only that it was not confirmed during our analysis. This may be due to several reasons including: the drug was not present in the sample, the drug is not included in our testing panel, or the drug was present at a response level that is below our reporting limit.
LT9P6J	Scope of testing for screening and cannabinoids confirmation: Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem Cannabinoids Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: THC, 11-nor-9-Carboxy-THC, 11-Hydroxy-THC Qualitatively: delta-8-THC, 11-nor-9-Carboxy-delta-8-THC
MEHD6T	Internal standards-mephobarbital, mepivacaine acetaminophen and salicylic acid found in screen.
MT3R8T	Internal Standard for LC-HRMS/MS: Mepivacaine and Mephobarbital
MW344T	mepivacaine and mephobarbital internal standards used in screening
NQPM33	Sheep's blood produces a known fentanyl interferent on our screening method, and did appear presumptive positive in this testing. The opioid confirmation method is currently in development.
NUPVAY	Internal standard used for drug screen was Promazine.
QC2GRC	GC/MS-FID Internal Standard: Mepivacaine.
QQ3VBU	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem.
R7V8YN	Internal Standards: Mepivacaine/Mephobarbital, Mepivacaine
T6EB7P	The Evidence MultiSTAT DOA Blood Assays competitive enzyme immunoassays run on the automated biochip array analyser, Evidence MultiSTAT. A competitive chemiluminescent immunoassay is employed for analysis. The Evidence MultiSTAT DOA Blood Assays provide only a preliminary analytical test result. The Evidence MultiSTAT DOA Blood Assay is designed for use only with human whole blood samples.
TB4N8D	Screening performed on 05/28/2025 Confirmation performed on 06/03/2025
UAL4UT	Promazine used as ISTD for GC/MS screening.
UN22YU	The sample was not tested for the following: GHB Norbuprenorphine Certain antipsychotics, anticonvulsants, and antidepressants LSD Zolpiclone
UR2DVU	1. Internal standards used: Promazine.
UZFC8J	Immunoassay Screening: Analyte/Cutoff (ng/mL) Amphetamine: 20 ng/mL Phenobarbital: 50 ng/mL Oxazepam: 10 ng/mL Lorazepam: 10 ng/mL Buprenorphine: 5 ng/mL C-THC: 10 ng/mL Benzoylecgonine: 50 ng/mL Dextromethorphan: 5 ng/mL Fentanyl: 2 ng/mL Oxycodone: 10 ng/mL Meprobamate: 100 ng/mL Methadone: 10 ng/mL Methamphetamine: 20 ng/mL Morphine: 10 ng/mL Phencyclidine: 5 ng/mL Tramadol: 5 ng/mL Nortriptyline: 60 ng/mL Zolpidem: 10 ng/mL
V3YTZN	Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, Triazolam-D4 IS used for LC-QTOF analysis.
VX7V8R	Traces of paracetamol was detected in the sample.
WGDDXM	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
XE3VDH	Internal Standards LC-HRMS/MS Screening: Mepivacaine/Mephobarbital Internal Standards GC/MS Confirmatory: Mepivacaine
XMZKW8	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS.
XT673P	Promazine was the internal standard used for Drug Screen by GC/MS. Testing performed 5/27/25-6/4/25.
YN6HYM	ISTD Drug Screen - Promazine
YQCUGN	Immunological Screen Cut-off blood: 9-Carboxy-THC 20ng/mL; Benzoylecgonine 25ng/mL; Amphetamines (AMP, MAMP, cross reaction MDMA) 20ng/mL; Opiates 10ng/mL; Generic Opioids & Oxycodone 10ng/mL; Methadone 10ng/mL, Benzodiazepines 10ng/mL; Barbiturates 50ng/mL; PCP 5ng/mL; Meprobamate 100ng/mL; Dextromethorphan 5ng/mL; Zolpidem 10ng/mL; Tricyclic Antidepressants 60ng/mL; Fentanyl 1ng/mL; Norbuprenorphine 1ng/mL, Tramadol 5ng/mL.
Z2UNE4	Screening indicated possible salicylic acid. Confirmatory test was negative.
ZHZWT6	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS.

Screening Results - Item 3

TABLE 3A

Item Scenario:

Toxicological analysis was performed following the death of a 32 year old man who had fallen off a raised outdoor deck at his residence. A post-mortem examination determined internal and external hemorrhage as the cause of death. His wife informed authorities about his behavior minutes prior to the fall, including panic, incoherent speech, and stupor. Drug paraphernalia was also found in his bedroom.

Item Contents and Preparation Concentration: Ketamine (1200 ng/mL)
MDA (100 ng/mL)
MDMA (900 ng/mL)

WebCode	Category	Drug/Metabolite
27ZRVP	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
28CJRC	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
2R2ZW7	[Participant reported that drugs were detected, but did not report the drug class or name]	[Participant reported that drugs were detected, but did not report the drug class or name]
3KUQ3H	CNS Stimulants	Methamphetamine
3L7B8L	CNS Stimulants	
3X2H8C	CNS Stimulants	Amphetamine
		Methamphetamine
		Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
47C7EH	CNS Stimulants	
	Miscellaneous	Ketamine
4CX2FM	CNS Stimulants	
		Amphetamine
4HMT92	CNS Stimulants	Amphetamine
		Methamphetamine
4UFZKK	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
4Y8J8Z	CNS Stimulants	Amphetamine
		Methamphetamine
4Z33A3	CNS Stimulants	
	Miscellaneous	Ketamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
634A8K	CNS Stimulants	Amphetamine
		Methamphetamine
		Methylenedioxymethamphetamine (MDMA)
66DDZB	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
69ZW6E	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
6CXF6R	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
6RMMYJ	CNS Stimulants	Amphetamine
		Methamphetamine
6RNHNG	CNS Stimulants	Methamphetamine
6VMUJG	CNS Stimulants	Methamphetamine
6YM3QD	CNS Stimulants	Amphetamine
		Methamphetamine
		Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
76WJY2	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
7DM2DA	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
7FQWWC	CNS Stimulants	Amphetamine
		Methamphetamine
7THLUX	CNS Stimulants	Amphetamine
		Methamphetamine
82MZ8J	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
82RCVE	CNS Stimulants	Methamphetamine
8ALF2W	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
94RZMA	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
9E9MWB	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
9E9R8D	CNS Stimulants	
	Miscellaneous	Ketamine
9L6JJD	CNS Stimulants	Methamphetamine
9UNPH6	CNS Stimulants	Amphetamine
		Methamphetamine
		Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
9WQNRD	CNS Stimulants	Methamphetamine
A8462V	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
ARQYNB	CNS Stimulants	Methamphetamine
	Miscellaneous	Ketamine
BBLR99	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
BCCXME	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
BEHBB8	CNS Stimulants	Amphetamine
		Methamphetamine
	Miscellaneous	Ketamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
BKMCB2	CNS Stimulants	Amphetamine
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
BTXFFE	CNS Stimulants	Amphetamine
		Methamphetamine
	Miscellaneous	Ketamine
BUY9F9	CNS Stimulants	
	Miscellaneous	Ketamine
CHEJU8	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
CU8ZLU	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
CYLKNA	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
CZG4PB	CNS Stimulants	
	Miscellaneous	Ketamine
D333M7	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
D3GPYT	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
DAH2VP	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
DPRW7C	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
DQQXEN	CNS Stimulants	Methamphetamine
DTCHJT	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
EATAEA	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
		Norketamine
EAXM37	CNS Stimulants	Amphetamine
		Methamphetamine
EC3D8Z	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
EDHCQP	CNS Stimulants	Amphetamine
		Methamphetamine
EHN6JZ	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
EQHD26	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
ERDW48	CNS Stimulants	
EVXLRQ	CNS Stimulants	Amphetamine
		Methamphetamine
F7PV7B	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
FDCNHA	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
FJGK7G	CNS Stimulants	Amphetamine
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
FN9UC9	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
FXJWXA	No drugs detected utilizing screening methods.	

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
GKQMUZ	CNS Stimulants	Amphetamine
		Methamphetamine
	Miscellaneous	Ketamine
GVA796	CNS Stimulants	
	Miscellaneous	Ketamine
H33YT6	CNS Stimulants	
	Miscellaneous	Ketamine
H97X9Z	CNS Stimulants	
HD3K3N	CNS Stimulants	Amphetamine
		Methamphetamine
HEVFPX	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
HHGZU2	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
HJCHV3	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
J6RHGN	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
JAHYN8	CNS Stimulants	Cocaine
		Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
JDG92U	CNS Stimulants	
JR4HMZ	CNS Stimulants	
	Miscellaneous	Ketamine
KHU9V2	CNS Stimulants	Amphetamine
		Methamphetamine
KKY2RK	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
L2ETM2	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
L44VYG	CNS Stimulants	Methamphetamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
LFXJL4	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
LJV3N3	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
LT9P6J	Analgesics	Buprenorphine
	CNS Stimulants	Amphetamine
		Methamphetamine
M43KEX	CNS Stimulants	
MDQGHK	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
MEHD6T	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
MT3R8T	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
MVA8GJ	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
MW344T	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
N6T7KU	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
NC8RUX	CNS Stimulants	Methamphetamine
NM9FLV	CNS Stimulants	Amphetamine
		Methamphetamine
NMQB83	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
NQPM33	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
NUPVAY	CNS Stimulants	
	Miscellaneous	Ketamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
PBUPGX	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
PNKA4G	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
QC2GRC	CNS Stimulants	Methamphetamine
QQ3VBU	CNS Stimulants	Amphetamine
		Methamphetamine
R7V8YN	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
RACEFW	CNS Stimulants	Amphetamine
		Methamphetamine
RYVNWT	CNS Stimulants	Methamphetamine
T38TAE	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
T6EB7P	CNS Stimulants	Amphetamine
		Methamphetamine
TB4N8D	CNS Stimulants	Amphetamine
		Methamphetamine
UAL4UT	CNS Stimulants	
	Miscellaneous	Ketamine
UEJHLP	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
UHWFTC	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
UR2DVU	CNS Stimulants	
UXAUBA	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
UZFC8J	CNS Stimulants	Amphetamine
		Methamphetamine
		Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
V3YTZN	CNS Stimulants	
VMLHAG	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
VNF7TC	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
VWVTKT	CNS Stimulants	Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
VX7V8R	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
		Norketamine
WGDDXM	CNS Stimulants	Amphetamine
		Methamphetamine
WQ2AZA	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
X6ZFLR	CNS Stimulants	Amphetamine
		Methamphetamine
XE3VDH	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
XMZKW8	CNS Stimulants	Amphetamine
		Methamphetamine
XT673P	CNS Stimulants	
	Miscellaneous	Ketamine
Y4NX9E	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine

TABLE 3 A: Screening Results - Item 3

WebCode	Category	Drug/Metabolite
Y8Z7AH	CNS Stimulants	Amphetamine
		Methamphetamine
	Miscellaneous	Ketamine
YJVEV7	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
YN6HYM	CNS Stimulants	
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
YQCUGN	CNS Stimulants	Amphetamine
		Methamphetamine
YXCCXL	CNS Stimulants	Methamphetamine
Z2UNE4	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)
	Miscellaneous	Ketamine
ZEF76L	CNS Stimulants	Methamphetamine
ZFBUGP	CNS Stimulants	Amphetamine
		Methamphetamine
	Miscellaneous	Ketamine
ZHZWT6	CNS Stimulants	Amphetamine
		Methamphetamine
ZJ89B8	CNS Stimulants	Methylenedioxyamphetamine (MDA)
		Methylenedioxymethamphetamine (MDMA)

Screening Response Summary for Item 3 **Participants: 133**

Drug Category Totals		Drug/Metabolite Totals	
CNS Stimulants	131	**Ketamine**	79
Miscellaneous	79	**Methylenedioxymethamphetamine (MDMA)**	72
		Methylenedioxyamphetamine (MDA)	60
		Methamphetamine	45
No drugs detected utilizing screening methods	1		

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 3

TABLE 3B

Item Scenario:

Toxicological analysis was performed following the death of a 32 year old man who had fallen off a raised outdoor deck at his residence. A post-mortem examination determined internal and external hemorrhage as the cause of death. His wife informed authorities about his behavior minutes prior to the fall, including panic, incoherent speech, and stupor. Drug paraphernalia was also found in his bedroom.

Item Contents and Preparation Concentration: Ketamine (1200 ng/mL)
MDA (100 ng/mL)
MDMA (900 ng/mL)

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
28CJRC	Ketamine		>1000		ng/mL
	Methylenedioxyamphetamine (MDA)		100.6	+/-12.1	ng/mL
	Methylenedioxymethamphetamine (MDMA)		>500		ng/mL
2R2ZW7	KETAMINE	✓			
	MDA	✓			
	MDMA	✓			
3KUQ3H	Ketamine	✓			ug/mL
	3,4-Methylenedioxyamphetamine (MDA)	✓			ug/mL
	3,4-Methylenedioxymethamphetamine (MDMA)	✓			ug/mL
3L7B8L	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
3X2H8C	Methylenedioxyamphetamine		0.091	0.014	µg/ml
	Methylenedioxymethamphetamine		0.86	0.14	µg/ml
47C7EH	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
4HMT92	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	3,4 - Methylenedioxymethamphetamine (MDMA)	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
4UFZKK	Ketamine	✓			
	Methylenedioxyamphetamine	✓			
	Methylenedioxymethamphetamine	✓			
4Y8J8Z	Ketamine		greater than 250 ng/mL		
	MDA	✓			
	MDMA	✓			
	Caffeine	✓			
4Z33A3	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
66DDZB	ketamine		1000	300	ng/mL
	methylenedioxyamphetamine (MDA)		120	30	ng/mL
	methylenedioxymethamphetamine (MDMA)		1100	300	ng/mL
69ZW6E	Ketamine	✓			
	3,4-Methylenedioxyamphetamine (MDA	✓			
	3,4-Methylenedioxymethamphetamine (MDMA	✓			
6CXF6R	Ketamine		1.0	15%	mg/L
	Methylenedioxyamphetamine (MDA)		0.10	15%	mg/L
	Methylenedioxymethamphetamine (MDMA)		0.93	15%	mg/L
6RMMYJ	Ketamine	✓			
	MDMA	✓			
6RNHNG	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
6VMUJG	Ketamine	✓			
	MDA	✓			
	MDMA	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
76WJY2	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
7DM2DA	ketamine		0.94	0.28	mg/L
	3,4-methylenedioxyamphetamine		0.13	0.04	mg/L
	3,4-methylenedioxymethamphetamine		1.1	0.3	mg/L
7THLUX	MDA		99	16	ng/mL
	MDMA		899	141	ng/mL
82MZ8J	Ketamine		>500	+/- 15%	ng/mL
	Methylenedioxyamphetamine (MDA)		98.99	+/- 15%	ng/mL
	Methylenedioxymethamphetamine (MDMA)		878.00	+/- 16%	ng/mL
82RCVE	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
8ALF2W	Ketamine		1136.46	79.55	ng/mL
	Methylenedioxyamphetamine (MDA)		83.00	11.62	ng/mL
	Methylenedioxymethamphetamine (MDMA)		927.84	92.78	ng/mL
94RZMA	Ketamine	✓			
	Methylenedioxyamphetamine	✓			
	Methlenedioxymethamphetamine	✓			
9E9MWB	Ketamine	✓			
	Methylenedioxyamphetamine	✓			
	Methylenedioxymethamphetamine	✓			
9E9R8D	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
9L6JJD	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
9UNPH6	Methylenedioxyamphetamine		0.092	0.014	mcg/mL
	Methylenedioxymethamphetamine		0.87	0.14	mcg/mL
9WQNRD	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
A8462V	ketamine		0,82		mg/l
	MDA		0,10		mg/l
	MDMA		0,60		mg/l
ARQYNB	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
BBLR99	Ketamine	✓			
	3,4-methylenedioxyAmphetamine (MDA)	✓			
	3,4-methylenedioxyMethamphetamine (MDMA)	✓			
BCCXME	Ketamine		1179		ng/mL
	Methylenedioxyamphetamine (MDA)		105		ng/mL
	Methylenedioxymethamphetamine (MDMA)		965		ng/mL
BEHBB8	Ketamine	✓			
	3,4-methylenedioxyamphetamine (MDA)		125		ng/mL
	3,4-methylenedioxymethamphetamine (MDMA)		>1000		ng/mL
BKMCB2	No drugs/metabolites detected utilizing confirmatory methods.				

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
BTXFFE	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
BUY9F9	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
CHEJU8	Methylenedioxyamphetamine (MDA)		98	20	ng/mL
	Methylenedioxymethamphetamine (MDMA)		834	167	ng/mL
CU8ZLU	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
CYLKNA	ketamine		1027		ng/ml
	MDA		80,8	22,2%	ng/ml
	MDMA		815	16,4%	ng/ml
CZG4PB	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
D333M7	Ketamine	✓			
	Methylenedioxyamphetamine	✓			
	Methylenedioxymethamphetamine	✓			
D3GPYT	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
DAH2VP	Ketamine		1002.97	70.20	ng/ml
	Methylenedioxyamphetamine (MDA)		76.36	10.69	ng/ml
	Methylenedioxymethamphetamine (MDMA)		862.30	86.23	ng/ml

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
DPRW7C	Ketamine		1211	108	ng/mL
	Methylenedioxyamphetamine		115	16	ng/mL
	Methylenedioxymethamphetamine		924	107	ng/mL
DQQXEN	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
DTCHJT	ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
EATAEA	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
	Norketamine	✓			
EAXM37	3,4-methylenedioxyamphetamine		89	±14	ng/mL
	3,4-methylenedioxymethamphetamine		0.9	±0.2	µg/mL
EC3D8Z	ketamine		0.87 mg/L	0.26	mg/L
	3,4-Methylenedioxyamphetamine		95 micrograms/liter	27	:rograms/l
	3,4-Methylenedioxymethamphetamine		0.85 mg/L	0.24	mg/L
EDHCQP	Methylenedioxyamphetamine (MDA)		96	16	ng/mL
	Methylenedioxymethamphetamine (MDMA)		821	129	ng/mL
EHN6JZ	Ketamine		1104	221	ng/mL
	Methylenedioxyamphetamine (MDA)		132	26	ng/mL
	Methylenedioxymethamphetamine (MDMA)		1128	226	ng/mL
EQHD26	ketamine		1300		ng/mL
	MDA		110		ng/mL
	MDMA		880		ng/mL

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
ERDW48	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
EVXLRQ	Ketamine		Present greater than 1000 ng/mL		ng/mL
	3,4-Methylenedioxyamphetamine (MDA)		86	25	ng/mL
	3,4-Methylenedioxymethamphetamine (MDMA)		847	240	ng/mL
F7PV7B	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
FDCNHA	Ketamine		>500		ng/ml
	Methylenedioxyamphetamine (MDA)		96.38	±14.45	ng/ml
	Methylenedioxymethamphetamine (MDMA)		816.75	±130.68	ng/ml
FJGK7G	Ketamine	✓			
	MDMA	✓			
	Amphetamine	✓			
FN9UC9	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
FXJWXA	Ketamine		> 400		ug/L
	Methylenedioxymethamphetamine		> 200		ug/L
GKQMUZ	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)		88		ng/mL
	Methylenedioxymethamphetamine (MDMA)		794		ng/mL
GVA796	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
H33YT6	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
H97X9Z	Ketamine		1.06	0.27	mg/L
	Methylenedioxyamphetamine (MDA)		0.094	0.027	mg/L
	Methylenedioxymethamphetamine (MDMA)		0.84	0.24	mg/L
HD3K3N	ketamine	✓			
	methylenedioxyamphetamine	✓			
	methylenedioxymethamphetamine	✓			
HEVFPX	Ketamine		1.1	0.3	mg/L
	Methylenedioxyamphetamine (MDA)		0.10	0.03	mg/L
	Methylenedioxymethamphetamine (MDMA)		0.86	0.24	mg/L
HHGZU2	Ketamine		1320.53	198.08	ng/mL
	Methylenedioxymethylamphetamine (MDMA)		935.73	187.15	ng/mL
HJCHV3	methylenedioxyamphetamine		92	17	ng/mL
	methylenedioxymethamphetamine		830	140	ng/mL
J6RHGN	KETAMINE	✓			
	MDMA	✓			
JAHYN8	MDMA		643.30	17.38	ng/ml
JDG92U	Ketamine		1.05	0.12	mg/L
	MDA		0.0894	0.0061	mg/L
	MDMA		0.846	0.060	mg/L
JR4HMZ	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
KHU9V2	MDA		93	±14	ng/ml
	MDMA		0.9	±0.2	µg/ml

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
L2ETM2	Ketamine	✓			
	methylenedioxyamphetamine	✓			
	methylenedioxymethamphetamine	✓			
L44VYG	Ketamine	✓			
	3,4-Methylenedioxyamphetamine (MDA)	✓			
	3,4-Methylenedioxymethamphetamine (MDMA)	✓			
LFXJL4	Ketamine		>250		ng/mL
	Methylenedioxyamphetamine (MDA)		96.18	+/- 14.42	ng/mL
	Methylenedioxymethamphetamine (MDMA)		817.09	+/- 130.73	ng/mL
LJV3N3	MDA		80.5	19.4	ng/mL
	MDMA		812.8	178.9	ng/mL
LT9P6J	Ketamine		918	290	ng/mL
	3,4-Methylenedioxyamphetamine (MDA)		81	23	ng/mL
	3,4-Methylenedioxymethamphetamine (MDMA)		852	240	ng/mL
M43KEX	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
MDQGHK	KETAMINE	✓			
	MDMA	✓			
MEHD6T	Ketamine		0.96	0.29	mg/L
	3,4-methylenedioxyamphetamine		0.11	0.03	mg/L
	3,4-methylenedioxymethamphetamine		0.88	0.25	mg/L
MT3R8T	Ketamine		1.1	0.3	mg/L
	Methylenedioxyamphetamine		0.10	0.03	mg/L
	Methylenedioxymethamphetamine		0.91	0.25	mg/L

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
MVA8GJ	Ketamine		869,3		ng/mL
	MDA		108,4		ng/mL
	MDMA		592,3		ng/mL
MW344T	ketamine		1.1	0.3	mg/L
	3,4-methylenedioxyamphetamine		93	26	µg/L
	3,4-methylenedioxymethamphetamine		0.88	0.25	mg/L
N6T7KU	Ketamine	✓			
	3,4-methylenedioxyAmphetamine (MDA)	✓			
	3,4-methylenedioxyMethamphetamine (MDMA)	✓			
NC8RUX	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
NM9FLV	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
NMQB83	KETAMINE	✓			
	MDMA	✓			
NQPM33	MDA		86	13	ng/mL
	MDMA		>500		ng/mL
NUPVAY	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
PBUPGX	Ketamine	✓			
	3,4-Methylenedioxyamphetamine (MDA)	✓			
	3,4-Methylenedioxymethamphetamine (MDMA)	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
PNKA4G	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
QC2GRC	Ketamine	✓			
	3,4-Methylenedioxyamphetamine (MDA)	✓			
	3,4-Methylenedioxymethamphetamine (MDMA)	✓			
QQ3VBU	Methylenedioxyamphetamine (MDA)		89	±14	ng/mL
	Methylenedioxymethamphetamine (MDMA)		0.8	±0.2	µg/mL
R7V8YN	Ketamine		1.1	0.3	mg/L
	Methylenedioxyamphetamine (MDA)		0.10	0.03	mg/L
	Methylenedioxymethamphetamine (MDMA)		0.93	0.26	mg/L
RACEFW	Amphetamine		None Detected	-	ng/mL
	Methamphetamine		None Detected		ng/mL
RYVNWT	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
T38TAE	ketamine	✓			
	MDMA	✓			
TB4N8D	Ketamine	✓	>100		ng/mL
	MDA		88	18	ng/mL
	MDMA		810	140	ng/mL
UAL4UT	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
UEJHLP	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
UHWFTC	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
UR2DVU	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
UXAUBA	ketamine		1.2	0.2	mg/L
	methylenedioxyamphetamine (MDA)		0.11	0.02	mg/L
	methylenedioxymethamphetamine (MDMA)		0.87	0.20	mg/L
UZFC8J	Methylenedioxyamphetamine		0.093	0.014	ug/mL
	Methylenedioxymethamphetamine		0.88	0.14	ug/mL
V3YTZN	Ketamine		1400	160	ng/mL
	MDA		110	10	ng/mL
	MDMA		850	110	ng/mL
VMLHAG	Ketamine		1100	272	ng/mL
	3,4-methylenedioxyamphetamine		110	na	ng/mL
	3,4-methylenedioxymethylamphetamine		910	na	ng/mL
VNF7TC	Ketamine				
	Methylenedioxyamphetamine (MDA)				
	Methylenedioxymethamphetamine (MDMA)),	✓			
VWVTKT	Ketamine	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
VX7V8R	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
	Norketamine	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
WGDDXM	3,4-Methylenedioxyamphetamine		96	±15	ng/mL
	3,4-Methylenedioxymethamphetamine		0.9	±0.2	µg/ml
WQ2AZA	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
X6ZFLR	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
XE3VDH	Ketamine		1.1	0.3	mg/L
	Methylenedioxyamphetamine		0.94	0.26	mg/L
	Methylenedioxymethamphetamine		0.11	0.03	mg/L
XMZKW8	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	3,4 - Methylenedioxymethamphetamine (MDMA)	✓			
XT673P	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
Y4NX9E	Ketamine		1.1	0.2	mg/L
	Methylenedioxyamphetamine		0.10	0.01	mg/L
	Methylenedioxymethamphetamine		0.97	0.13	mg/L
Y8Z7AH	Ketamine	✓			
	MDA		87		ng/mL
	MDMA		>1000		ng/mL
YJVEV7	ketamine	✓			
	MDA	✓			
	MDMA	✓			

TABLE 3B: Confirmatory Results - Item 3

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
YN6HYM	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
YXCCXL	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
Z2UNE4	Ketamine		1.2	0.2	mg/L
	MDA		0.099	0.017	mg/L
	MDMA		0.91	0.20	mg/L
ZEF76L	Ketamine	✓			
	MDA	✓			
	MDMA	✓			
ZFBUGP	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	Methylenedioxymethamphetamine (MDMA)	✓			
ZHZWT6	Ketamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
	3,4 - Methylenedioxymethamphetamine (MDMA)	✓			
ZJ89B8	MDA		82.31	13.16	ng/mL
	3, 4-Methylenedioxymethamphetamine (MDMA)		793.94	119.09	ng/mL

Confirmatory Response Summary for Item 3 **Participants: 125**

Ketamine:	108
Methylenedioxyamphetamine (MDA):	113
Methylenedioxymethamphetamine (MDMA):	123
Other identified drugs/metabolites:	6
No drugs/metabolites detected utilizing confirmatory methods:	1

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 3

TABLE 3C

Item 3 Raw Data - Ketamine
Preparation concentration: 1200 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
4Y8J8Z	816.48		816.50	
66DDZB	1,020.0		1,020.0	
6CXF6R	1,036.0	1,045.0	1,040.5	
7DM2DA	944.00		944.00	
82MZ8J	1,174.6		1,174.6	
8ALF2W	1,136.5		1,136.5	
BCCXME	1,198.7	1,158.9	1,178.8	
BEHBB8	980.40	887.40	933.90	
CYLKNA	1,027.0		1,027.0	
DAH2VP	1,003.0		1,003.0	
EC3D8Z	873.00		873.00	
EHN6JZ	1,104.0		1,104.0	
EQHD26	1,289.6	1,332.8	1,311.2	
EVXLRQ	1,495.5	1,057.8	1,276.7	
FXJWXA	1,198.3	1,215.9	1,207.1	
GKQMUZ	1,117.9	1,200.0	1,159.0	
H97X9Z	1,069.3		1,069.3	
HEVFPX	1,085.6		1,085.6	
HHGZU2	1,320.5		1,320.5	
JDG92U	1,055.7	1,042.8	1,049.3	
LT9P6J	1,126.8	918.60	1,022.7	
MEHD6T	958.00		958.00	
MT3R8T	1.1046		1.1050	X
MVA8GJ	869.30		869.30	
MW344T	1,069.0		1,069.0	
R7V8YN	1,123.0		1,123.0	
TB4N8D	417.75		417.80	X
UXAUBA	1,165.7		1,165.7	
V3YTZN	1,425.7	1,445.5	1,435.6	

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Ketamine
Preparation concentration: 1200 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)	Participant Mean
VMLHAG	1,089.0	1,089.0
XE3VDH	1,100.0	1,100.0
Y4NX9E	1,065.4	1,065.4
Z2UNE4	1,164.5	1,164.5

Statistical Analysis for Item 3 - Ketamine (ng/mL)

Grand Mean	1,090.08	Number of Participants Included	31
Standard Deviation	137.23	Number of Participants Excluded	2
		by Critical H value of	2.648

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Methylenedioxyamphetamine (MDA)
Preparation concentration: 100 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
28CJRC	100.60	111.00	105.80	
3X2H8C	91.000		91.000	
66DDZB	117.36		117.40	
6CXF6R	97.000	94.000	95.500	
7DM2DA	126.93		126.90	X
7THLUX	98.640		98.640	
82MZ8J	98.990		98.990	
8ALF2W	83.000		83.000	
9UNPH6	92.000		92.000	
BCCXME	107.96	102.50	105.20	
BEHBB8	125.80		125.80	X
CHEJU8	98.000		98.000	
CYLKNA	80.800		80.800	
DAH2VP	76.360	85.990	81.180	
EAXM37	89.818		89.820	
EC3D8Z	94.622		94.620	
EDHCQP	96.410		96.410	
EHN6JZ	132.00		132.00	X
EQHD26	106.98	108.90	107.90	
EVXLRQ	90.260	86.470	88.370	
FDCNHA	96.380		96.380	
GKQMUZ	88.900		88.900	
H97X9Z	94.100		94.100	
HEVFPX	99.906		99.910	
HJCHV3	92.000		92.000	
JDG92U	91.660	87.240	89.450	
KHU9V2	93.331		93.330	
LFXJL4	96.180		96.180	
LJV3N3	80.530		80.530	
LT9P6J	83.590	81.410	82.500	

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Methylenedioxyamphetamine (MDA)
Preparation concentration: 100 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)			
MEHD6T	106.60		106.60	
MT3R8T	100.62		100.60	
MVA8GJ	108.40		108.40	
MW344T	92.746		92.750	
NQPM33	86.000		86.000	
QQ3VBU	89.211		89.210	
R7V8YN	101.17		101.20	
TB4N8D	88.440		88.440	
UXAUBA	108.90		108.90	
UZFC8J	93.000		93.000	
V3YTZN	112.29	113.00	112.60	
VMLHAG	108.00	105.00	106.50	
WGDDXM	96.216		96.220	
XE3VDH	940.00		940.00	X
Y4NX9E	104.11		104.10	
Y8Z7AH	87.900		87.900	
Z2UNE4	99.242		99.240	
ZJ89B8	82.310		82.310	

Statistical Analysis for Item 3 - Methylenedioxyamphetamine (MDA) (ng/mL)

Grand Mean **95.50**
Standard Deviation **9.05**
Number of Participants Included **44**
Number of Participants Excluded **4**
by Critical H value of **2.695**

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Methylenedioxymethamphetamine (MDMA)
Preparation concentration: 900 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
3X2H8C	863.00		863.00	
66DDZB	1,092.5		1,092.5	X
6CXF6R	930.00	926.00	928.00	
7DM2DA	1,096.3		1,096.3	X
7THLUX	898.72		898.70	
82MZ8J	878.00		878.00	
8ALF2W	927.84		927.80	
9UNPH6	873.00		873.00	
BCCXME	998.84	931.00	964.90	
BEHBB8	1,045.7		1,045.7	X
CHEJU8	834.00		834.00	
CYLKNA	815.00		815.00	
DAH2VP	862.30		862.30	
EAXM37	924.63		924.60	
EC3D8Z	853.38		853.40	
EDHCQP	820.93		820.90	
EHN6JZ	1,128.0		1,128.0	X
EQHD26	883.02	881.10	882.10	
EVXLRQ	862.14	847.60	854.90	
FDCNHA	816.75		816.80	
FXJWXA	1,022.3	1,036.2	1,029.2	X
GKQMUZ	794.50		794.50	
H97X9Z	844.60		844.60	
HEVFPX	855.15		855.20	
HHGZU2	935.73		935.70	
HJCHV3	830.00		830.00	
JAHYN8	643.30		643.30	X
JDG92U	849.13	843.60	846.40	
KHU9V2	930.30		930.30	
LFXJL4	817.09		817.10	

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Methylenedioxymethamphetamine (MDMA)
Preparation concentration: 900 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
LJV3N3	812.80		812.80	
LT9P6J	857.79	852.40	855.10	
MEHD6T	882.21		882.20	
MT3R8T	910.28		910.30	
MVA8GJ	592.30		592.30	X
MW344T	877.53		877.50	
NQPM33	861.00		861.00	
QQ3VBU	827.72		827.70	
R7V8YN	933.31	932.40	932.90	
TB4N8D	812.31		812.30	
UXAUBA	873.40		873.40	
UZFC8J	881.00		881.00	
V3YTZN	854.71	851.60	853.10	
VMLHAG	919.00	895.00	907.00	
WGDDXM	923.96		924.00	
XE3VDH	110.00		110.00	X
Y4NX9E	966.97		967.00	
Y8Z7AH	1,188.5		1,188.5	X
Z2UNE4	907.21		907.20	
ZJ89B8	793.94		793.90	

Statistical Analysis for Item 3 - Methylenedioxymethamphetamine (MDMA) (ng/mL)

Grand Mean **871.45**
Standard Deviation **46.11**
Number of Participants Included **41**
Number of Participants Excluded **9**
by Critical H value of **2.687**

Reporting Procedures - Item 3

TABLE 3D - Item 3

WebCode	Quantitative Reporting Procedures
28CJRC	The sample is analyzed in duplicate, and the results have to be within +/-20% of their mean. The lowest of the two quantitative results is reported.
3KUQ3H	Qualitative only.
3X2H8C	A single determination.
4Y8J8Z	A single determination.
66DDZB	A single determination.
6CXF6R	The mean of duplicate/several determinations.
6RNHNG	A single determination.
6VMUJG	A single determination.
7DM2DA	A single determination.
7THLUX	A single determination.
82MZ8J	A single determination.
8ALF2W	A single determination.
94RZMA	A single determination.
9L6JJD	A single determination.
9UNPH6	A single determination.
9WQNRD	A single determination.
A8462V	A single determination.
BCCXME	The mean of duplicate/several determinations.
BEHBB8	A single determination.
BUY9F9	A single determination.
CHEJU8	A single determination.
CYLKNA	A single determination.
DAH2VP	lowest of two quantitative values due to screen and confirmation being performed on the quantitative/confirmatory method
DPRW7C	The mean of duplicate/several determinations.
DQQXEN	A single determination.
EAXM37	A single determination.
EC3D8Z	A single determination.
EDHCQP	A single determination.

TABLE 3D: Reporting Procedures - Item 3

WebCode	Quantitative Reporting Procedures
EHN6JZ	A single determination.
EQHD26	The mean of duplicate/several determinations.
ERDW48	A single determination.
EVXLRQ	The lowest value of duplicate sampling
FDCNHA	A single determination.
FXJWXA	The mean of duplicate/several determinations.
GKQMUZ	A single determination.
H97X9Z	A single determination.
HEVFPX	A single determination.
HHGZU2	A single determination.
HJCHV3	A single determination.
JAHYN8	A single determination.
JDG92U	The mean of duplicate/several determinations.
KHU9V2	A single determination.
LFXJL4	A single determination.
LJV3N3	A single determination.
LT9P6J	The lowest of the duplicates
MEHD6T	A single determination.
MT3R8T	A single determination.
MVA8GJ	A single determination.
MW344T	A single determination.
NC8RUX	A single determination.
NQPM33	A single determination.
QQ3VBU	A single determination.
R7V8YN	The mean of duplicate/several determinations.
RACEFW	A single determination.
TB4N8D	A single determination.
UXAUBA	A single determination.
UZFC8J	A single determination.
V3YTZN	The mean of duplicate/several determinations.

TABLE 3D: Reporting Procedures - Item 3

WebCode	Quantitative Reporting Procedures
VMLHAG	The mean of duplicate/several determinations.
WGDDXM	A single determination.
XE3VDH	A single determination.
Y4NX9E	A single determination.
Y8Z7AH	A single determination.
YXCCXL	A single determination.
Z2UNE4	A single determination.
ZJ89B8	A single determination.

Response Summary for Item 3	Participants: 66
A single determination:	52 (78.8%)
The mean of duplicate/several determinations:	9 (13.6%)
Other:	5 (7.6%)

Methods of Analysis - Item 3

TABLE 3E - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
27ZRVP	GC/MS	✓		
28CJRC	LC/MS/MS	✓	✓	✓
2R2ZW7	GC/MS		✓	
3KUQ3H	Immunoassay	✓		
	GC/MS		✓	✓
3L7B8L	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
	LC-QTOF-MS	✓	✓	
3X2H8C	Immunoassay	✓		
	GC/MS		✓	✓
47C7EH	Immunoassay	✓		
	GC/MS	✓	✓	
4CX2FM	Immunoassay	✓		
4HMT92	Immunoassay	✓		
	GC/MS		✓	
4UFZKK	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	
4Y8J8Z	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	✓
4Z33A3	Immunoassay	✓		
	GC/MS	✓	✓	
634A8K	Immunoassay	✓		
66DDZB	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
69ZW6E	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
6CXF6R	LC-QTOF-MS	✓		
	LC/MS/MS	✓	✓	
6RMMYJ	Immunoassay	✓		
	LC-QTOF		✓	
6RNHNG	Immunoassay	✓		
	GC/MS		✓	
6VMUJG	Immunoassay	✓		
	GC/MS		✓	
6YM3QD	Immunoassay	✓		
	LC/MS/MS	✓		
76WJY2	Immunoassay	✓		
	GC/MS	✓	✓	
7DM2DA	LC-HRMSMS	✓		
	LC/MS/MS		✓	✓
7FQWWC	Immunoassay	✓		
7THLUX	Immunoassay	✓		
	LC/MS/MS		✓	✓
82MZ8J	LC/MS/MS	✓	✓	✓
82RCVE	Immunoassay	✓		
	GC/MS	✓	✓	
8ALF2W	LC/MS/MS	✓	✓	✓
94RZMA	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	
9E9MWB	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	
9E9R8D	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
9L6JJD	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
9UNPH6	Immunoassay	✓		
	GC/MS		✓	✓
9WQNRD	GC/MS			
A8462V	LC/MS/MS	✓	✓	✓
	GC/MS	✓	✓	✓
ARQYNB	Immunoassay	✓		
	GC/MS	✓	✓	
BBLR99	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS		✓	
BCCXME	Immunoassay	✓		
	LC-QTOF	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	✓
BEHBB8	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
BKMCB2	Immunoassay	✓		
	GC/MS	✓	✓	
BTXFFE	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
BUY9F9	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	
CHEJU8	LC/MS/MS	✓	✓	
CU8ZLU	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
CYLKNA	LC/MS/MS	✓		
	LC-QTOF	✓	✓	
	GC/MS		✓	✓
CZG4PB	Immunoassay	✓		
	GC/MS	✓	✓	
D333M7	Immunoassay	✓		
	LC/MS	✓	✓	
	GC/MS		✓	
D3GPYT	Immunoassay	✓		
	GC/MS	✓	✓	
DAH2VP	LC/MS/MS	✓	✓	✓
DPRW7C	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC-QTOF-MS	✓		
	GC/MS		✓	
DQQXEN	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
DTCHJT	Immunoassay	✓		
	GC/MS	✓	✓	
EATAEA	Immunoassay	✓		
	GC/MS		✓	
	UPLC-QTOF		✓	
EAXM37	Immunoassay	✓		
	LC/MS/MS		✓	✓
EC3D8Z	LC-HRMS/MS	✓		
	LC/MS		✓	✓
EDHCQP	Immunoassay	✓		
	LC/MS/MS		✓	✓
EHN6JZ	LC/HRAM/MS	✓		
	LC/MS/MS		✓	✓

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
EQHD26	Immunoassay	✓		
	LC-QTOF	✓		
	LC/MS/MS			✓
ERDW48	Immunoassay	✓		
	GC/MS		✓	
EVXLRQ	Immunoassay	✓		
	LC/MS/MS		✓	✓
F7PV7B	LC/MS/MS	✓	✓	
FDCNHA	LC/MS/MS	✓	✓	
FJGK7G	GC/MS	✓	✓	
	Immunoassay	✓	✓	
FN9UC9	Immunoassay	✓		
	LC/MS	✓	✓	
	GC/MS		✓	
FXJWXA	LC/MS/MS			✓
GKQMUZ	Immunoassay	✓		
	LC/MS/MS	✓	✓	
GVA796	Immunoassay	✓		
	GC/MS	✓	✓	
H33YT6	Immunoassay	✓		
	GC/MS	✓	✓	
H97X9Z	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	
HD3K3N	Immunoassay	✓		
	GC/MS		✓	
HEVFPX	LC-HRMS/MS	✓		
	LC/MS/MS			✓
HHGZU2	LC/MS/MS	✓	✓	✓
HJCHV3	Immunoassay	✓		
	LC/MS/MS		✓	✓

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
J6RHGN	LC-QTOF	✓		
	LC-QTOF-MS		✓	
	GC/MS	✓	✓	
JAHYN8	LC/MS/MS	✓	✓	✓
JDG92U	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC-QTOF	✓	✓	
JR4HMZ	Immunoassay	✓		
	LC/MS		✓	
	GC/MS		✓	
KHU9V2	Immunoassay	✓		
	LC/MS/MS		✓	✓
KKY2RK	LC/MS/MS	✓		
L2ETM2	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	
L44VYG	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
LFXJL4	LC/MS/MS	✓	✓	
LJV3N3	LC/MS/MS	✓	✓	✓
LT9P6J	Immunoassay	✓		
	LC/MS/MS		✓	✓
M43KEX	Immunoassay	✓		
	GC/MS	✓		
	GC/FID		✓	✓
MDQGHK	LC/MS/MS	✓	✓	
MEHD6T	LC/HRAMS/MS	✓		
	LC/MS/MS		✓	
MT3R8T	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
MVA8GJ	LC/MS/MS	✓	✓	✓
MW344T	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
N6T7KU	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
NC8RUX	Immunoassay	✓		
	GC/MS		✓	
NM9FLV	Randox Investigator Immunoassay	✓		
	LC/MS		✓	
NMQB83	GC/MS	✓	✓	
NQPM33	LC-TOF	✓		
	LC/MS/MS		✓	✓
NUPVAY	Immunoassay	✓		
	GC/MS	✓	✓	
PBUPGX	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	
PNKA4G	Immunoassay	✓		
	GC/MS	✓	✓	
QC2GRC	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
QQ3VBU	Immunoassay	✓		
	LC/MS/MS		✓	✓
R7V8YN	LC-HRMS/MS	✓		
	LC/MS		✓	✓
RACEFW	Immunoassay	✓		
	LC/MS/MS		✓	✓
RYVNWT	Immunoassay	✓		
	GC/MS		✓	
	GC/FID		✓	✓

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
T38TAE	LC/MS/MS	✓		
	GC/MS		✓	
T6EB7P	Randox Evidence MutiStat DOA Blood Assays	✓		
TB4N8D	Immunoassay	✓		
	LC/MS/MS		✓	✓
UAL4UT	Immunoassay	✓		
	GC/MS	✓	✓	
UEJHLP	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	
UHWFTC	Immunoassay	✓		
	GC/MS	✓	✓	
UR2DVU	Immunoassay	✓		
	GC/MS	✓	✓	
UXAUBA	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
	GC-NPD			✓
UZFC8J	Immunoassay	✓		
	GC/MS		✓	✓
V3YTZN	Immunoassay	✓		
	LC-QTOF	✓	✓	
	LC-QTOF-MS			✓
VMLHAG	Immunoassay	✓		
	LC-QTOF-MS	✓	✓	✓
	LC/MS/MS			✓
VNF7TC	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
VWVTKT	LC/MS/MS	✓	✓	
VX7V8R	GC/MS	✓		
	LC/MS/MS	✓	✓	
	LC-HRMS	✓		

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
WGDDXM	Immunoassay	✓		
	LC/MS/MS		✓	✓
WQ2AZA	Immunoassay	✓		
	GC/MS	✓	✓	
X6ZFLR	Immunoassay	✓		
	LC-QTOF-MS		✓	
	GC/MS		✓	
XE3VDH	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
XMZKW8	Immunoassay	✓		
	GC/MS		✓	
XT673P	Immunoassay	✓		
	GC/MS	✓	✓	
Y4NX9E	LC-QTOF-MS	✓		
	LC/MS/MS		✓	✓
Y8Z7AH	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
YJVEV7	GC/MS	✓	✓	
	Immunoassay	✓		
YN6HYM	Immunoassay	✓		
	GC/MS	✓	✓	
YQCUGN	Immunoassay	✓		
YXCCXL	Immunoassay	✓		
	GC/MS		✓	✓
Z2UNE4	Immunoassay	✓		
	GC/MS	✓	✓	
	GC-NPD		✓	✓
	LC/MS/MS		✓	✓
ZEF76L	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
ZFBUGP	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
ZHZWT6	Immunoassay	✓		
	GC/MS		✓	
ZJ89B8	LC/MS/MS	✓	✓	✓

Response Summary for Item 3 - Methods of Analysis **Participants: 133**

	Screening	Confirmatory	Quantitation
Immunoassay:	91	1	0
GC/MS:	42	70	8
LC/MS:	2	7	2
LC/MS/MS:	33	59	41
LC-QTOF:	6	4	0
LC-QTOF-MS:	10	4	2
Other:	14	8	8

Additional Comments for Item 3

TABLE 3F

WebCode	Item Comments
27ZRVP	Acidification, and extraction with DCM with and without derivatization . Sample volume : 600 uL. Derivatization : BSTFA (50 uL) + EtOAc (100 uL). Washing of remaining aqueous extract with Hexane. Ketamine Basification, and extraction with DCM with and without derivatization . Sample volume : 600 uL. Derivatization : BSTFA (50 uL) + EtOAc (100 uL). Washing of remaining aqueous extract with Hexane. MDMA and Ketamine Basification, and extraction with EtOAc with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL). MDMA and Ketamine Basification, and extraction with Hexane:EtOAc (9:1) with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL). MDMA and Ketamine
28CJRC	MDA lower limit of quantitation (LLOQ) is 10 ng/mL with a working range of 10-500 ng/mL. The internal standard used was MDA-D5. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. MDMA lower limit of quantitation (LLOQ) is 10 ng/mL with a working range of 10-500 ng/mL. The internal standard used was MDMA-D5. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. Results which are greater than its working range are reported out as being greater than the concentration of its highest calibrator. Ketamine lower limit of quantitation (LLOQ) is 20 ng/mL with a working range of 20-1000 ng/mL. The internal standard used was Ketamine-D4. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. Results which are greater than its working range are reported out as being greater than the concentration of its highest calibrator.
3KUQ3H	ELISA was used as the Immunoassay screening method. Mepivacaine was used as the internal standard for the basic drug analysis (GC/MS). For qualitative only analytes, the response of the analyte is greater than 10% of the analyte response in the control which is why it is called positive.
3X2H8C	Immunoassay: Amphetamine and Methamphetamine cutoff 20ng/mL. GC/MS: Amphetamine, Methamphetamine, MDA, MDMA LOQ 0.020 ug/ml. Internal Standards Amphetamine-D11, Methamphetamine-D11, MDA-D5, and MDMA-D5.
47C7EH	Drug Screen used Promazine as the Internal Standard. SMA used N-Propylamphetamine as the Internal Standard.
4CX2FM	Screening testing only is performed. Methamphetamine/MDMA
4HMT92	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS.
4Y8J8Z	The established linear range for Ketamine at our laboratory is 5-250 ng/mL.
66DDZB	Internal Standards: mepivacaine & methamphetamine-d11.
69ZW6E	IS- Mepivacaine, Amphetamine-D11, Methamphetamine-D11
6CXF6R	Internal standards used for LC-QTOF-MS screen/confirmation were D3-Morphine, D3 Hydromorphine, D3 Oxycodone, D5 MA, D3 BZE, D5 Doxylamine, D3 Tramadol, D3 Cocaine, D6 Zolpidem, D5-Fentanyl, D4 Buprenorphine, D3 Nortriptyline, D3 Methadone, D3 Sertraline, D9 25-NB2OMe, D5 desmethyldiazepam. Internal standard used for Ketamine quantitation (LC/MS/MS) is D4 Ketamine and limit of reporting = 0.01 mg/L. Internal standards used for MDMA and MDA quantitation (LC/MS/MS) is D5 MDMA and D5 MDA respectively and limit of reporting = 0.01 mg/L.
6VMUJG	MDA is reported as qualitative only (positive). MDMA is reported as qualitative only (positive). Ketamine is reported as qualitative only (positive).
7DM2DA	MDMA internal standard=Methamphetamine-d11. LOD=10ng/mL. MDA internal standard=Methamphetamine-d11. LOD=10ng/mL. Ketamine internal standard=Mepivacaine. LOD=0.025 mg/L.

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
7THLUX	Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL) Analyte Quantitative Range (ng/mL) Fentanyl 0.5 – 50 Methamphetamine 10 – 1000 Norfentanyl 0.5 – 50 Amphetamine 10 – 1000 Codeine 5.0 – 500 MDMA 10 – 1000 Hydrocodone 5.0 – 500 MDA 10 – 1000 Morphine 5.0 – 500 Cocaine 10 – 1000 Hydromorphone 5.0 – 500 Benzoylecgonine 20 – 2000 Oxycodone 5.0 – 500 Methadone 20 – 2000 Oxymorphone 5.0 – 500 EDDP 20 – 2000 Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses. Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Meprobamate 100 Barbiturates 50 Methadone 10 Benzodiazepines 10 Opiates 10 Buprenorphine 1 Opioids 10 Cannabinoids 10 Phencyclidine 5 Benzoylecgonine 50 TCA 25 Dextromethorphan 5 Tramadol 5 Fentanyl 1 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive.
8ALF2W	A 10x dilution was performed for reported value for both Ketamine and MDMA based on semi-quantitative screen results. Ketamine LOQ 5ng/mL; ISTD Ketamine-d4; Linear range 5-1000ng/mL MDA LOQ 5ng/mL; ISTD MDA-d5; Linear range 5-500ng/mL MDMA 5ng/mL; ISTD MDMA-d5; Linear range 5-250ng/mL
8JNXCZ	Item 3 involves non-criminal incidents taken from individuals that are deceased and will not be analyzed for drugs.
8N3D4C	Item not tested
9E9R8D	ELISA cut-off for Amphetamines is 100 ug/L. Result for this determination was below the cut-off value, but procedure allows pursuit to approximately the midpoint between the cut-off and the negative calibrator. Internal standard for GC/MS drug screening and confirmation is Promazine. Internal standard for GC/MS amphetamine confirmation is n-Propylamphetamine.
9L6JJD	No Methamphetamine detected.
9UNPH6	Immunoassay: Methamphetamine/MDMA and Amphetamine/MDA cutoff 20ng/mL. Amphetamine, Methamphetamine, MDA, MDMA LOQ 0.020mcg/mL. Internal standards: Amphetamine-D11, Methamphetamine-D11, MDA-D5, MDMA-D5.
BKMCB2	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP. Sample 3: Submitted blood sample did not contain amphetamine and methamphetamine during confirmatory analysis. GC/MS scan detected Methylenedioxymethamphetamine (MDMA) and Ketamine. GC/MS and was not quantitated.
BTXFFE	[Table 3A: Screening Results] - We screen for meth/amphetamine class.
CHEJU8	Methylenedioxyamphetamine (MDA): LOD/LLOQ - 10 ng/mL ULOQ - 2000 ng/mL Internal Standard: d5-Methylenedioxyamphetamine Methylenedioxymethamphetamine (MDMA): LOD/LLOQ - 10 ng/mL ULOQ - 2000 ng/mL Internal Standard: d5-Methylenedioxymethamphetamine
DAH2VP	First two extractions for Ketamine were greater than the 1000ng/ml linear range; sample was diluted 10x and reextracted. First two extractions for MDMA were greater than the 500ng/ml linear range; sample was diluted 10x and reextracted. Sample was screened and confirmed using two extractions run on the confirmation/quantitative method with the lower of the two results utilized for reporting. Ketamine linear range is 5ng/ml-1000ng/ml with Ketamine-d4 utilized as the ISTD. MDA linear range is 5ng/ml-500ng/ml with MDA-d5 utilized as the ISTD. MDMA linear range is 5ng/ml-250ng/ml with MDMA-d5 utilized as the ISTD.
DQQXEN	Methamphetamine detected on immunoassay due to cross-reactivity with MDMA.

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
EAXM37	Post-mortem testing is outside the laboratory's scope of analysis. ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive amphetamine and/or methamphetamine screen, confirmation/quantitation of amphetamine (AMP), 3,4-methylenedioxyamphetamine (MDA), methamphetamine (mAMP), and 3,4-methylenedioxymethamphetamine (MDMA) is performed using AMP-D5, MDA-D5, mAMP-D11, and MDMA-D5 as internal standards, respectively. LOD for each target drug is 4 ng/mL; LOQ for each target drug is 10 ng/mL. The ULOQ for MDMA is 400 ng/mL. Samples quantitating greater than the ULOQ undergo pre-extract dilution(s) accordingly, and the result is multiplied by the dilution factor and reported.
EDHCQP	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Barbiturates 50 Benzodiazepines 10 Buprenorphine 1 Cannabinoids 10 Benzoylecgonine 50 Dextromethorphan 5 Fentanyl 1 Meprobamate 100 Methadone 10 Opiates 10 Opioids 10 Phencyclidine 5 TCA 25 Tramadol 5 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive. Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Analyte Quantitative Range (ng/mL) Fentanyl 0.5 – 50 Norfentanyl 0.5 – 50 Codeine 5.0 – 500 Hydrocodone 5.0 – 500 Morphine 5.0 – 500 Hydromorphone 5.0 – 500 Oxycodone 5.0 – 500 Oxymorphone 5.0 – 500 Methamphetamine 10 – 1000 Amphetamine 10 – 1000 MDMA 10 – 1000 MDA 10 – 1000 Cocaine 10 – 1000 Benzoylecgonine 20 – 2000 Methadone 20 – 2000 EDDP 20 – 2000
ERDW48	No methamphetamine was detected using GC/MS in basic/neutral extraction.
EVXLRQ	Item 3 was analyzed using Immunoassay Drug Screen and Basic Drug Confirmation. The scopes of both methods are listed below: Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay-ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem Basic Drug Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: amphetamine, diphenhydramine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, LSD Qualitatively: ephedrine/pseudoephedrine, psilocin The upper limit of quantitation for Ketamine is 1000 ng/mL. Item 3 was analyzed twice - on 06/19/2025 and on 07/07/2025. Ketamine controls failed QC acceptance criteria, so ketamine data was rejected. The MDA and MDMA QC criteria were acceptable, so the results issued were from the 06/19/2025 date. On 07/07/2025, item 3 was rerun and QC criteria was acceptable, so ketamine data was issued.
F7PV7B	MDMA LOD: 20 ng/mL MDA LOD: 20 ng/mL Ketamine LOD: 20 ng/mL
FDCNHA	Ketamine uncertainty K3 15% Methylenedioxyamphetamine (MDA) uncertainty K3 15% Methylenedioxymethamphetamine (MDMA) uncertainty K3 16%
FN9UC9	Codeine-D3 was used as the internal standard.
FXJWXA	The results reported above for ketamine and MDMA do not include a deduction for analytical variation, in accordance with the [State Guideline]. The Upper Limit of Quantification (ULOQ) for ketamine is 200 ug/mL. Both replicates measurements were greater than the sample ULOQ of 400 ug/mL due to the sample being diluted 2-fold for analysis. The ULOQ for MDMA is 200 ug/mL. Both replicates measurements of MDMA were greater than ULOQ (sample analysed without dilution). Results were obtained using a dedicated Section 5A method. No additional drug screening was performed. The blood was examined for the full panel of Section 5A drugs [6-monoacetylmorphine (6-MAM, from heroin use), amphetamine, benzoylecgonine (from cocaine use), clonazepam, cocaine, diazepam, flunitrazepam, ketamine, lorazepam, lysergic acid diethylamide (LSD), methadone, methylamphetamine, methylenedioxymethamphetamine (MDMA, 'ecstasy'), morphine, oxazepam, temazepam and delta-9-tetrahydrocannabinol (THC, from cannabis use)] as well as etizolam, 11-hydroxy-delta-9-tetrahydrocannabinol (from cannabis use) and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (from cannabis use).
FYVPUW	Item not analyzed - lab does not complete postmortem testing.

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
GVA796	The internal standard used for the full panel drug screen procedure was promazine. The internal standards used for the SMA confirmation was N-propylamphetamine.
H33YT6	Butyl Acetate Internal Standard: Promazine SMA Confirmation Internal Standard: N-Propylamphetamine
H97X9Z	The immunoassay was positive for the amphetamines category. Ketamine was not included in the screen, but confirmed with GCMS. There is a 95.45% level of confidence for the uncertainty calculation.
HD3K3N	tfa-n-propylamphetamine used for istd. barbital and SKF-525a used for istd.
HEVFPX	IS: mepivacaine, mephobarbital, methamphetamine-d11. LOR: MDA 10 mcg/L, MDMA 10 mcg/L, ketamine 0.050 mg/L
J6RHGN	ESTAZOLAM WAS USED AS INTERNAL ESTANDAR
JAHYN8	Apart from MDMA (643 ng/ml), MDA and Cocaine were also detected with concentrations 204.30 ng/ml and 6.9 ng/ml respectively.
JDG92U	Limit of detection: Ketamine - 20 ng/mL, MDMA - 25 ng/mL, MDA - 25 ng/mL. Internal Standards used: Ketamine - Ketamine-d4, MDMA - MDMA-d5, MDA - MDA-d5. Ketamine, MDA, and MDMA screened for via LC-QTOF.
KHU9V2	Laboratory does not analyze postmortem samples (outside scope of testing). ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Amphetamine/Methamphetamine confirmation panel includes amphetamine, methamphetamine, MDA and MDMA. LOD is 4ng/ml and LOQ is 10ng/ml. Amphetamine-D5, methamphetamine-D11, MDMA-D5 and MDA-D5 were used as internal standards. ULOQ for MDMA is 400ng/ml. Samples quantitating greater than the ULOQ undergo pre-extract dilution(s) accordingly, and the result is multiplied by the dilution factor and reported.
L2ETM2	The cut-off value of ketamine is 30 ng/mL for GC/MS. The cut-off value of MDA is 150 ng/mL for LC/MS/MS and the cut-off value of MDMA is 30 ng/mL for LC/MS/MS
L44VYG	Internal Standard in GC/MS/FID is Mepivacaine. No Methamphetamine detected.
LJV3N3	Internal standard - MDMA-D5 for both analytes. Cal 1 was dropped for MDA due to Control 1 being out of range. Reportable ranges: MDA - 50-1000 ng/mL, MDMA - 20-1000 ng/mL. LOD: MDA - 2 ng/mL, MDMA - 10 ng/mL.
LT9P6J	Item 3 screened presumptive positive for buprenorphine. Our laboratory does not currently have the ability to confirm buprenorphine so confirmation for this result was not performed.
MEHD6T	Internal standards-mepivacaine and nalorphine, d-11 amphetamine and d-11 methamphetamine, cocaine-d3, benzoylecgonine-d8 gabapentin-d4, olanzapine-d8, bupropion-d9, mephobarbital. 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine: Limit of Detection: 10 mcg/L Lowest Calibrator: 20 mcg/L Highest Calibrator: 1600 mcg/L Ketamine: Limit of Detection:0.025 mg/L Lowest Calibrator: 0.125 mg/L Highest Calibrator: 2.0 mg/L Acetaminophen was also found in screen
MT3R8T	Internal Standards for LC-HRMS/MS: Mepivacaine and Mephobarbital Internal Standards for LC/MS/MS (Ketamine confirmation): Mepivacaine and Gabapentin-d4 Internal Standards for LC/MS/MS (stimulants confirmation): Amphetamine-d11, Methamphetamine-d11, Cocaine-d3, Benzoylecgonine-d8 Limit of detection for Ketamine: 25 µg/L Limit of detection for Methylenedioxyamphetamine: 10 µg/L Limit of detection for Methylenedioxymethamphetamine: 10 µg/L
MW344T	mepivacaine and mephobarbital internal standards for screening mepivacaine internal standard for ketamine quantitation methamphetamine-d11 internal standard for MDA and MDMA quantitation

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
NM9FLV	Internal Standards: MDMA-D5 - LOD 10 ng. MDA-D5 - LOD 10 ng. PCP-D5 - LOD 10 ng.
NUPVAY	Internal standard used for drug screen was Promazine. Internal standard used for amphetamine confirmation was N-propylamphetamine.
PBUPGX	10 ng/mL confirmation LOD for MDMA, MDA, and Ketamine.
QC2GRC	GC/MS-FID Internal Standard: Mepivacaine. No methamphetamine detected. (ELISA assay cross-reactive with 3,4-Methylenedioxymethamphetamine (MDMA)).
QQ3VBU	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Laboratory does not analyze postmortem samples (outside scope of testing). Amphetamine/methamphetamine confirmation panel includes amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA). LOD for each target drug is 4 ng/mL; LOQ for each target drug is 10 ng/mL. AMP-D5, MDA-D5, mAMP-D11, and MDMA-D5 are used as internal standards. The ULOQ for MDMA is 400 ng/mL. Samples quantitating greater than the ULOQ undergo pre-extract dilution(s) accordingly, and the result is multiplied by the dilution factor and reported.
R7V8YN	Internal Standards: Mepivacaine/Mephobarbital, Mepivacaine, Gabapentin d-4, Bupropion d-9, Olanzapine d-8, Amphetamine d-11, Methamphetamine d-11, Benzoylecgonine d-8, Cocaine d-3 The first value of MDA of 110.216 failed for that run. Data was not used. Test was repeated.
RACEFW	Amphetamine screening cut off is 20 ng/mL. Methamphetamine screening cut off is 20 ng/mL. The Basic Drug quantification can confirm amphetamine and methamphetamine. The lower reporting limits are as follows; amphetamine is 10 ng/mL and methamphetamine is 10 ng/mL. Dilutions of the sample was prepared for analysis, but not included in the raw data.
T6EB7P	The Evidence MultiSTAT DOA Blood Assays competitive enzyme immunoassays run on the automated biochip array analyser, Evidence MultiSTAT. A competitive chemiluminescent immunoassay is employed for analysis. The Evidence MultiSTAT DOA Blood Assays provide only a preliminary analytical test result. The Evidence MultiSTAT DOA Blood Assay is designed for use only with human whole blood samples.
TB4N8D	Screening performed on 05/28/2025 MDA (Confirmation performed on 06/03/2025) Internal Standard: MDA-D5 Limit of Detection: 10 ng/mL MDMA (Confirmation performed on 06/03/2025) Internal Standard: MDMA-D5 Limit of Detection: 10 ng/mL Ketamine (Confirmation performed on 06/03/2025) Internal Standard: Norfentanyl-D5 Limit of Detection: 1 ng/mL Upper limit of Quantitation: 100 ng/mL
UAL4UT	Promazine used as ISTD for GC/MS screening and Ketamine confirmation. N-propylamphetamine used as ISTD for GC/MS confirmation MDMA and MDA.
UR2DVU	1. Internal standards used: Promazine, N-Propylamphetamine.
UZFC8J	Immunoassay Screening: Analyte/Cutoff (ng/mL) Amphetamine: 20 ng/mL Phenobarbital: 50 ng/mL Oxazepam: 10 ng/mL Lorazepam: 10 ng/mL Buprenorphine: 5 ng/mL C-THC: 10 ng/mL Benzoylecgonine: 50 ng/mL Dextromethorphan: 5 ng/mL Fentanyl: 2 ng/mL Oxycodone: 10 ng/mL Meprobamate: 100 ng/mL Methadone: 10 ng/mL Methamphetamine: 20 ng/mL Morphine: 10 ng/mL Phencyclidine: 5 ng/mL Tramadol: 5 ng/mL Nortriptyline: 60 ng/mL Zolpidem: 10 ng/mL Amphetamines Confirmation Reporting Limits Amphetamine: 0.020 ug/mL Methamphetamine: 0.020 ug/mL MDA: 0.020 ug/mL MDMA: 0.020 ug/mL
V3YTZN	Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, Triazolam-D4 IS used for LC-QTOF analysis. ELISA screen positive for "methamphetamine"

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
VMLHAG	3,4-methylenedioxymethylamphetamine and 3,4-methylenedioxyamphetamine: Screening: Immunoassay Quantitation: LC MS/MS (Sciex) IS: D5-Methylamphetamine LOD: 0.5 ng/mL Ketamine: Screening & confirmation Technique: UPLC-QTOF-MS (Waters) - Internal Standard: D3-Methadone and Prazepam - LOD: 50 ng/mL
VWVTKT	No reference standard for MDMA and Ketamine available to perform quantification.
VX7V8R	Traces of diclofenac, paracetamol and hydrochlorothiazide were detected in the sample.
WGDDXM	Laboratory does not analyze postmortem samples (outside scope of testing). ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Amphetamine confirmation panel includes amphetamine, methamphetamine, 3,4-Methylenedioxyamphetamine (MDA) and 3,4-Methylenedioxymethamphetamine (MDMA). LOD is 4ng/ml and LOQ is 10ng/ml. Amphetamine-D5, methamphetamine-D11, MDMA-D5 and MDA-D5 were used as internal standards. The ULOQ for MDMA is 400ng/mL. Samples quantitating greater than the ULOQ undergo pre-extract dilution(s) accordingly, and the result is multiplied by the dilution factor and reported.
XE3VDH	Internal Standards LC-HRMS/MS Screening: Mepivacaine/Mephobarbital Internal Standards LC/MS/MS Confirmatory/Quantitation: methamphetamine-d11 & mepivacaine
XMZKW8	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS.
XT673P	Promazine was the internal standard used for Drug Screen by GC/MS. N-propylamphetamine was the internal standard used for SMA confirmation by GC/MS.
YN6HYM	ISTD Drug Screen - Promazine SMA Confirm - N-Propylamphetamine
YQCUGN	Immunological Screen Cut-off blood: 9-Carboxy-THC 20ng/mL; Benzoylecgonine 25ng/mL; Amphetamines (AMP, MAMP, cross reaction MDMA) 20ng/mL; Opiates 10ng/mL; Generic Opioids & Oxycodone 10ng/mL; Methadone 10ng/mL, Benzodiazepines 10ng/mL; Barbiturates 50ng/mL; PCP 5ng/mL; Meprobamate 100ng/mL; Dextromethorphan 5ng/mL; Zolpidem 10ng/mL; Tricyclic Antidepressants 60ng/mL; Fentanyl 1ng/mL; Norbuprenorphine 1ng/mL, Tramadol 5ng/mL.
ZFBUGP	[Table 3A: Screening Results] - We screen for the meth/amphetamine class.
ZHZWT6	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS.

Screening Results - Item 4

TABLE 4A

Item Scenario:

A 42 year old female was found unresponsive on the side of the road and presented to the hospital via EMS after life-saving efforts were attempted, but unsuccessful. She had an unlabeled baggie of pills on her person.

Item Contents and Preparation Concentration: Doxylamine (250 ng/mL)
Fentanyl (40 ng/mL)
Gabapentin (800 ng/mL)

WebCode	Category	Drug/Metabolite
27ZRVP	Antihistamines, Cold Treatment	Doxylamine
28CJRC	Analgesics	Fentanyl
		Norfentanyl
2R2ZW7	[Participant reported that drugs were detected, but did not report the drug class or name]	[Participant reported that drugs were detected, but did not report the drug class or name]
3KUQ3H	Analgesics	Fentanyl
3L7B8L	Analgesics	Fentanyl
3X2H8C	Analgesics	Fentanyl
47C7EH	Antihistamines, Cold Treatment	Doxylamine
4CX2FM	Analgesics	
4UFZKK	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
4Y8J8Z	Analgesics	Fentanyl
4Z33A3	Antihistamines, Cold Treatment	Doxylamine
634A8K	No drugs detected utilizing screening methods.	
66DDZB	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
69ZW6E	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
6CXF6R	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
6RMMYJ	Analgesics	Fentanyl
6RNHNG	Analgesics	Fentanyl
6VMUJG	Analgesics	Fentanyl

TABLE 4 A: Screening Results - Item 4

WebCode	Category	Drug/Metabolite
6YM3QD	Analgesics	Fentanyl
76WJY2	Antihistamines, Cold Treatment	Doxylamine
7DM2DA	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
7FQWWC	Analgesics	Fentanyl
7THLUX	Analgesics	Fentanyl
82MZ8J	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
82RCVE	Analgesics	Fentanyl
8ALF2W	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
94RZMA	Analgesics	Fentanyl
9E9MWB	Analgesics	Fentanyl
9E9R8D	Antihistamines, Cold Treatment	Doxylamine
9L6JJD	Analgesics	Fentanyl
9UNPH6	Analgesics	Fentanyl
9WQNRD	No drugs detected utilizing screening methods.	
A8462V	Analgesics	Fentanyl
ARQYNB	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
BCCXME	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
BEHBB8	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
BKMCB2	No drugs detected utilizing screening methods.	
BTXFFE	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
BUY9F9	Analgesics	Fentanyl
CHEJU8	Analgesics	Fentanyl
CU8ZLU	Antihistamines, Cold Treatment	Doxylamine

TABLE 4 A: Screening Results - Item 4

WebCode	Category	Drug/Metabolite
CYLKNA	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
CZG4PB	Antihistamines, Cold Treatment	Doxylamine
D333M7	Analgesics	Fentanyl
D3GPYT	Antihistamines, Cold Treatment	Doxylamine
DAH2VP	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
DQQXEN	Analgesics	Fentanyl
DTCHJT	Antihistamines, Cold Treatment	Doxylamine
EATAEA	Antihistamines, Cold Treatment	Doxylamine
EAXM37	Analgesics	Fentanyl
EC3D8Z	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
EDHCQP	Analgesics	Fentanyl
EHN6JZ	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
EQHD26	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
ERDW48	Analgesics	
EVXLRQ	Analgesics	Fentanyl
F3UZQW	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
F7PV7B	Anticonvulsants	Gabapentin
FDCNHA	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
FJGK7G	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
FN9UC9	Analgesics	Fentanyl
FXJWXA	No drugs detected utilizing screening methods.	
GKQMUZ	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine

TABLE 4 A: Screening Results - Item 4

WebCode	Category	Drug/Metabolite
GVA796	Antihistamines, Cold Treatment	Doxylamine
H33YT6	Antihistamines, Cold Treatment	Doxylamine
H97X9Z	Analgesics	Fentanyl
HD3K3N	Analgesics	Fentanyl
HEVFPX	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
HHGZU2	Analgesics	Fentanyl
		Norfentanyl
HJCHV3	Analgesics	Fentanyl
J6RHGN	Analgesics	Fentanyl
JAHYN8	Analgesics	Fentanyl
	CNS Stimulants	Cocaine
JDG92U	No drugs detected utilizing screening methods.	
JR4HMZ	Analgesics	Fentanyl
KHU9V2	Analgesics	Fentanyl
KKY2RK	No drugs detected utilizing screening methods.	
L2ETM2	Analgesics	Fentanyl
L44VYG	Analgesics	Fentanyl
LFXJL4	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
LJV3N3	Analgesics	Fentanyl
LT9P6J	Analgesics	Fentanyl
M43KEX	Analgesics	
MDQGHK	Analgesics	Fentanyl
MEHD6T	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
	CNS Stimulants	Amphetamine
MT3R8T	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine

TABLE 4 A: Screening Results - Item 4

WebCode	Category	Drug/Metabolite
MVA8GJ	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
MW344T	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
NC8RUX	Analgesics	Fentanyl
NM9FLV	Analgesics	Fentanyl
NMQB83	Antihistamines, Cold Treatment	Doxylamine
NQPM33	No drugs detected utilizing screening methods.	
NUPVAY	Antihistamines, Cold Treatment	Doxylamine
PBUPGX	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
PNKA4G	Antihistamines, Cold Treatment	Doxylamine
QC2GRC	Analgesics	Fentanyl
QQ3VBU	Analgesics	Fentanyl
R7V8YN	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
RACEFW	Analgesics	Fentanyl
RYVNWT	Analgesics	Fentanyl
T38TAE	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
T6EB7P	Analgesics	Fentanyl
TB4N8D	Analgesics	Fentanyl
UAL4UT	Antihistamines, Cold Treatment	Doxylamine
UEJHLP	Analgesics	Fentanyl
UHWFTC	Antihistamines, Cold Treatment	Doxylamine
UR2DVU	No drugs detected utilizing screening methods.	
UXAUBA	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
UZFC8J	Analgesics	Fentanyl

TABLE 4 A: Screening Results - Item 4

WebCode	Category	Drug/Metabolite
V3YTZN	Analgesics	
VMLHAG	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
VNF7TC	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
VWVTKT	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
VX7V8R	Analgesics	Fentanyl
		Norfentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
WGDDXM	Analgesics	Fentanyl
WQ2AZA	Antihistamines, Cold Treatment	Doxylamine
X6ZFLR	Analgesics	Fentanyl
XE3VDH	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
XMZKW8	Analgesics	Fentanyl
XT673P	Antihistamines, Cold Treatment	Doxylamine
Y4NX9E	Analgesics	Fentanyl
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine
Y8Z7AH	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
YJVEV7	Antihistamines, Cold Treatment	Doxylamine
YN6HYM	Antihistamines, Cold Treatment	Doxylamine
YQCUGN	Analgesics	Fentanyl
YXCCXL	Analgesics	Fentanyl
Z2UNE4	Analgesics	Fentanyl
		Tramadol
	Anticonvulsants	Gabapentin
	Antihistamines, Cold Treatment	Doxylamine

TABLE 4 A: Screening Results - Item 4

WebCode	Category	Drug/Metabolite
ZEF76L	Analgesics	Fentanyl
ZFBUGP	Analgesics	Fentanyl
	Antihistamines, Cold Treatment	Doxylamine
ZHZWT6	Analgesics	Fentanyl
ZJ89B8	Analgesics	Fentanyl

Screening Response Summary for Item 4 **Participants: 130**

Drug Category Totals		Drug/Metabolite Totals	
Analgesics	99	**Fentanyl**	95
Antihistamines, Cold Treatment	60	**Doxylamine**	60
Anticonvulsants	23	**Gabapentin**	23
		Norfentanyl	3
No drugs detected utilizing screening methods	8		

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 4

TABLE 4B

Item Scenario:

A 42 year old female was found unresponsive on the side of the road and presented to the hospital via EMS after life-saving efforts were attempted, but unsuccessful. She had an unlabeled baggie of pills on her person.

Item Contents and Preparation Concentration: Doxylamine (250 ng/mL)
Fentanyl (40 ng/mL)
Gabapentin (800 ng/mL)

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
28CJRC	Fentanyl		>10		ng/mL
	Norfentanyl		0.2	+/-0.1	ng/mL
2R2ZW7	DOXYLAMINE				
	FENTANYL	✓			
3KUQ3H	Doxylamine		0.24	10.86%	ug/mL
	Fentanyl		27	26.53%	ng/mL
3L7B8L	Fentanyl	✓			
47C7EH	Doxylamine	✓			
4UFZKK	Doxylamine	✓			
	Fentanyl	✓			
	Gabapentin	✓			
4Y8J8Z	Fentanyl		27 ng/mL	+/- 3	ng/mL
	Caffeine	✓			
4Z33A3	Doxylamine	✓			
66DDZB	doxylamine		240	70	ng/mL
	fentanyl		32	10	ng/mL
	gabapentin		< 1000		ng/mL
69ZW6E	Doxylamine	✓			
	Fentanyl		32	12	ng/ml
	Gabapentin	✓			

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
6CXF6R	Doxylamine		0.2	15%	mg/L
	Fentanyl		29	15%	ug/L
	Gabapentin		0.8	15%	mg/L
6RMMYJ	Doxylamine	✓			
	Fentanyl	✓			
	Gabapentin	✓			
6RNHNG	Doxylamine		0.46	0.05	ug/ml
	Fentanyl		39	10	ng/ml
6VMUJG	Doxylamine		0.24	10.86%	ug/mL
	Fentanyl		28	26.53%	ng/mL
76WJY2	Doxylamine	✓			
7DM2DA	Doxylamine		0.24	0.07	mg/L
	Fentanyl		31	9	ng/mL
	Gabapentin		<1.0		
7THLUX	Fentanyl		33	6	ng/mL
82MZ8J	Doxylamine		221.54	+/- 16%	ng/mL
	Fentanyl		34.47	+/- 18%	ng/mL
82RCVE	Doxylamine		0.26	0.03	ug/mL
	Fentanyl		31	8	ng/mL
8ALF2W	Doxylamine		237.12	33.19	ng/mL
	Fentanyl		36.19	4.34	ng/mL
94RZMA	Fentanyl		33		ng/mL
9E9MWB	Fentanyl		34		ng/mL
9E9R8D	Doxylamine	✓			
9L6JJD	Doxylamine		0.25	10.86%	ug/mL
	Fentanyl		33	26.53%	ng/mL

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
9WQNRD	Doxylamine		0.23	0.03	ug/mL
	Fentanyl		40	11	ng/mL
A8462V	fentanyl		33		ng/ml
ARQYNB	doxylamine		0.26	10.86%	ug/ml
	fentanyl		28	26.53%	ng/ml
BCCXME	Doxylamine	✓			
	Fentanyl		36		ng/mL
	Gabapentin	✓			
BEHBB8	Doxylamine	✓			
	Fentanyl		42		ng/mL
BTXFFE	Doxylamine	✓			
	Fentanyl		36		ng/mL
BUY9F9	Fentanyl		37		ng/mL
CHEJU8	Fentanyl		29	6	
CU8ZLU	Doxylamine	✓			
CYLKNA	doxylamine	✓			
	fentanyl	✓			
	gabapentin		1255		ng/ml
CZG4PB	Doxylamine	✓			
D333M7	Fentanyl		30		ng/mL
D3GPYT	Doxylamine	✓			
DAH2VP	Doxylamine		208.90	29.24	ng/ml
	Fentanyl		35.22	4.22	ng/ml
DQQXEN	Doxylamine		0.25	10.86%	ug/mL
	Fentanyl		33	26.53%	ng/mL

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
DTCHJT	Doxylamine	✓			
EATAEA	Doxylamine	✓			
EAXM37	Fentanyl		31	±6	ng/mL
EC3D8Z	doxylamine		0.22 mg/L	0.07	mg/L
	fentanyl		27 micrograms/liter	8	:rograms/l
	gabapentin		lower than the lowest calibrator		
EDHCQP	Fentanyl		30	5	ng/mL
EHN6JZ	Doxylamine	✓			
	Fentanyl		32	12	ng/mL
EQHD26	doxylamine		250		ng/mL
	fentanyl		36		ng/mL
	gabapentin		1.0		mg/L
ERDW48	Doxylamine		0.27	10.86% k=2	ug/mL
	Fentanyl		39	26.53% k=2	ng/mL
F3UZQW	Doxylamine	✓			
	fentanyl		35	3	ng/mL
F7PV7B	Gabapentin	✓			
FDCNHA	Doxylamine		221.38	±35.42	ng/ml
	Fentanyl		29.37	±5.28	ng/ml
FJGK7G	Doxylamine	✓			
	Fentanyl	✓			
FN9UC9	Fentanyl	✓			
FXJWXA	No drugs/metabolites detected utilizing confirmatory methods.				
GKQMUZ	Doxylamine	✓			
	Fentanyl	✓	>10		ng/mL

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
GVA796	Doxylamine	✓			
H33YT6	Doxylamine	✓			
H97X9Z	Fentanyl	✓			
HD3K3N	doxylamine	✓			
	fentanyl	✓			
HEVFPX	Doxylamine		0.24	0.07	mg/L
	Fentanyl		30	9	mcg/L
	Gabapentin		1.1	0.3	mg/L
HHGZU2	Fentanyl		33.80	6.76	ng/mL
HJCHV3	fentanyl		32.5	4.2	ng/mL
J6RHGN	FENTANYL	✓			
JAHYN8	Fentanyl		423.211	8.15	ng/ml
JDG92U	Doxylamine		0.220	0.022	mg/L
	Fentanyl		0.028	0.0034	mg/L
	Gabapentin		0.870	0.081	mg/L
JR4HMZ	Fentanyl		30		ng/mL
KHU9V2	Fentanyl		32	±6	ng/ml
L2ETM2	Fentanyl	✓			
L44VYG	Doxylamine		0.25	10.86%	ug/mL
	Fentanyl		33	26.53%	ng/mL
LFXJL4	Doxylamine		239.96	+/-38.39	ng/mL
	Fentanyl		32.00	+/- 5.76	ng/mL
LJV3N3	Fentanyl	✓			
M43KEX	Doxylamine		0.24	10.86%	ug/mL
	Fentanyl		29	26.53%	ng/mL

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
MDQGHK	FENTANYL	✓			
MEHD6T	doxylamine		0.24	0.07	mg/L
	Fentanyl		31	9	mcg/L
	gabapentin	✓			
MT3R8T	Doxylamine		0.25	0.08	mg/L
	Fentanyl		31	9	µg/L
	Gabapentin		1.1	0.3	mg/L
MVA8GJ	Doxylamine		200		ng/mL
	Fentanyl		30		ng/mL
	Gabapentin		1100		ng/mL
MW344T	doxylamine		0.20	0.06	mg/L
	fentanyl		27	8	µg/L
	gabapentin		LLC 1.0		mg/L
NC8RUX	Doxylamine		0.27	0.03	ug/mL
	Fentanyl		33	9	ng/mL
NM9FLV	fentanyl	✓			
NMQB83	Doxylamine	✓			
NUPVAY	Doxylamine	✓			
PBUPGX	Doxylamine	✓			
	Fentanyl	✓			
PNKA4G	Doxylamine	✓			
QC2GRC	Doxylamine		0.22	10.86%	ug/mL
	Fentanyl		38	26.53%	ng/mL
QQ3VBU	Fentanyl		30	±5	ng/mL

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
R7V8YN	Doxylamine		0.20	0.06	mg/L
	Fentanyl		27	8	µg/L
	Gabapentin	✓			
RACEFW	Fentanyl		37	4	ng/mL
	Norfentanyl		None detected	-	ng/mL
RYVNWT	Doxylamine		0.26	10.86%	ug/mL
	Fentanyl		34	26.53%	ng/mL
T38TAE	doxylamine	✓			
	fentanyl	✓			
	gabapentin	✓			
TB4N8D	Doxylamine	✓			
	Fentanyl		30	6	ng/mL
UAL4UT	Doxylamine	✓			
UEJHLP	Fentanyl		33		ng/mL
UHWFTC	Doxylamine	✓			
UR2DVU	Doxylamine	✓			
UXAUBA	Doxylamine		0.24	0.05	mg/L
	Fentanyl		0.035	0.009	mg/L
V3YTZN	Doxylamine		270	29	ng/mL
	Fentanyl		45	11	ng/mL
	Gabapentin		0.78	0.16	mg/L
VMLHAG	Doxylamine		220	6	ng/mL
	Fentanyl		20	na	ng/mL
	Gabapentin		<2000	NA	ng/mL
VNF7TC	Doxylamine				
	Fentanyl	✓			

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
VWVTKT	Doxylamine	✓			
	Fentanyl	✓			
	Gabapentin	✓			
VX7V8R	Doxylamine	✓			
	Fentanyl	✓			
	Gabapentin	✓			
	Norfentanyl	✓			
WGDDXM	Fentanyl		32	±6	ng/mL
WQ2AZA	Doxylamine	✓			
X6ZFLR	Doxylamine	✓			
	Fentanyl	✓			
	Gabapentin	✓			
XE3VDH	Doxylamine		0.27	0.08	mg/L
	Fentanyl		32	10	µg/L
	Gabapentin		Lower than the lowest calibrator of 1.0	N/A	mg/L
XMZKW8	Doxylamine	✓			
	Fentanyl	✓			
XT673P	Doxylamine	✓			
Y4NX9E	Doxylamine		0.23	0.01	mg/L
	Fentanyl		33	4	ng/mL
	Gabapentin		0.83	0.05	mg/L
Y8Z7AH	Doxylamine	✓			
	Fentanyl		45		ng/mL
YJVEV7	Doxylamine	✓			
YN6HYM	Doxylamine	✓			

TABLE 4B: Confirmatory Results - Item 4

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
YXCCXL	Doxylamine		0.26	10.86%	ug/mL
	Fentanyl		33	26.53%	ng/mL
Z2UNE4	Doxylamine		0.23	0.05	mg/L
	Fentanyl		0.035	0.009	mg/L
	Gabapentin	✓			
ZEF76L	Doxylamine		0.29	0.03	ug/mL
	Fentanyl		30	8	ng/mL
ZFBUGP	Doxylamine	✓			
	Fentanyl		34		ng/mL
ZHZWT6	Doxylamine	✓			
	Fentanyl	✓			
ZJ89B8	Fentanyl		32.20	4.50	ng/mL

Confirmatory Response Summary for Item 4 **Participants: 115**

Doxylamine:	84
Fentanyl:	92
Gabapentin:	27
Other identified drugs/metabolites:	4
No drugs/metabolites detected utilizing confirmatory methods:	1

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 4

TABLE 4C

Item 4 Raw Data - Doxylamine
Preparation concentration: 250 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
3KUQ3H	249.00		249.00	
66DDZB	235.00		235.00	
6CXF6R	229.00	230.00	229.50	
6RNHNG	467.00		467.00	X
6VMUJG	243.00		243.00	
7DM2DA	243.00		243.00	
82RCVE	264.00		264.00	
8ALF2W	237.12		237.10	
9L6JJD	259.00		259.00	
9WQNRD	234.00		234.00	
ARQYNB	265.00		265.00	
BEHBB8	245.90	319.70	282.80	
DAH2VP	226.87	208.90	217.90	
DQQXEN	259.00		259.00	
EC3D8Z	221.00		221.00	
EQHD26	252.09	248.60	250.30	
ERDW48	271.00		271.00	
FDCNHA	221.38		221.40	
GKQMUZ	291.80	334.80	313.30	X
HEVFPX	242.06		242.10	
JDG92U	214.53	225.60	220.10	
L44VYG	259.00		259.00	
LFXJL4	239.96		240.00	
M43KEX	240.00		240.00	
MEHD6T	243.00		243.00	
MT3R8T	254.56		254.60	
MVA8GJ	200.00		200.00	
MW344T	198.00		198.00	
NC8RUX	273.00		273.00	

TABLE 4C: Raw Data - Item 4

Item 4 Raw Data - Doxylamine
Preparation concentration: 250 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		
QC2GRC	224.00		224.00
R7V8YN	202.00		202.00
RYVNWT	266.00		266.00
UXAUBA	239.14		239.10
V3YTZN	270.82	266.50	268.70
VMLHAG	219.00		219.00
XE3VDH	270.00		270.00
Y4NX9E	231.00		231.00
YXCCXL	265.00		265.00
Z2UNE4	226.54		226.50
ZEF76L	290.00		290.00

Statistical Analysis for Item 4 - Doxylamine (ng/mL)

Grand Mean **243.50**
Standard Deviation **22.78**
Number of Participants Included **38**
Number of Participants Excluded **2**
by Critical H value of **2.677**

TABLE 4C: Raw Data - Item 4

Item 4 Raw Data - Fentanyl
Preparation concentration: 40 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean
3KUQ3H	27.700		27.700
4Y8J8Z	27.520		27.520
66DDZB	32.293	31.000	31.640
69ZW6E	32.400		32.400
6CXF6R	29.000	29.000	29.000
6RNHNG	39.200		39.200
6VMUJG	28.810		28.810
7DM2DA	31.430		31.430
7THLUX	33.190		33.190
82RCVE	31.900		31.900
8ALF2W	36.190		36.190
94RZMA	33.350		33.350
9E9MWB	34.560		34.560
9L6JJD	33.200		33.200
9WQNRD	40.900		40.900
A8462V	33.000		33.000
ARQYNB	28.630		28.630
BCCXME	36.660	35.450	36.060
BEHBB8	40.900	4.2000	22.550
BTXFFE	35.580		35.580
BUY9F9	37.200		37.200
CHEJU8	29.000		29.000
D333M7	30.770		30.770
DAH2VP	36.660	35.220	35.940
DQQXEN	33.540		33.540
EAXM37	31.276		31.280
EC3D8Z	27.376		27.380
EDHCQP	29.910		29.910
EHN6JZ	32.000		32.000
EQHD26	36.230	36.530	36.380

TABLE 4C: Raw Data - Item 4

Item 4 Raw Data - Fentanyl
Preparation concentration: 40 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)		Participant Mean	
ERDW48	39.260		39.260	
F3UZQW	34.890	34.430	34.660	
FDCNHA	29.370		29.370	
GKQMUZ	58.900		58.900	X
HEVFPX	30.274		30.270	
HHGZU2	33.802		33.800	
HJCHV3	32.500		32.500	
JAHYN8	423.21		423.20	X
JDG92U	28.820	27.160	27.990	
JR4HMZ	30.440		30.440	
KHU9V2	32.693		32.690	
L44VYG	33.890		33.890	
LFXJL4	32.000		32.000	
M43KEX	29.900		29.900	
MEHD6T	30.694		30.690	
MT3R8T	31.144		31.140	
MVA8GJ	30.000		30.000	
MW344T	26.712		26.710	
NC8RUX	33.400		33.400	
QC2GRC	38.360		38.360	
QQ3VBU	30.291		30.290	
R7V8YN	27.235		27.240	
RACEFW	37.508		37.510	
RYVNWT	34.040		34.040	
TB4N8D	30.060		30.060	
UEJHLP	33.660		33.660	
UXAUBA	34.900		34.900	
V3YTZN	44.500	46.330	45.420	X
VMLHAG	23.000	24.000	23.500	
WGDDXM	32.785		32.790	

TABLE 4C: Raw Data - Item 4

Item 4 Raw Data - Fentanyl
Preparation concentration: 40 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)	
XE3VDH	32.000	32.000
Y4NX9E	33.000	33.000
YXCCXL	33.300	33.300
Z2UNE4	35.013	35.010
ZEF76L	30.400	30.400
ZFBUGP	34.450	34.450
ZJ89B8	32.200	32.200

Statistical Analysis for Item 4 - Fentanyl (ng/mL)

Grand Mean **32.21**

Standard Deviation **3.55**

Number of Participants Included **64**

Number of Participants Excluded **3**

by Critical H value of **2.731**

TABLE 4C: Raw Data - Item 4

Item 4 Raw Data - Gabapentin
Preparation concentration: 800 ng/mL

WebCode	List of Raw Data Determinations (ng/mL)			
66DDZB	779.00		779.00	
6CXF6R	809.00	818.00	813.50	
7DM2DA	913.00		913.00	
CYLKNA	1,255.0		1,255.0	
EC3D8Z	847.00		847.00	
EQHD26	1,063.4	1,008.7	1,036.0	
HEVFPX	1,051.7		1,051.7	
JDG92U	932.12	807.60	869.90	
MEHD6T	839.00		839.00	
MT3R8T	108.20		108.20	X
MVA8GJ	1,100.0		1,100.0	
MW344T	730.00		730.00	
V3YTZN	792.81	776.80	784.80	
VMLHAG	1,233.0		1,233.0	
Y4NX9E	830.00		830.00	

Statistical Analysis for Item 4 - Gabapentin (ng/mL)

Grand Mean **934.42**
Standard Deviation **170.66**
Number of Participants Included **14**
Number of Participants Excluded **1**
by Critical H value of **2.444**

Reporting Procedures - Item 4

TABLE 4D - Item 4

WebCode	Quantitative Reporting Procedures
28CJRC	The sample is analyzed in duplicate, and the results have to be within +/-20% of their mean. The lowest of the two quantitative results is reported.
3KUQ3H	A single determination.
4Y8J8Z	A single determination.
66DDZB	The mean of duplicate/several determinations.
69ZW6E	A single determination.
6CXF6R	The mean of duplicate/several determinations.
6RNHNG	A single determination.
6VMUJG	A single determination.
7DM2DA	A single determination.
7THLUX	A single determination.
82MZ8J	A single determination.
82RCVE	A single determination.
8ALF2W	A single determination.
94RZMA	A single determination.
9E9MWB	A single determination.
9L6JJD	A single determination.
9WQNRD	A single determination.
A8462V	A single determination.
ARQYNB	A single determination.
BCCXME	The mean of duplicate/several determinations.
BEHBB8	A single determination.
BTXFFE	A single determination.
BUY9F9	A single determination.
CHEJU8	A single determination.
CYLKNA	A single determination.
D333M7	A single determination.
DAH2VP	lowest of two quantitative values due to screen and confirmation being performed on the quantitative/confirmatory method
DQQXEN	A single determination.

TABLE 4D: Reporting Procedures - Item 4

WebCode	Quantitative Reporting Procedures
EAXM37	A single determination.
EC3D8Z	A single determination.
EDHCQP	A single determination.
EHN6JZ	A single determination.
EQHD26	The mean of duplicate/several determinations.
ERDW48	A single determination.
F3UZQW	The mean of duplicate/several determinations.
FDCNHA	A single determination.
GKQMUZ	A single determination.
HEVFPX	A single determination.
HHGZU2	A single determination.
HJCHV3	A single determination.
JAHYN8	A single determination.
JDG92U	The mean of duplicate/several determinations.
JR4HMZ	A single determination.
KHU9V2	A single determination.
L44VYG	A single determination.
LFXJL4	A single determination.
LJV3N3	A single determination.
M43KEX	A single determination.
MEHD6T	A single determination.
MT3R8T	A single determination.
MVA8GJ	A single determination.
MW344T	A single determination.
NC8RUX	A single determination.
QC2GRC	A single determination.
QQ3VBU	A single determination.
R7V8YN	The mean of duplicate/several determinations.
RACEFW	A single determination.
RYVNWT	A single determination.

TABLE 4D: Reporting Procedures - Item 4

WebCode	Quantitative Reporting Procedures
TB4N8D	A single determination.
UEJHLP	A single determination.
UXAUBA	A single determination.
V3YTZN	The mean of duplicate/several determinations.
VMLHAG	Gabapentin & Doxylamine were single determination
WGDDXM	A single determination.
XE3VDH	A single determination.
Y4NX9E	A single determination.
Y8Z7AH	A single determination.
YXCCXL	A single determination.
Z2UNE4	A single determination.
ZEF76L	A single determination.
ZFBUGP	A single determination.
ZJ89B8	A single determination.

Response Summary for Item 4	Participants: 72
A single determination:	61 (84.7%)
The mean of duplicate/several determinations:	8 (11.1%)
Other:	3 (4.2%)

Methods of Analysis - Item 4

TABLE 4E - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
27ZRVP	GC/MS	✓		
28CJRC	LC/MS/MS	✓	✓	✓
2R2ZW7	GC/MS		✓	
3KUQ3H	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
3L7B8L	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
	LC-QTOF-MS	✓	✓	
3X2H8C	Immunoassay	✓		
47C7EH	Immunoassay	✓		
	GC/MS	✓	✓	
4CX2FM	Immunoassay	✓		
4UFZKK	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
4Y8J8Z	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	✓
4Z33A3	Immunoassay	✓		
	GC/MS	✓	✓	
634A8K	Immunoassay	✓		
66DDZB	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
69ZW6E	Immunoassay	✓		
	LC-QTOF-MS	✓	✓	
	GC/MS		✓	
	LC/MS/MS		✓	✓

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
6CXF6R	LC-QTOF-MS	✓		
	LC/MS/MS	✓	✓	
6RMMYJ	Immunoassay	✓		
	LC-QTOF		✓	
6RNHNG	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
6VMUJG	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
6YM3QD	Immunoassay	✓		
	LC/MS/MS	✓		
76WJY2	Immunoassay	✓		
	GC/MS	✓	✓	
7DM2DA	LC-HRMSMS	✓		
	LC/MS/MS		✓	✓
7FQWWC	Immunoassay	✓		
7THLUX	Immunoassay	✓		
	LC/MS/MS		✓	✓
82MZ8J	LC/MS/MS	✓	✓	✓
82RCVE	Immunoassay	✓		
	GC/MS	✓	✓	✓
	LC/MS/MS		✓	✓
8ALF2W	LC/MS/MS	✓	✓	✓
94RZMA	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	✓
9E9MWB	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	✓
9E9R8D	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
9L6JJD	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
9UNPH6	Immunoassay	✓		
9WQNRD	LC/MS/MS		✓	✓
	GC/MS		✓	✓
A8462V	LC/MS/MS	✓	✓	✓
	GC/MS	✓		
ARQYNB	Immunoassay	✓		
	GC/MS	✓	✓	✓
	LC/MS/MS		✓	✓
BCCXME	Immunoassay	✓		
	LC-QTOF	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	✓
BEHBB8	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
BKMCB2	Immunoassay	✓		
BTXFFE	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
BUY9F9	LC/MS/MS	✓		
	GC/MS		✓	✓
CHEJU8	LC/MS/MS	✓	✓	
CU8ZLU	Immunoassay	✓		
	GC/MS	✓	✓	
CYLKNA	LC/MS/MS	✓		✓
	LC-QTOF	✓	✓	
	GC/MS		✓	
CZG4PB	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
D333M7	Immunoassay	✓		
	LC/MS	✓		
	GC/MS		✓	✓
D3GPYT	Immunoassay	✓		
	GC/MS	✓	✓	
DAH2VP	LC/MS/MS	✓	✓	✓
DQQXEN	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
	GC-FID		✓	✓
DTCHJT	Immunoassay	✓		
	GC/MS	✓	✓	
EATAEA	Immunoassay	✓		
	GC/MS		✓	
	UPLC-QTOF		✓	
EAXM37	Immunoassay	✓		
	LC/MS/MS		✓	✓
EC3D8Z	LC/MS/MS		✓	✓
	LC-HRMS/MS	✓		
	GC/MS	✓	✓	
EDHCQP	Immunoassay	✓		
	LC/MS/MS		✓	✓
EHN6JZ	LC/HRAM/MS	✓		
	LC/MS/MS		✓	✓
EQHD26	Immunoassay	✓		
	LC-QTOF	✓		
	LC/MS/MS			✓
ERDW48	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓
EVXLRQ	Immunoassay	✓		

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
F3UZQW	Immunoassay	✓		
	GC/MS	✓	✓	
	LC-QTOF	✓		
	LC/MS/MS	✓	✓	✓
F7PV7B	LC/MS/MS	✓	✓	
FDCNHA	LC/MS/MS	✓	✓	
FJGK7G	GC/MS	✓		
	LC/MS/MS		✓	
FN9UC9	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	
FXJWXA	LC/MS/MS			✓
GKQMUZ	Immunoassay	✓		
	LC/MS/MS	✓	✓	
GVA796	Immunoassay	✓		
	GC/MS	✓	✓	
H33YT6	Immunoassay	✓		
	GC/MS	✓	✓	
H97X9Z	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
HD3K3N	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
HEVFPX	LC-HRMS/MS	✓		
	LC/MS/MS			✓
HHGZU2	LC/MS/MS	✓	✓	✓
HJCHV3	Immunoassay	✓		
	LC/MS/MS		✓	✓
J6RHGN	LC-QTOF	✓		
	LC-QTOF-MS		✓	
	GC/MS	✓	✓	

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
JAHYN8	LC/MS/MS	✓	✓	✓
JDG92U	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC-QTOF	✓	✓	
JR4HMZ	LC/MS/MS	✓		
	GC/MS		✓	✓
KHU9V2	Immunoassay	✓		
	LC/MS/MS		✓	✓
KKY2RK	LC/MS/MS	✓		
L2ETM2	LC/MS/MS	✓	✓	
L44VYG	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
LFXJL4	LC/MS/MS	✓	✓	
LJV3N3	LC/MS/MS	✓	✓	✓
LT9P6J	Immunoassay	✓		
M43KEX	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS	✓		
	GC/FID		✓	✓
MDQGHK	LC/MS/MS	✓	✓	
MEHD6T	LC/HRMS/MS	✓		
	LC/MS/MS		✓	
MT3R8T	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
MVA8GJ	GC/MS	✓	✓	✓
	LC/MS/MS	✓	✓	✓
MW344T	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
NC8RUX	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
NM9FLV	Randox Investigator Immunoassay	✓		
	LC/MS		✓	
NMQB83	GC/MS	✓	✓	
NQPM33	LC-TOF	✓		
NUPVAY	Immunoassay	✓		
	GC/MS	✓	✓	
PBUPGX	Immunoassay	✓		
	LC-QTOF-MS	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
PNKA4G	Immunoassay	✓		
	GC/MS	✓	✓	
QC2GRC	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
	GC/FID		✓	✓
QQ3VBU	Immunoassay	✓		
	LC/MS/MS		✓	✓
R7V8YN	LC-HRMS/MS	✓		
	LC/MS		✓	✓
RACEFW	Immunoassay	✓		
	LC/MS/MS		✓	✓
RYVNWT	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
	GC/FID		✓	✓
T38TAE	LC/MS/MS	✓	✓	
	GC/MS		✓	
T6EB7P	Randox Evidence MutiStat DOA Blood Assays	✓		

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
TB4N8D	Immunoassay	✓		
	LC/MS/MS		✓	✓
UAL4UT	Immunoassay	✓		
	GC/MS	✓	✓	
UEJHLP	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
UHWFTC	Immunoassay	✓		
	GC/MS	✓	✓	
UR2DVU	Immunoassay	✓		
	GC/MS	✓	✓	
UXAUBA	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
	GC-NPD			✓
UZFC8J	Immunoassay	✓		
V3YTZN	Immunoassay	✓		
	LC-QTOF	✓	✓	
	LC-QTOF-MS			✓
VMLHAG	LC-QTOF-MS	✓	✓	✓
	LC/MS/MS		✓	✓
VNF7TC	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
VWVTKT	LC/MS/MS	✓	✓	
VX7V8R	GC/MS	✓		
	LC/MS/MS	✓	✓	
	LR-HRMS	✓		
WGDDXM	Immunoassay	✓		
	LC/MS/MS		✓	✓
WQ2AZA	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
X6ZFLR	Immunoassay	✓		
	LC-QTOF-MS		✓	
	GC/MS		✓	
XE3VDH	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
XMZKW8	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
XT673P	Immunoassay	✓		
	GC/MS	✓	✓	
Y4NX9E	LC-QTOF-MS	✓		
	LC/MS/MS		✓	✓
Y8Z7AH	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
YJVEV7	GC/MS	✓	✓	
	Immunoassay	✓		
YN6HYM	Immunoassay	✓		
	GC/MS	✓	✓	
YQCUGN	Immunoassay	✓		
YXCCXL	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
Z2UNE4	Immunoassay	✓		
	GC/MS	✓		
	GC-NPD		✓	✓
	LC/MS/MS	✓	✓	✓
ZEF76L	Immunoassay	✓		
	GC/MS	✓	✓	✓
	LC/MS/MS	✓	✓	✓
ZFBUGP	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
ZHZWT6	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
ZJ89B8	LC/MS/MS	✓	✓	✓

Response Summary for Item 4 - Methods of Analysis **Participants: 130**

	Screening	Confirmatory	Quantitation
Immunoassay:	83	0	0
GC/MS:	44	65	16
LC/MS:	1	2	1
LC/MS/MS:	38	77	59
LC-QTOF:	7	4	0
LC-QTOF-MS:	7	5	2
Other:	14	8	8

Additional Comments for Item 4

TABLE 4F

WebCode	Item Comments
27ZRVP	Basification, and extraction with DCM with and without derivatization . Sample volume : 600 uL. Derivatization : BSTFA (50 uL) + EtOAc (100 uL). Doxylamine Basification, and extraction with EtOAc with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL). Doxylamine Basification, and extraction with Hexane:EtOAc (9:1) with and without derivatization . Sample volume : 1 mL. Derivatization : BSTFA (50 uL) + EtOAc (50 uL). Doxylamine
28CJRC	Fentanyl lower limit of quantitation (LLOQ) is 0.2 ng/mL with a working range of 0.2-10 ng/mL. The internal standard used was Fentanyl-D5. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. Results which are greater than its working range are reported out as being greater than the concentration of its highest calibrator. Norfentanyl lower limit of quantitation (LLOQ) is 0.2 ng/mL with a working range of 0.2-10 ng/mL. The internal standard used was Norfentanyl-D5. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration.
3KUQ3H	ELISA was used as the Immunoassay screening method. Mepivacaine was used as the internal standard for the basic drug analysis (GC/MS). Internal standards for the opioid analysis were Morphine D3, Oxycodone D6, and Buprenorphine D4. Buprenorphine D4 is the internal standard that was used to calculate the Fentanyl result. Expanded Uncertainty 95.45%, k=2
3X2H8C	Immunoassay: Fentanyl cutoff 2ng/mL
47C7EH	Drug Screen used Promazine as the Internal Standard.
4CX2FM	Screening testing only is performed. Fentanyl/Acetyl Fentanyl
66DDZB	Internal Standards: mepivacaine & gabapentin-d4. Gabapentin: limit of report is 300 ng/mL and lowest calibrator is 1000 ng/mL, the way this result would be reported in our laboratory is lower than the lowest calibrator of 1000 ng/mL.
69ZW6E	LC-QTOF-MS and GC/MS internal standard - Mepivacaine, LC/MS/MS internal standard - Fentanyl-D5
6CXF6R	Internal standards used for LC-QTOF-MS screen/confirmation were D3-Morphine, D3 Hydromorphine, D3 Oxycodone, D5 MA, D3 BZE, D5 Doxylamine, D3 Tramadol, D3 Cocaine, D6 Zolpidem, D5-Fentanyl, D4 Buprenorphine, D3 Nortriptyline, D3 Methadone, D3 Sertraline, D9 25-NB2OMe, D5 desmethyldiazepam. Internal standard used for Doxylamine quantitation (LC/MS/MS) is D5 Doxylamine and limit of reporting = 0.01 mg/L. Internal standard used for Fentanyl quantitation (LC/MS/MS) is D5 Fentanyl and limit of reporting = 1 ug/L. Internal standard used for Gabapentin quantitation (LC/MS/MS) is D10 Gabapentin and limit of reporting = 0.15 mg/L
7DM2DA	Fentanyl internal standard=Mepivacaine. LOD=0.5 ng/mL. Doxylamine internal standard=Mepivacaine. LOD=25 ng/mL. Gabapentin internal standard=Gabapentin-d4. LOD=0.3 ng/mL.
7THLUX	Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL) Analyte Quantitative Range (ng/mL) Fentanyl 0.5 – 50 Methamphetamine 10 – 1000 Norfentanyl 0.5 – 50 Amphetamine 10 – 1000 Codeine 5.0 – 500 MDMA 10 – 1000 Hydrocodone 5.0 – 500 MDA 10 – 1000 Morphine 5.0 – 500 Cocaine 10 – 1000 Hydromorphone 5.0 – 500 Benzoylecgonine 20 – 2000 Oxycodone 5.0 – 500 Methadone 20 – 2000 Oxymorphone 5.0 – 500 EDDP 20 – 2000 Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses. Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Meprobamate 100 Barbiturates 50 Methadone 10 Benzodiazepines 10 Opiates 10 Buprenorphine 1 Opioids 10 Cannabinoids 10 Phencyclidine 5 Benzoylecgonine 50 TCA 25 Dextromethorphan 5 Tramadol 5 Fentanyl 1 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive.
8ALF2W	Fentanyl LOQ 0.5ng/mL; ISTD Fentanyl-d5; Linear range 0.5-100ng/mL Doxylamine LOQ 5ng/mL; ISTD Doxylamine-d5; Linear range 5-250ng/mL

TABLE 4F: Additional Comments for Item 4

WebCode	Item Comments
8JNXCZ	Item 4 involves non-criminal incidents taken from individuals that are deceased and will not be analyzed for drugs.
8N3D4C	Item not tested
9E9R8D	Internal standard for GC/MS drug screening and confirmation is Promazine.
9UNPH6	Immunoassay: Fentanyl cutoff 2ng/mL.
9WQNRD	ELISA positive for Fentanyl
BKMCB2	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP.
CHEJU8	Fentanyl: LOD/LLOQ - 0.25 ng/mL ULOQ - 50 ng/mL Internal Standard: d5-Fentanyl
DAH2VP	Sample was screened and confirmed using two extractions run on the confirmation/quantitative method with the lower of the two results utilized for reporting. Fentanyl linear range is 0.5ng/ml-100ng/ml with Fentanyl-d5 utilized as the ISTD. Doxylamine linear range is 5ng/ml-250ng/ml with Doxylamine-d5 utilized as the ISTD.
EAXM37	Post-mortem testing is outside the laboratory's scope of analysis. ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive fentanyl screen, confirmation/quantitation of fentanyl (FENT) is performed using FENT-D5 as the internal standard. LOD for FENT is 0.5 ng/mL; LOQ for FENT is 1 ng/mL.
EC3D8Z	Gabapentin: lower than the lowest calibrator of 1.0 mg/L
EDHCQP	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Meth/Amphetamines 20 Barbiturates 50 Benzodiazepines 10 Buprenorphine 1 Cannabinoids 10 Benzoylecgonine 50 Dextromethorphan 5 Fentanyl 1 Meprobamate 100 Methadone 10 Opiates 10 Opioids 10 Phencyclidine 5 TCA 25 Tramadol 5 Zolpidem 10 * Results within 20% of these concentrations are also reported as preliminarily positive. Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Analyte Quantitative Range (ng/mL) Fentanyl 0.5 – 50 Norfentanyl 0.5 – 50 Codeine 5.0 – 500 Hydrocodone 5.0 – 500 Morphine 5.0 – 500 Hydromorphone 5.0 – 500 Oxycodone 5.0 – 500 Oxymorphone 5.0 – 500 Methamphetamine 10 – 1000 Amphetamine 10 – 1000 MDMA 10 – 1000 MDA 10 – 1000 Cocaine 10 – 1000 Benzoylecgonine 20 – 2000 Methadone 20 – 2000 EDDP 20 – 2000
EVXLRQ	Item 4 screened presumptive positive for fentanyl. The [Laboratory] is not currently able to confirm and quantitate this class of drugs. These results are presumptive only. Item 4 was analyzed using Immunoassay Drug Screen (scope included below). Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem
F7PV7B	Gabapentin LOD: 100 ng/mL
FDCNHA	Doxylamine uncertainty K3 16% Fentanyl uncertainty K3 18%
FN9UC9	Codeine-D3 was used as the internal standard.

TABLE 4F: Additional Comments for Item 4

WebCode	Item Comments
FXJWXA	The blood was examined for the full panel of Section 5A drugs (6-monoacetylmorphine (6-MAM, from heroin use), amphetamine, benzoylecgonine (from cocaine use), clonazepam, cocaine, diazepam, flunitrazepam, ketamine, lorazepam, lysergic acid diethylamide (LSD), methadone, methylamphetamine, methylenedioxymethamphetamine (MDMA, 'ecstasy'), morphine, oxazepam, temazepam and delta-9-tetrahydrocannabinol (THC, from cannabis use)) as well as etizolam, 11-hydroxy-delta-9-tetrahydrocannabinol (from cannabis use) and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (from cannabis use). Sample was analysed using a dedicated Section 5A method. No additional drug screening was performed.
FYVPUW	Item not analyzed - lab does not complete postmortem testing.
GKQMUZ	Fentanyl calibration curve from 0.2-10 ng/mL, no dilution performed on sample.
GVA796	The internal standard used for the full panel drug screen procedure was promazine.
H33YT6	Butyl Acetate Internal Standard: Promazine
H97X9Z	The immunoassay was positive for the fentanyl category.
HD3K3N	SKF-525a istd used. d5-fentanyl istd used
HEVFPX	IS: mepivacaine, mephobarbital, gabapentin-d4. LOR: doxylamine 0.050 mg/L, fentanyl 0.5 mcg/L, gabapentin 0.30 mg/L
J6RHGN	ESTAZOLAM WAS USED AS INTERNAL ESTANDAR.
JAHYN8	Apart from fentanyl 423.211 ng/ml , cocaine 7.28 ng/ml was also detected
JDG92U	Limit of detection: Fentanyl - 0.5 ng/mL, Gabapentin - 500 ng/mL, Doxylamine - 25 ng/mL. Internal standards: Fentanyl - Fentanyl-d5, Gabapentin - Gabapentin-d10, Doxylamine - Doxylamine-d5. Fentanyl, gabapentin, and doxylamine screened for via LC-QTOF.
KHU9V2	Laboratory does not analyze postmortem samples (outside scope of testing). ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Fentanyl confirmation panel tests for fentanyl. Fentanyl has an LOD of 0.5ng/ml and a LOQ of 1ng/ml. Fentanyl-D5 was used as the internal standard.
L2ETM2	The cut-off value of fentanyl is 5 ng/mL for LC/MS/MS.
L44VYG	Internal Standard in GC/MS/FID is Mepivacaine. Internal Standard in LC/MS/MS confirmation is Morphine D3, Oxycodone D6, and Buprenorphine D4.
LJV3N3	Internal standard - Fentanyl-D5. Surrounding controls for Fentanyl was out of range; reported qualitatively. LOD: Fentanyl - 0.25 ng/mL.
LT9P6J	Item 4 screened presumptive positive for fentanyl, however our laboratory does not currently have the capability to confirm this drug therefore confirmation testing was not performed.
MEHD6T	Internal standards-mephobarbital, mepivacaine, gabapentin-d4, olanzepine-d8, bupropion-d9, d-11 amphetamine and d-11 methamphetamine, cocaine-d3, benzoylecgonine-d8 Fentanyl: Limit of Detection:0.5mcg/L Lowest Calibrator: 2.5 mcg/L Highest Calibrator: 40 mcg/L Gabapentin: was also found in the sample lower than the lowest calibrator of 1 mg/L Limit of Detection:0.30 mg/L Lowest Calibrator: 1 mg/L Highest Calibrator: 16 mg/L Doxylamine: Limit of Detection:0.025 mg/L Lowest Calibrator: 0.125 mg/L Highest Calibrator:2.0 mg/L
MT3R8T	Internal Standards for LC-HRMS/MS: Mepivacaine and Mephobarbital Internal Standards for LC/MS/MS: Mepivacaine and Gabapentin-d4 Limit of detection for Doxylamine: 25 µg/L Limit of detection for Fentanyl: 0.5 µg/L Limit of detection for Gabapentin: 25 µg/L

TABLE 4F: Additional Comments for Item 4

WebCode	Item Comments
MW344T	mepivacaine and mephobarbital internal standards for screening mepivacaine internal standard for fentanyl and doxylamine quantitation gabapentin-d4 internal standard used for gabapentin quantitation for gabapentin quantitation, "LLC" means "lower than the lowest calibrator of" which means gabapentin quantitated above our limit of report but below the lowest calibrator used to create the quantitation curve
NM9FLV	Internal Standard: buprenorphine D4 - LOD 10 ng.
NQPM33	Fentanyl did appear presumptive positive in this testing. The opioid confirmation method is currently in development.
NUPVAY	Internal standard used for drug screen was Promazine.
PBUPGX	0.5 ng/mL confirmation LOD for Fentanyl.
QC2GRC	GC/MS-FID Internal Standard: Mepivacaine. Doxylamine units converted from ug/mL to ng/mL. LC/MS/MS Internal Standards: Morphine-d3, Oxycodone-d3, Buprenorphine-d3. Quantitation of Fentanyl from dilution due to ULOQ of 35ng/mL. Dilution factor: 2 x (19.18) = 38.36.
QQ3VBU	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Laboratory does not analyze postmortem samples (outside scope of testing). Fentanyl has a LOD of 0.5 ng/mL and a LOQ of 1 ng/mL. Fentanyl-D5 is used as the internal standard.
R7V8YN	Internal Standards: Mepivacaine/Mephobarbital, Mepivacaine, Gabapentin d-4, Bupropion d-9, Olanzapine d-8 Gabapentin value was 0.725mg/L which is lower than that lowest calibrator of 1.0 mg/L
RACEFW	Fentanyl screening cut off is 1 ng/mL. The Basic Drug quantification can confirm fentanyl and norfentanyl. The lower reporting limits are as follows; fentanyl is 1.0 ng/mL and norfentanyl is 1.0 ng/mL. Dilutions of the sample was prepared for analysis but not included in the raw data. Extraction from 05/29/2025 was rejected due to chromatography and poor signal. The calibration was not acceptable. Per SOP, sequence data from 05/29/2025 was reinjected and resulted in the same outcome; case sample was re-extracted on 06/09/2025. Norfentanyl is reported as none detected due to a very weak signal and marginal chromatography. It did not meet acceptance criteria as listed in our SOP.
T38TAE	Gabapentin was quantified below the lowest calibrator and would be reported as < 1 ng/mL. Fentanyl was quantified above the highest calibrator and would be reported as > 20 ng/mL. Gabapentin and fentanyl were confirmed with LCMSMS and doxylamine was confirmed with GCMS.
T6EB7P	The Evidence MultiSTAT DOA Blood Assays competitive enzyme immunoassays run on the automated biochip array analyser, Evidence MultiSTAT. A competitive chemiluminescent immunoassay is employed for analysis. The Evidence MultiSTAT DOA Blood Assays provide only a preliminary analytical test result. The Evidence MultiSTAT DOA Blood Assay is designed for use only with human whole blood samples.
TB4N8D	Screening performed on 05/28/2025 Fentanyl (Confirmation performed on 06/03/2025) Internal Standard: Fentanyl-D5 Limit of Detection: 0.5 ng/mL Doxylamine (Confirmation performed on 06/03/2025) Internal Standard: Zolpidem-D6 Limit of Detection: 10 ng/mL
UAL4UT	Promazine used as ISTD for GC/MS screening and Doxylamine confirmation.
UR2DVU	1. Non-panel drug Fentanyl was detected in initial GC/MS screening. This was not pursued, not reported. 2. Internal standards used: Promazine.
UZFC8J	Immunoassay Screening: Analyte/Cutoff (ng/mL) Amphetamine: 20 ng/mL Phenobarbital: 50 ng/mL Oxazepam: 10 ng/mL Lorazepam: 10 ng/mL Buprenorphine: 5 ng/mL C-THC: 10 ng/mL Benzoylecgonine: 50 ng/mL Dextromethorphan: 5 ng/mL Fentanyl: 2 ng/mL Oxycodone: 10 ng/mL Meprobamate: 100 ng/mL Methadone: 10 ng/mL Methamphetamine: 20 ng/mL Morphine: 10 ng/mL Phencyclidine: 5 ng/mL Tramadol: 5 ng/mL Nortriptyline: 60 ng/mL Zolpidem: 10 ng/mL

TABLE 4F: Additional Comments for Item 4

WebCode	Item Comments
V3YTZN	Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, Triazolam-D4 IS used for LC-QTOF analysis. ELISA screen positive for Fentanyl
VMLHAG	Fentanyl - Screening Technique: UPLC-QTOF-MS (Waters) - Internal Standard: D3-Methadone and Prazepam Confirmation: LC-MS/MS (Sciex) IS: D4-Pethidine, LOD: 0.5 ng/mL Gabapentin & Doxylamine: - Screening Techniqueand confirmation: UPLC-QTOF-MS (Waters) - Internal Standard: D3-Methadone and Prazepam Doxylamine LOD: 5ng/mL
VWVTKT	No reference standard for Doxylamine, fentanyl and Gabapentin available to perform quantification.
VX7V8R	Traces of diclofenac, paracetamol, hydrochlorothiazide and ketamine were detected in the sample.
WGDDXM	Laboratory does not analyze postmortem samples (outside scope of testing). ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Fentanyl confirmation used Fentanyl-D5 as an internal standard. The LOD for fentanyl is 0.5ng/ml, LOQ is 1ng/ml and the ULOQ is 50ng/ml.
XE3VDH	Internal Standards LC-HRMS/MS Screening: Mepivacaine/Mephobarbital Internal Standards LC/MS/MS Confirmatory/Quantitation: Mepivacaine & Gabapentin-d4 Gabapentin quantitated below the lowest calibrator of the curve of 1.0 mg/L, and our laboratory reports it as "lower than the lowest calibrator of 1.0 mg/L" and there is no uncertainty number for that analyte due to this.
XMZKW8	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS. Fentanyl-13C6 and betahydroxythio-fentanyl-13C6 are the internal standards used for fentanyl screen by LC/MS/MS.
XT673P	Promazine was the internal standard used for Drug Screen by GC/MS. Fentanyl was identified in the initial Drug Screen by GC/MS, but is not included on the [Laboratory] Toxicology reportable blood drug panel. Therefore Fentanyl was not pursued or reported.
YN6HYM	ISTD Drug Screen - Promazine
YQCUGN	Immunological Screen Cut-off blood: 9-Carboxy-THC 20ng/mL; Benzoylecgonine 25ng/mL; Amphetamines (AMP, MAMP, cross reaction MDMA) 20ng/mL; Opiates 10ng/mL; Generic Opioids & Oxycodone 10ng/mL; Methadone 10ng/mL, Benzodiazepines 10ng/mL; Barbiturates 50ng/mL; PCP 5ng/mL; Meprobamate 100ng/mL; Dextromethorphan 5ng/mL; Zolpidem 10ng/mL; Tricyclic Antidepressants 60ng/mL; Fentanyl 1ng/mL; Norbuprenorphine 1ng/mL, Tramadol 5ng/mL.
ZHZWT6	SKF 525-A and NPA are the internal standards used for basic drug screen by GC/MS. Fentanyl-13C6 and betahydroxythio-fentanyl-13C6 are the internal standards used for fentanyl screen by LC/MS/MS.

Additional Test Comments

TABLE 5

WebCode	Additional Comments
82MZ8J	Pre-distribution samples were received on 4/9/25 and analyzed. The samples received for this test were received on 5/23/25, but were not opened/analyzed as the pre-distribution testing had already been completed for this test number.
JAHYN8	All four (04) blood samples received were already Hemolyzed, which has potential factors on drug concentrations. Hemolyzed blood is generally not suitable for drug analysis. Hemolysis, the rupture of red blood cells, releases intracellular components that can interfere with various analytical techniques. Hemolysis can also dilute the sample, affecting the concentration of the drug being analysed, leading to inaccurate drug concentration measurements. This interference can cause false increases or decreases in measured drug levels, especially when using techniques such as immunoassays and chromatographic methods
L2ETM2	In our laboratory routine we use a Q exactive LC/MS/MS (orbitrap) equipment with high sensitivity, however at the time of analysis of this proficiency test, the equipment was damaged and we used a less sensitive linear trap LC/MS/MS equipment.
LFXJL4	The expanded uncertainty (UofM) value was calculated at the 99.7% confidence level (K=3).
NQPM33	Presumptive positives without matched confirmations are listed only in notes, as they would not be reported in regular casework. Opioid confirmation testing was not performed on any item as that method is currently undergoing development.
NUPVAY	Only reported drugs following the [Laboratory] Toxicology Drug Panel.
VMLHAG	Item 1 & 2 : Salicylic acid was detected but it was not list in CTS_BloodDrug_AnalyteList.pdf therefore it was not submitted. Item 3 & 4: Diclofenac was detected but it was not list in CTS_BloodDrug_AnalyteList.pdf therefore it was not submitted.

-End of Report-
(Appendix may follow)

Collaborative Testing Services ~ Forensic Testing Program

Test No. 25-5661: Blood Drug Analysis

DATA MUST BE SUBMITTED BY **July 21, 2025, 11:59 p.m. EDT** TO BE INCLUDED IN THE REPORT

Participant Code: U1234A WebCode: JBF8YC

Scenario:

Investigators have submitted two vials of blood from each of four separate cases for your analysis. Using your laboratory's procedures, analyze each item and report the presence of any drugs and/or metabolites.

Case 1: A 29 year old female was pulled over for driving recklessly while taking friends home from a night club. The female, as well as many of the passengers, showed signs of impairment, including a lack of convergence, slurred speech, and nystagmus. A blood specimen was collected from the driver 1.5 hours later.

Case 2: A 24 year old female was arrested after swerving across lanes on a busy highway. She claimed to have fallen asleep at the wheel. A blood specimen was collected 1 hour after arrest.

Case 3: Toxicological analysis was performed following the death of a 32 year old man who had fallen off a raised outdoor deck at his residence. A post-mortem examination determined internal and external hemorrhage as the cause of death. His wife informed authorities about his behavior minutes prior to the fall, including panic, incoherent speech, and stupor. Drug paraphernalia was also found in his bedroom.

Case 4: A 42 year old female was found unresponsive on the side of the road and presented to the hospital via EMS after life-saving efforts were attempted, but unsuccessful. She had an unlabeled baggie of pills on her person.

-For a comprehensive list of potential analytes that may be present in these samples, please refer to the following link: https://cts-forensics.com/pdfs/CTS_BloodDrug_AnalyteList.pdf

-Samples may contain methanol and acetonitrile as artifacts from production.

Items Submitted (Sample Pack BDRG):

Item 1: Two vials of sheep blood from Case 1
Item 2: Two vials of sheep blood from Case 2
Item 3: Two vials of human whole blood from Case 3
Item 4: Two vials of human whole blood from Case 4

Screening Results for Item 1:

1-1). Please indicate the screening results for Item 1. If your instrumentation only returns general drug categories and not specific drugs/metabolites, report your findings within the Drug Category section only.

(Select from the following drop-down menus. If the terminology below differs from your typical screening categories, select the response that best fits and indicate your preferred language in the comment section.)

○ No drugs detected utilizing screening methods.

○ Drug(s) detected. Select each drug category and drug below.

Drug Category	Drug/Metabolite

Confirmatory Results for Item 1:

1-2). Was confirmatory analysis performed for this item? ○ Yes ○ No

1-3). What drugs/metabolites were detected in Item 1? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

1-4). If quantitative analysis was performed, are the reported concentrations above

○ A single determination? ○ The mean of duplicate / several determinations?

○ Other? (Specify):

1-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

1-6). Additional Comments for Item 1

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Note: *Please use appropriate punctuation to indicate the end of sentences, sections, and statements in the free-form space below. Extra spacing and returns used for separation within your text will not transfer and may cause your information to be illegible in the Summary Report. The use of lists and tabular formats to deliver information is also cautioned against, as these do not transfer.*

Screening Results for Item 2:

2-1). Please indicate the screening results for Item 2. If your instrumentation only returns general drug categories and not specific drugs/metabolites, report your findings within the Drug Category section only.

(Select from the following drop-down menus. If the terminology below differs from your typical screening categories, select the response that best fits and indicate your preferred language in the comment section.)

○ No drugs detected utilizing screening methods.

○ Drug(s) detected. Select each drug category and drug below.

Drug Category	Drug/Metabolite

Confirmatory Results for Item 2:

2-2). Was confirmatory analysis performed for this item? ○ Yes ○ No

2-3). What drugs/metabolites were detected in Item 2? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

2-4). If quantitative analysis was performed, are the reported concentrations above

○ A single determination? ○ The mean of duplicate / several determinations?

○ Other? (Specify):

2-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

2-6). Additional Comments for Item 2

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Note: *Please use appropriate punctuation to indicate the end of sentences, sections, and statements in the free-form space below. Extra spacing and returns used for separation within your text will not transfer and may cause your information to be illegible in the Summary Report. The use of lists and tabular formats to deliver information is also cautioned against, as these do not transfer.*

Screening Results for Item 3:

3-1). Please indicate the screening results for Item 3. If your instrumentation only returns general drug categories and not specific drugs/metabolites, report your findings within the Drug Category section only.

(Select from the following drop-down menus. If the terminology below differs from your typical screening categories, select the response that best fits and indicate your preferred language in the comment section.)

○ No drugs detected utilizing screening methods.

○ Drug(s) detected. Select each drug category and drug below.

Drug Category	Drug/Metabolite

Confirmatory Results for Item 3:

3-2). Was confirmatory analysis performed for this item? ○ Yes ○ No

3-3). What drugs/metabolites were detected in Item 3? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

3-4). If quantitative analysis was performed, are the reported concentrations above

○ A single determination? ○ The mean of duplicate / several determinations?

○ Other? (Specify):

3-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

3-6). Additional Comments for Item 3

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Note: *Please use appropriate punctuation to indicate the end of sentences, sections, and statements in the free-form space below. Extra spacing and returns used for separation within your text will not transfer and may cause your information to be illegible in the Summary Report. The use of lists and tabular formats to deliver information is also cautioned against, as these do not transfer.*

Screening Results for Item 4:

4-1). Please indicate the screening results for Item 4. If your instrumentation only returns general drug categories and not specific drugs/metabolites, report your findings within the Drug Category section only.

(Select from the following drop-down menus. If the terminology below differs from your typical screening categories, select the response that best fits and indicate your preferred language in the comment section.)

○ No drugs detected utilizing screening methods.

○ Drug(s) detected. Select each drug category and drug below.

Drug Category	Drug/Metabolite

Confirmatory Results for Item 4:

4-2). Was confirmatory analysis performed for this item? ○ Yes ○ No

4-3). What drugs/metabolites were detected in Item 4? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

4-4). If quantitative analysis was performed, are the reported concentrations above

○ A single determination? ○ The mean of duplicate / several determinations?

○ Other? (Specify):

4-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

4-6). Additional Comments for Item 4

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Note: *Please use appropriate punctuation to indicate the end of sentences, sections, and statements in the free-form space below. Extra spacing and returns used for separation within your text will not transfer and may cause your information to be illegible in the Summary Report. The use of lists and tabular formats to deliver information is also cautioned against, as these do not transfer.*

Date Samples Received:

Additional Comments on Test

Note: *Please use appropriate punctuation to indicate the end of sentences, sections, and statements in the free-form space below. Extra spacing and returns used for separation within your text will not transfer and may cause your information to be illegible in the Summary Report. The use of lists and tabular formats to deliver information is also cautioned against, as these do not transfer.*

RELEASE OF DATA TO ACCREDITATION BODIES

The Accreditation Release is accessed by pressing the "Continue to Final Submission" button online and can be completed at any time prior to submission to CTS.

CTS submits external proficiency test data directly to ANAB and/or A2LA. Please select one of the following statements to ensure your data is handled appropriately.

- ○ This participant's data is intended for submission to ANAB and/or A2LA. (Accreditation Release section below must be completed.)
- ○ This participant's data is **not** intended for submission to ANAB and/or A2LA.

Have the laboratory's designated individual complete the following steps
only if your laboratory is accredited in this testing/calibration discipline
by one or more of the following Accreditation Bodies.

Step 1: Provide the applicable Accreditation Certificate Number(s) for your laboratory

ANAB Certificate No.

A2LA Certificate No.

Step 2: Complete the Laboratory Identifying Information in its entirety

Authorized Contact Person and Title

Laboratory Name

Location (City/State)